Upload
others
View
2
Download
0
Embed Size (px)
Citation preview
0
Section XII ndash Vaccines Making difference on reduction
Chair Patriacutecia dos Santos Carneiro
(Instituto Butantan SP)
Patriacutecia dos Santos Carneiro PhD
Manager of Quality Control and
Analytical Development
Aug 24 2018
Alternative methods insertion
into the QC lab routine status
and challenges
Instituto Butantan | 2
Butantan Institute 116 years old of history
wwwbutantangovbr
bull Since 1901
bull Responsible for the majority of sera and vaccines used
in Brazil
All Butantan Institute production is sent to PNI ndash Ministry of
Health in order to comply with national demand
Instituto Butantan | 3
- The National Immunization Program (PNI) in Brazil is
an international reference for public health policy
- It was created in 1973 and the program seeks social
inclusion
- All Brazilians have free access to all vaccines
recommended by the World Health Organization (WHO)
Brazilian Immunization Programe (PNI )
Instituto Butantan | 4
- ANVISA (National Health Surveillance Agency) - NRA
- Butantan has GMP certifications for API (active pharmaceutical input)
for vaccines and sera lines
- Butantan has GMP certifications for two pharmaceutical forms
solutions and suspensions of sterile small volume parenteral
solutions
- Waiting for WHO inspection ndash PQ Influenza Seasonal Vaccine
GMP Certifications ndash ANVISAWHO
Instituto Butantan | 5
Butantan Institute hyperimmune sera portfolio
13 immunoglobulins
400000 vialsyear
Instituto Butantan | 6
Butantan Institute vaccines portfolio
Ongoing
Dengue
Pandemic Influenza
Quadrivalent
Influenza rBCG
DTPHB HPV DTPa
HepA mAbs
6 vaccines of the national calendar
150 million dosesyear
Instituto Butantan |
Human resources team training (multidisciplinary training including
management and innovation) dedicated group to AM and talent setting
(attractive remuneration)
Infrastructure academia-industry interaction (transfer and commercialization
of technologies import process) technological support structures (reference
centers) and technological services (conformity assessment)
Investments financing (irregularity discontinuity) and investment in RampDampI
(tax exemption and import)
Source Agecircncia Brasileira de Desenvolvimento Industrial 2012
Alternative methods - challenges
Instituto Butantan |
Regulatory approval
Alternative methods
Instituto Butantan |
Alternative methods ndash Regulatory proposal
Associated
Labs -
RENAMA
BRACVAM CONCEAANVISA and Br Ph
propose submit recommends
approves recognizesdevelopment
validation
Instituto Butantan | 10
3Rs iniciatives in Butantan Institute
Alternative methods can be defined as any method that can be used to
replace reduce or refine the use of animal in biomedical research
testing or teaching
Instituto Butantan | 11
J Virol Methods 2008 Dec154(1-2)7-13 doi 101016jjviromet200809010 Epub 2008 Oct 30
Validation of a virus neutralization potency test in BHK-21 cells for rabies
immunoglobulins in a two-center study
de Moura WC1 Gallina NM Fuches RM Romijn PC Leite JP
In vitro test (RFFIT) in rabies serum - Replacement
Save 600 mice per batch
Instituto Butantan | 12
Tetanus antitoxin potency by ToBI test - Replacement
Po
ten
cy
(UI
mL
)
Samples
-- In vivo--In vitro
Correl = 094
0
500
1000
1500
2000
2500
3000
1 2 3 4 5 6 7 8 9 10 11 12
Tetanus Antitoxin
Save 330 mice per batch
Instituto Butantan |
Single bleeding for both fractions - ReduceRefinement
Animal reduction proposal bleeding at 6 weeks for both D and T fractions
D for dT
D for DTP
T for dT and DTP
Change Control CMCB-0012418 approved in 07 may 18
Save 6 guinea-pig per batch
Instituto Butantan |
0
2
4
6
8
10
12
1 2 3 4 5 6 7 8 9 10 11
In vivo In vitro
14
dT DT DTP and DTPHB vaccines Diphtheria fraction potency analysis in vitro and in vivo - Replacement
-- In vivo -- In vitro
R=098P
ote
nc
y(U
Im
L)
Correl = 098
Save 88 guinea-pig per batch
Instituto Butantan | 15
dT DT DTP and DTPHB vaccines Tetanus fraction potency analysis in vitro and in vivo - Replacement
0
2
4
6
8
10
12
14
16
0 1 2 3 4 5 6
-- In vivo -- In vitro
Po
ten
cy
(UI
mL
)
Correl = 099
Save 220 mice per batch
Instituto Butantan | 16
LAL method for endotoxin quantification in hyperimmune sera -
Replacement
0 1 2 3 4 5 6 7 800
05
10
15
LPS standard [UEmL]
Tem
pera
ture
[C
els
ius d
eg
ree]
110
120
-100
-50
00
100
200
300
+ 10UEmL
+ 1UEml
+ 01UEml
+ 001UEml
LP
S r
eco
very
[
]
LPS standard curveIn
viv
oIn
vit
ro -
LA
L
Save 6-16 rabbits per batch
Instituto Butantan | 17
Bothrops jararaca sera potency by ToBI test - Replacement
Correl = 093
Save 330 mice per batch
Instituto Butantan | 18
Other 3Rs iniciatives in Butantan InstituteReplacement
On going in developmentinternal validation phase
MAT ndash Monocyte Activation Test (consortium by RENAMA)
Diphteria sera potency by ToBI test
Rabies potency test by ELISA (glycoproteinanti-glycoprotein)
Abnormal toxicity test banishment (already done for Influenza vaccine ndash 70 millions doses per year) on going for other
vaccines already registered (DTP DT dT HepB)
Instituto Butantan | 19
Other 3Rs iniciatives in Butantan Institute Refinement
Previous anesthesia to intracerebral challenge for
rabies and pertussis vaccines testsChange Control CMCB-0013418 approved in 14 ago 18 and
just implemented
End point to tetanus rabies and pertussis tests
Change Control CMCB-0011618 approved in 23 march 18 and
just implemented
Instituto Butantan | 20
Other 3Rs iniciatives in Butantan Institute Refinement
Pool for pyrogen and potency tests in antitoxins bulk
ready-to-fillChange Control CMCB-0013118 approved in 29 june 18 and
just implemented
Previous anesthesia to bleeding guinea-pigs
immunized for dT DT and DTP vaccines
Euthanasia by isofluorane in mice
Instituto Butantan | 21
Av Vital Brasil 1500 ndash Butantatilde - Satildeo Paulo ndash SP - Brazil
Zip code - 05503-900
(+ 55 11) 26279453
wwwbutantangovbr
Instituto Butantan | 22
Diphtheria and Tetanus combined vaccine potency
by ToBI
Alternative methods recommended by Eur Ph and WHO ndash determination of Ab titration (potency)
- T fraction ELISA andor ToBI test
- D fraction ELISA andor Vero cell tests
Our propose
- Both fractions titration by ToBI test
Instituto Butantan | 23
In vitro potency test of vaccines dT DT DTP and DTPHB
+ diphtheria and tetanus toxoid
bull ToBI test (Toxin Binding Inhibition Test)
Hendriksen et al J Biol Stand 1988 The toxin binding inhibition test as areliable in vitro alternative to the toxin neutralization test in mice for theestimation of tetanus antitoxin in human sera
Similar principle of the in vivo potency test
Decrease of 200 mice per batch of each vaccine and 400 mice per batch
of anti-tetanus serum
Instituto Butantan | 24
dT DT DTP and DTPHB vaccines selectivity
Sample + toxoidSample + both (tetanus and
diphteria) toxoid
DTPHB313 UImL 318 UImL
100 1016
DTP497 UImL 514 UImL
100 1034
Tetanus Toxoid801 UImL 724 UImL
100 904
dT1001 UImL 101 UImL
100 1001
DT1381 UImL 1448 UImL
100 1048
Tetanus antitoxin NIBSC1038 UImL 1058 UImL
100 102
All results between 80-120
Instituto Butantan | 25
dT DT DTP and DTPHB vaccines linearity Diphtheria fraction
Parameter SpecificationExperimental
Results
Correlation
coefficient (r)ge 0950 09979
Y-intercept --------- 00816
slope --------- 09753
Coefficient of
determination (r2)ge 0950 09958
Relative Standard
Deviation (RSD)le 20 1 to 6
Instituto Butantan | 26
dT DT DTP and DTPHB vaccines linearity Tetanus fraction
Parameter SpecificationExperimental
Results
Correlation
coefficient (r)ge 0950 09996
Y-intercept --------- - 03059
slope --------- 1059
Coefficient of
determination (r2)ge 0950 09992
Relative Standard
Deviation (RSD)le 20 2 to 8
Instituto Butantan | 27
dT DT DTP and DTPHB vaccines repeatability Diphtheria fraction
dT(n=7)
DT(n=7)
DTPHB(n=9)
Diphtheria Toxoid(n=8)
DTP(n=7)
Mean (UImL) 338 467 657 668 1038
Standard Deviation 043 071 062 085 107
Relative Standard Deviation
(le20)13 15 9 13 10
An
aly
st
I
dT(n=3)
DT(n=3)
DTPHB(n=3)
Diphtheria Toxoid(n=3)
DTP(n=3)
Mean (UImL) 276 399 609 582 927
Standard Deviation 021 015 025 036 068
Relative Standard Deviation
(le20)8 4 4 6 7
An
aly
st
II
Instituto Butantan | 28
dT DT DTP and DTPHB vaccines repeatability Tetanus fraction
DTPHB(n=3)
DTP(n=3)
Tetanus Toxoid(n=3)
dT(n=3)
DT(n=3)
Mean (UImL) 313 497 801 1001 1381
Standard Deviation 027 068 064 014 026
Relative Standard Deviation
(le20)9 14 8 1 2
An
aly
st
I
DTPHB(n=3)
DTP(n=3)
Tetanus Toxoid(n=3)
dT(n=3)
DT(n=3)
Mean (UImL) 321 53 874 1031 1391
Standard Deviation 012 031 099 098 023
Relative Standard Deviation
(le20)4 6 11 10 2
An
aly
st
II
Instituto Butantan | 29
dT DT DTP and DTPHB vaccines intermediate precision Diphtheria fraction
SAMPLES
ANALYSTS I + II | X(An II) ndash X(An I) | x 100
X(An I)
(le20)
Mean(UImL)
SDRSD(le20)
dT 319 047 15 18
DT 446 067 15 15
DTPHB 645 058 9 7
Diphtheria Toxoid 645 084 13 13
DTP 1005 107 11 11
RE 8992003 (ANVISA) RSD le 5)
Instituto Butantan | 30
dT DT DTP and DTPHB vaccines intermediate precision Tetanus fraction
SAMPLES
ANALYSTS I + II | X(An II) ndash X(An I) | x 100
X(An I)
(le20)
Mean(UImL)
SDRSD(le20)
DTPHB 317 019 6 3
DTP 513 051 10 7
Tetanus Toxoid 837 085 10 9
dT 1016 065 6 3
DT 1386 023 2 1
RE 8992003 (ANVISA) RSD le 5)
Instituto Butantan | 31
dT DT DTP and DTPHB vaccines accuracy Diphtheria fraction
SAMPLESX (ToBI)(UImL)
n = 7
Official ResultIn vivo
(UImL)
n = 1
X (ToBI) x 100
Official Result(80 to 120)
dT 338 30 113
DT 467 49 95
DTPHB 657 60 110
Diphtheria
Toxoid668 66 101
DTP 1038 114 91
Instituto Butantan | 32
dT DT DTP and DTPHB vaccines accuracy Tetanus fraction
SAMPLESX (ToBI)(UImL)
n = 3
Official ResultIn vivo
(UImL)
n = 1
X (ToBI) x 100
Official Result(80 to 120)
DTPHB 313 28 112
DTP 497 46 108
Tetanus Toxoid 801 89 90
dT 1001 123 81
DT 1381 152 91
Instituto Butantan | 33
in vivo e in vitro correlation
dT DT DTP and DTPHB vaccines Diphtheria fraction potency analysis
Instituto Butantan | 34
in vivo e in vitro correlation
dT DT DTP and DTPHB vaccines Tetanus fraction potency analysis
Instituto Butantan | 35
Internal validated ToBI tests presented suitable to estimate the potency not only to
tetanus fraction but ALSO to diphtheria fraction in combined vaccines
Our data met all acceptance validation criteria as specificityselectivity linearity
precision (repeatability and intermediate precision) accuracy and in vitro and in vivo
concordance showed strong correlation (R=096) for both D and T components
The high relevance of these data for replacement of animal testing strongly impacts
the routine of Quality Control turning the analyses faster accurate and cheaper and
more importantly saving the lives of hundred of animals per year
Diphtheria and Tetanus combined vaccine potency by ToBI
Conclusion after internal validation
Instituto Butantan | 36
Av Vital Brasil 1500 ndash Butantatilde - Satildeo Paulo ndash SP -
Brazil
Zip code - 05503-900
(+ 55 11) 26279453
Thank you
patriciacarneirobutantangovbr
Biotech QC team
Patriacutecia dos Santos Carneiro PhD
Manager of Quality Control and
Analytical Development
Aug 24 2018
Alternative methods insertion
into the QC lab routine status
and challenges
Instituto Butantan | 2
Butantan Institute 116 years old of history
wwwbutantangovbr
bull Since 1901
bull Responsible for the majority of sera and vaccines used
in Brazil
All Butantan Institute production is sent to PNI ndash Ministry of
Health in order to comply with national demand
Instituto Butantan | 3
- The National Immunization Program (PNI) in Brazil is
an international reference for public health policy
- It was created in 1973 and the program seeks social
inclusion
- All Brazilians have free access to all vaccines
recommended by the World Health Organization (WHO)
Brazilian Immunization Programe (PNI )
Instituto Butantan | 4
- ANVISA (National Health Surveillance Agency) - NRA
- Butantan has GMP certifications for API (active pharmaceutical input)
for vaccines and sera lines
- Butantan has GMP certifications for two pharmaceutical forms
solutions and suspensions of sterile small volume parenteral
solutions
- Waiting for WHO inspection ndash PQ Influenza Seasonal Vaccine
GMP Certifications ndash ANVISAWHO
Instituto Butantan | 5
Butantan Institute hyperimmune sera portfolio
13 immunoglobulins
400000 vialsyear
Instituto Butantan | 6
Butantan Institute vaccines portfolio
Ongoing
Dengue
Pandemic Influenza
Quadrivalent
Influenza rBCG
DTPHB HPV DTPa
HepA mAbs
6 vaccines of the national calendar
150 million dosesyear
Instituto Butantan |
Human resources team training (multidisciplinary training including
management and innovation) dedicated group to AM and talent setting
(attractive remuneration)
Infrastructure academia-industry interaction (transfer and commercialization
of technologies import process) technological support structures (reference
centers) and technological services (conformity assessment)
Investments financing (irregularity discontinuity) and investment in RampDampI
(tax exemption and import)
Source Agecircncia Brasileira de Desenvolvimento Industrial 2012
Alternative methods - challenges
Instituto Butantan |
Regulatory approval
Alternative methods
Instituto Butantan |
Alternative methods ndash Regulatory proposal
Associated
Labs -
RENAMA
BRACVAM CONCEAANVISA and Br Ph
propose submit recommends
approves recognizesdevelopment
validation
Instituto Butantan | 10
3Rs iniciatives in Butantan Institute
Alternative methods can be defined as any method that can be used to
replace reduce or refine the use of animal in biomedical research
testing or teaching
Instituto Butantan | 11
J Virol Methods 2008 Dec154(1-2)7-13 doi 101016jjviromet200809010 Epub 2008 Oct 30
Validation of a virus neutralization potency test in BHK-21 cells for rabies
immunoglobulins in a two-center study
de Moura WC1 Gallina NM Fuches RM Romijn PC Leite JP
In vitro test (RFFIT) in rabies serum - Replacement
Save 600 mice per batch
Instituto Butantan | 12
Tetanus antitoxin potency by ToBI test - Replacement
Po
ten
cy
(UI
mL
)
Samples
-- In vivo--In vitro
Correl = 094
0
500
1000
1500
2000
2500
3000
1 2 3 4 5 6 7 8 9 10 11 12
Tetanus Antitoxin
Save 330 mice per batch
Instituto Butantan |
Single bleeding for both fractions - ReduceRefinement
Animal reduction proposal bleeding at 6 weeks for both D and T fractions
D for dT
D for DTP
T for dT and DTP
Change Control CMCB-0012418 approved in 07 may 18
Save 6 guinea-pig per batch
Instituto Butantan |
0
2
4
6
8
10
12
1 2 3 4 5 6 7 8 9 10 11
In vivo In vitro
14
dT DT DTP and DTPHB vaccines Diphtheria fraction potency analysis in vitro and in vivo - Replacement
-- In vivo -- In vitro
R=098P
ote
nc
y(U
Im
L)
Correl = 098
Save 88 guinea-pig per batch
Instituto Butantan | 15
dT DT DTP and DTPHB vaccines Tetanus fraction potency analysis in vitro and in vivo - Replacement
0
2
4
6
8
10
12
14
16
0 1 2 3 4 5 6
-- In vivo -- In vitro
Po
ten
cy
(UI
mL
)
Correl = 099
Save 220 mice per batch
Instituto Butantan | 16
LAL method for endotoxin quantification in hyperimmune sera -
Replacement
0 1 2 3 4 5 6 7 800
05
10
15
LPS standard [UEmL]
Tem
pera
ture
[C
els
ius d
eg
ree]
110
120
-100
-50
00
100
200
300
+ 10UEmL
+ 1UEml
+ 01UEml
+ 001UEml
LP
S r
eco
very
[
]
LPS standard curveIn
viv
oIn
vit
ro -
LA
L
Save 6-16 rabbits per batch
Instituto Butantan | 17
Bothrops jararaca sera potency by ToBI test - Replacement
Correl = 093
Save 330 mice per batch
Instituto Butantan | 18
Other 3Rs iniciatives in Butantan InstituteReplacement
On going in developmentinternal validation phase
MAT ndash Monocyte Activation Test (consortium by RENAMA)
Diphteria sera potency by ToBI test
Rabies potency test by ELISA (glycoproteinanti-glycoprotein)
Abnormal toxicity test banishment (already done for Influenza vaccine ndash 70 millions doses per year) on going for other
vaccines already registered (DTP DT dT HepB)
Instituto Butantan | 19
Other 3Rs iniciatives in Butantan Institute Refinement
Previous anesthesia to intracerebral challenge for
rabies and pertussis vaccines testsChange Control CMCB-0013418 approved in 14 ago 18 and
just implemented
End point to tetanus rabies and pertussis tests
Change Control CMCB-0011618 approved in 23 march 18 and
just implemented
Instituto Butantan | 20
Other 3Rs iniciatives in Butantan Institute Refinement
Pool for pyrogen and potency tests in antitoxins bulk
ready-to-fillChange Control CMCB-0013118 approved in 29 june 18 and
just implemented
Previous anesthesia to bleeding guinea-pigs
immunized for dT DT and DTP vaccines
Euthanasia by isofluorane in mice
Instituto Butantan | 21
Av Vital Brasil 1500 ndash Butantatilde - Satildeo Paulo ndash SP - Brazil
Zip code - 05503-900
(+ 55 11) 26279453
wwwbutantangovbr
Instituto Butantan | 22
Diphtheria and Tetanus combined vaccine potency
by ToBI
Alternative methods recommended by Eur Ph and WHO ndash determination of Ab titration (potency)
- T fraction ELISA andor ToBI test
- D fraction ELISA andor Vero cell tests
Our propose
- Both fractions titration by ToBI test
Instituto Butantan | 23
In vitro potency test of vaccines dT DT DTP and DTPHB
+ diphtheria and tetanus toxoid
bull ToBI test (Toxin Binding Inhibition Test)
Hendriksen et al J Biol Stand 1988 The toxin binding inhibition test as areliable in vitro alternative to the toxin neutralization test in mice for theestimation of tetanus antitoxin in human sera
Similar principle of the in vivo potency test
Decrease of 200 mice per batch of each vaccine and 400 mice per batch
of anti-tetanus serum
Instituto Butantan | 24
dT DT DTP and DTPHB vaccines selectivity
Sample + toxoidSample + both (tetanus and
diphteria) toxoid
DTPHB313 UImL 318 UImL
100 1016
DTP497 UImL 514 UImL
100 1034
Tetanus Toxoid801 UImL 724 UImL
100 904
dT1001 UImL 101 UImL
100 1001
DT1381 UImL 1448 UImL
100 1048
Tetanus antitoxin NIBSC1038 UImL 1058 UImL
100 102
All results between 80-120
Instituto Butantan | 25
dT DT DTP and DTPHB vaccines linearity Diphtheria fraction
Parameter SpecificationExperimental
Results
Correlation
coefficient (r)ge 0950 09979
Y-intercept --------- 00816
slope --------- 09753
Coefficient of
determination (r2)ge 0950 09958
Relative Standard
Deviation (RSD)le 20 1 to 6
Instituto Butantan | 26
dT DT DTP and DTPHB vaccines linearity Tetanus fraction
Parameter SpecificationExperimental
Results
Correlation
coefficient (r)ge 0950 09996
Y-intercept --------- - 03059
slope --------- 1059
Coefficient of
determination (r2)ge 0950 09992
Relative Standard
Deviation (RSD)le 20 2 to 8
Instituto Butantan | 27
dT DT DTP and DTPHB vaccines repeatability Diphtheria fraction
dT(n=7)
DT(n=7)
DTPHB(n=9)
Diphtheria Toxoid(n=8)
DTP(n=7)
Mean (UImL) 338 467 657 668 1038
Standard Deviation 043 071 062 085 107
Relative Standard Deviation
(le20)13 15 9 13 10
An
aly
st
I
dT(n=3)
DT(n=3)
DTPHB(n=3)
Diphtheria Toxoid(n=3)
DTP(n=3)
Mean (UImL) 276 399 609 582 927
Standard Deviation 021 015 025 036 068
Relative Standard Deviation
(le20)8 4 4 6 7
An
aly
st
II
Instituto Butantan | 28
dT DT DTP and DTPHB vaccines repeatability Tetanus fraction
DTPHB(n=3)
DTP(n=3)
Tetanus Toxoid(n=3)
dT(n=3)
DT(n=3)
Mean (UImL) 313 497 801 1001 1381
Standard Deviation 027 068 064 014 026
Relative Standard Deviation
(le20)9 14 8 1 2
An
aly
st
I
DTPHB(n=3)
DTP(n=3)
Tetanus Toxoid(n=3)
dT(n=3)
DT(n=3)
Mean (UImL) 321 53 874 1031 1391
Standard Deviation 012 031 099 098 023
Relative Standard Deviation
(le20)4 6 11 10 2
An
aly
st
II
Instituto Butantan | 29
dT DT DTP and DTPHB vaccines intermediate precision Diphtheria fraction
SAMPLES
ANALYSTS I + II | X(An II) ndash X(An I) | x 100
X(An I)
(le20)
Mean(UImL)
SDRSD(le20)
dT 319 047 15 18
DT 446 067 15 15
DTPHB 645 058 9 7
Diphtheria Toxoid 645 084 13 13
DTP 1005 107 11 11
RE 8992003 (ANVISA) RSD le 5)
Instituto Butantan | 30
dT DT DTP and DTPHB vaccines intermediate precision Tetanus fraction
SAMPLES
ANALYSTS I + II | X(An II) ndash X(An I) | x 100
X(An I)
(le20)
Mean(UImL)
SDRSD(le20)
DTPHB 317 019 6 3
DTP 513 051 10 7
Tetanus Toxoid 837 085 10 9
dT 1016 065 6 3
DT 1386 023 2 1
RE 8992003 (ANVISA) RSD le 5)
Instituto Butantan | 31
dT DT DTP and DTPHB vaccines accuracy Diphtheria fraction
SAMPLESX (ToBI)(UImL)
n = 7
Official ResultIn vivo
(UImL)
n = 1
X (ToBI) x 100
Official Result(80 to 120)
dT 338 30 113
DT 467 49 95
DTPHB 657 60 110
Diphtheria
Toxoid668 66 101
DTP 1038 114 91
Instituto Butantan | 32
dT DT DTP and DTPHB vaccines accuracy Tetanus fraction
SAMPLESX (ToBI)(UImL)
n = 3
Official ResultIn vivo
(UImL)
n = 1
X (ToBI) x 100
Official Result(80 to 120)
DTPHB 313 28 112
DTP 497 46 108
Tetanus Toxoid 801 89 90
dT 1001 123 81
DT 1381 152 91
Instituto Butantan | 33
in vivo e in vitro correlation
dT DT DTP and DTPHB vaccines Diphtheria fraction potency analysis
Instituto Butantan | 34
in vivo e in vitro correlation
dT DT DTP and DTPHB vaccines Tetanus fraction potency analysis
Instituto Butantan | 35
Internal validated ToBI tests presented suitable to estimate the potency not only to
tetanus fraction but ALSO to diphtheria fraction in combined vaccines
Our data met all acceptance validation criteria as specificityselectivity linearity
precision (repeatability and intermediate precision) accuracy and in vitro and in vivo
concordance showed strong correlation (R=096) for both D and T components
The high relevance of these data for replacement of animal testing strongly impacts
the routine of Quality Control turning the analyses faster accurate and cheaper and
more importantly saving the lives of hundred of animals per year
Diphtheria and Tetanus combined vaccine potency by ToBI
Conclusion after internal validation
Instituto Butantan | 36
Av Vital Brasil 1500 ndash Butantatilde - Satildeo Paulo ndash SP -
Brazil
Zip code - 05503-900
(+ 55 11) 26279453
Thank you
patriciacarneirobutantangovbr
Biotech QC team
Instituto Butantan | 2
Butantan Institute 116 years old of history
wwwbutantangovbr
bull Since 1901
bull Responsible for the majority of sera and vaccines used
in Brazil
All Butantan Institute production is sent to PNI ndash Ministry of
Health in order to comply with national demand
Instituto Butantan | 3
- The National Immunization Program (PNI) in Brazil is
an international reference for public health policy
- It was created in 1973 and the program seeks social
inclusion
- All Brazilians have free access to all vaccines
recommended by the World Health Organization (WHO)
Brazilian Immunization Programe (PNI )
Instituto Butantan | 4
- ANVISA (National Health Surveillance Agency) - NRA
- Butantan has GMP certifications for API (active pharmaceutical input)
for vaccines and sera lines
- Butantan has GMP certifications for two pharmaceutical forms
solutions and suspensions of sterile small volume parenteral
solutions
- Waiting for WHO inspection ndash PQ Influenza Seasonal Vaccine
GMP Certifications ndash ANVISAWHO
Instituto Butantan | 5
Butantan Institute hyperimmune sera portfolio
13 immunoglobulins
400000 vialsyear
Instituto Butantan | 6
Butantan Institute vaccines portfolio
Ongoing
Dengue
Pandemic Influenza
Quadrivalent
Influenza rBCG
DTPHB HPV DTPa
HepA mAbs
6 vaccines of the national calendar
150 million dosesyear
Instituto Butantan |
Human resources team training (multidisciplinary training including
management and innovation) dedicated group to AM and talent setting
(attractive remuneration)
Infrastructure academia-industry interaction (transfer and commercialization
of technologies import process) technological support structures (reference
centers) and technological services (conformity assessment)
Investments financing (irregularity discontinuity) and investment in RampDampI
(tax exemption and import)
Source Agecircncia Brasileira de Desenvolvimento Industrial 2012
Alternative methods - challenges
Instituto Butantan |
Regulatory approval
Alternative methods
Instituto Butantan |
Alternative methods ndash Regulatory proposal
Associated
Labs -
RENAMA
BRACVAM CONCEAANVISA and Br Ph
propose submit recommends
approves recognizesdevelopment
validation
Instituto Butantan | 10
3Rs iniciatives in Butantan Institute
Alternative methods can be defined as any method that can be used to
replace reduce or refine the use of animal in biomedical research
testing or teaching
Instituto Butantan | 11
J Virol Methods 2008 Dec154(1-2)7-13 doi 101016jjviromet200809010 Epub 2008 Oct 30
Validation of a virus neutralization potency test in BHK-21 cells for rabies
immunoglobulins in a two-center study
de Moura WC1 Gallina NM Fuches RM Romijn PC Leite JP
In vitro test (RFFIT) in rabies serum - Replacement
Save 600 mice per batch
Instituto Butantan | 12
Tetanus antitoxin potency by ToBI test - Replacement
Po
ten
cy
(UI
mL
)
Samples
-- In vivo--In vitro
Correl = 094
0
500
1000
1500
2000
2500
3000
1 2 3 4 5 6 7 8 9 10 11 12
Tetanus Antitoxin
Save 330 mice per batch
Instituto Butantan |
Single bleeding for both fractions - ReduceRefinement
Animal reduction proposal bleeding at 6 weeks for both D and T fractions
D for dT
D for DTP
T for dT and DTP
Change Control CMCB-0012418 approved in 07 may 18
Save 6 guinea-pig per batch
Instituto Butantan |
0
2
4
6
8
10
12
1 2 3 4 5 6 7 8 9 10 11
In vivo In vitro
14
dT DT DTP and DTPHB vaccines Diphtheria fraction potency analysis in vitro and in vivo - Replacement
-- In vivo -- In vitro
R=098P
ote
nc
y(U
Im
L)
Correl = 098
Save 88 guinea-pig per batch
Instituto Butantan | 15
dT DT DTP and DTPHB vaccines Tetanus fraction potency analysis in vitro and in vivo - Replacement
0
2
4
6
8
10
12
14
16
0 1 2 3 4 5 6
-- In vivo -- In vitro
Po
ten
cy
(UI
mL
)
Correl = 099
Save 220 mice per batch
Instituto Butantan | 16
LAL method for endotoxin quantification in hyperimmune sera -
Replacement
0 1 2 3 4 5 6 7 800
05
10
15
LPS standard [UEmL]
Tem
pera
ture
[C
els
ius d
eg
ree]
110
120
-100
-50
00
100
200
300
+ 10UEmL
+ 1UEml
+ 01UEml
+ 001UEml
LP
S r
eco
very
[
]
LPS standard curveIn
viv
oIn
vit
ro -
LA
L
Save 6-16 rabbits per batch
Instituto Butantan | 17
Bothrops jararaca sera potency by ToBI test - Replacement
Correl = 093
Save 330 mice per batch
Instituto Butantan | 18
Other 3Rs iniciatives in Butantan InstituteReplacement
On going in developmentinternal validation phase
MAT ndash Monocyte Activation Test (consortium by RENAMA)
Diphteria sera potency by ToBI test
Rabies potency test by ELISA (glycoproteinanti-glycoprotein)
Abnormal toxicity test banishment (already done for Influenza vaccine ndash 70 millions doses per year) on going for other
vaccines already registered (DTP DT dT HepB)
Instituto Butantan | 19
Other 3Rs iniciatives in Butantan Institute Refinement
Previous anesthesia to intracerebral challenge for
rabies and pertussis vaccines testsChange Control CMCB-0013418 approved in 14 ago 18 and
just implemented
End point to tetanus rabies and pertussis tests
Change Control CMCB-0011618 approved in 23 march 18 and
just implemented
Instituto Butantan | 20
Other 3Rs iniciatives in Butantan Institute Refinement
Pool for pyrogen and potency tests in antitoxins bulk
ready-to-fillChange Control CMCB-0013118 approved in 29 june 18 and
just implemented
Previous anesthesia to bleeding guinea-pigs
immunized for dT DT and DTP vaccines
Euthanasia by isofluorane in mice
Instituto Butantan | 21
Av Vital Brasil 1500 ndash Butantatilde - Satildeo Paulo ndash SP - Brazil
Zip code - 05503-900
(+ 55 11) 26279453
wwwbutantangovbr
Instituto Butantan | 22
Diphtheria and Tetanus combined vaccine potency
by ToBI
Alternative methods recommended by Eur Ph and WHO ndash determination of Ab titration (potency)
- T fraction ELISA andor ToBI test
- D fraction ELISA andor Vero cell tests
Our propose
- Both fractions titration by ToBI test
Instituto Butantan | 23
In vitro potency test of vaccines dT DT DTP and DTPHB
+ diphtheria and tetanus toxoid
bull ToBI test (Toxin Binding Inhibition Test)
Hendriksen et al J Biol Stand 1988 The toxin binding inhibition test as areliable in vitro alternative to the toxin neutralization test in mice for theestimation of tetanus antitoxin in human sera
Similar principle of the in vivo potency test
Decrease of 200 mice per batch of each vaccine and 400 mice per batch
of anti-tetanus serum
Instituto Butantan | 24
dT DT DTP and DTPHB vaccines selectivity
Sample + toxoidSample + both (tetanus and
diphteria) toxoid
DTPHB313 UImL 318 UImL
100 1016
DTP497 UImL 514 UImL
100 1034
Tetanus Toxoid801 UImL 724 UImL
100 904
dT1001 UImL 101 UImL
100 1001
DT1381 UImL 1448 UImL
100 1048
Tetanus antitoxin NIBSC1038 UImL 1058 UImL
100 102
All results between 80-120
Instituto Butantan | 25
dT DT DTP and DTPHB vaccines linearity Diphtheria fraction
Parameter SpecificationExperimental
Results
Correlation
coefficient (r)ge 0950 09979
Y-intercept --------- 00816
slope --------- 09753
Coefficient of
determination (r2)ge 0950 09958
Relative Standard
Deviation (RSD)le 20 1 to 6
Instituto Butantan | 26
dT DT DTP and DTPHB vaccines linearity Tetanus fraction
Parameter SpecificationExperimental
Results
Correlation
coefficient (r)ge 0950 09996
Y-intercept --------- - 03059
slope --------- 1059
Coefficient of
determination (r2)ge 0950 09992
Relative Standard
Deviation (RSD)le 20 2 to 8
Instituto Butantan | 27
dT DT DTP and DTPHB vaccines repeatability Diphtheria fraction
dT(n=7)
DT(n=7)
DTPHB(n=9)
Diphtheria Toxoid(n=8)
DTP(n=7)
Mean (UImL) 338 467 657 668 1038
Standard Deviation 043 071 062 085 107
Relative Standard Deviation
(le20)13 15 9 13 10
An
aly
st
I
dT(n=3)
DT(n=3)
DTPHB(n=3)
Diphtheria Toxoid(n=3)
DTP(n=3)
Mean (UImL) 276 399 609 582 927
Standard Deviation 021 015 025 036 068
Relative Standard Deviation
(le20)8 4 4 6 7
An
aly
st
II
Instituto Butantan | 28
dT DT DTP and DTPHB vaccines repeatability Tetanus fraction
DTPHB(n=3)
DTP(n=3)
Tetanus Toxoid(n=3)
dT(n=3)
DT(n=3)
Mean (UImL) 313 497 801 1001 1381
Standard Deviation 027 068 064 014 026
Relative Standard Deviation
(le20)9 14 8 1 2
An
aly
st
I
DTPHB(n=3)
DTP(n=3)
Tetanus Toxoid(n=3)
dT(n=3)
DT(n=3)
Mean (UImL) 321 53 874 1031 1391
Standard Deviation 012 031 099 098 023
Relative Standard Deviation
(le20)4 6 11 10 2
An
aly
st
II
Instituto Butantan | 29
dT DT DTP and DTPHB vaccines intermediate precision Diphtheria fraction
SAMPLES
ANALYSTS I + II | X(An II) ndash X(An I) | x 100
X(An I)
(le20)
Mean(UImL)
SDRSD(le20)
dT 319 047 15 18
DT 446 067 15 15
DTPHB 645 058 9 7
Diphtheria Toxoid 645 084 13 13
DTP 1005 107 11 11
RE 8992003 (ANVISA) RSD le 5)
Instituto Butantan | 30
dT DT DTP and DTPHB vaccines intermediate precision Tetanus fraction
SAMPLES
ANALYSTS I + II | X(An II) ndash X(An I) | x 100
X(An I)
(le20)
Mean(UImL)
SDRSD(le20)
DTPHB 317 019 6 3
DTP 513 051 10 7
Tetanus Toxoid 837 085 10 9
dT 1016 065 6 3
DT 1386 023 2 1
RE 8992003 (ANVISA) RSD le 5)
Instituto Butantan | 31
dT DT DTP and DTPHB vaccines accuracy Diphtheria fraction
SAMPLESX (ToBI)(UImL)
n = 7
Official ResultIn vivo
(UImL)
n = 1
X (ToBI) x 100
Official Result(80 to 120)
dT 338 30 113
DT 467 49 95
DTPHB 657 60 110
Diphtheria
Toxoid668 66 101
DTP 1038 114 91
Instituto Butantan | 32
dT DT DTP and DTPHB vaccines accuracy Tetanus fraction
SAMPLESX (ToBI)(UImL)
n = 3
Official ResultIn vivo
(UImL)
n = 1
X (ToBI) x 100
Official Result(80 to 120)
DTPHB 313 28 112
DTP 497 46 108
Tetanus Toxoid 801 89 90
dT 1001 123 81
DT 1381 152 91
Instituto Butantan | 33
in vivo e in vitro correlation
dT DT DTP and DTPHB vaccines Diphtheria fraction potency analysis
Instituto Butantan | 34
in vivo e in vitro correlation
dT DT DTP and DTPHB vaccines Tetanus fraction potency analysis
Instituto Butantan | 35
Internal validated ToBI tests presented suitable to estimate the potency not only to
tetanus fraction but ALSO to diphtheria fraction in combined vaccines
Our data met all acceptance validation criteria as specificityselectivity linearity
precision (repeatability and intermediate precision) accuracy and in vitro and in vivo
concordance showed strong correlation (R=096) for both D and T components
The high relevance of these data for replacement of animal testing strongly impacts
the routine of Quality Control turning the analyses faster accurate and cheaper and
more importantly saving the lives of hundred of animals per year
Diphtheria and Tetanus combined vaccine potency by ToBI
Conclusion after internal validation
Instituto Butantan | 36
Av Vital Brasil 1500 ndash Butantatilde - Satildeo Paulo ndash SP -
Brazil
Zip code - 05503-900
(+ 55 11) 26279453
Thank you
patriciacarneirobutantangovbr
Biotech QC team
Instituto Butantan | 3
- The National Immunization Program (PNI) in Brazil is
an international reference for public health policy
- It was created in 1973 and the program seeks social
inclusion
- All Brazilians have free access to all vaccines
recommended by the World Health Organization (WHO)
Brazilian Immunization Programe (PNI )
Instituto Butantan | 4
- ANVISA (National Health Surveillance Agency) - NRA
- Butantan has GMP certifications for API (active pharmaceutical input)
for vaccines and sera lines
- Butantan has GMP certifications for two pharmaceutical forms
solutions and suspensions of sterile small volume parenteral
solutions
- Waiting for WHO inspection ndash PQ Influenza Seasonal Vaccine
GMP Certifications ndash ANVISAWHO
Instituto Butantan | 5
Butantan Institute hyperimmune sera portfolio
13 immunoglobulins
400000 vialsyear
Instituto Butantan | 6
Butantan Institute vaccines portfolio
Ongoing
Dengue
Pandemic Influenza
Quadrivalent
Influenza rBCG
DTPHB HPV DTPa
HepA mAbs
6 vaccines of the national calendar
150 million dosesyear
Instituto Butantan |
Human resources team training (multidisciplinary training including
management and innovation) dedicated group to AM and talent setting
(attractive remuneration)
Infrastructure academia-industry interaction (transfer and commercialization
of technologies import process) technological support structures (reference
centers) and technological services (conformity assessment)
Investments financing (irregularity discontinuity) and investment in RampDampI
(tax exemption and import)
Source Agecircncia Brasileira de Desenvolvimento Industrial 2012
Alternative methods - challenges
Instituto Butantan |
Regulatory approval
Alternative methods
Instituto Butantan |
Alternative methods ndash Regulatory proposal
Associated
Labs -
RENAMA
BRACVAM CONCEAANVISA and Br Ph
propose submit recommends
approves recognizesdevelopment
validation
Instituto Butantan | 10
3Rs iniciatives in Butantan Institute
Alternative methods can be defined as any method that can be used to
replace reduce or refine the use of animal in biomedical research
testing or teaching
Instituto Butantan | 11
J Virol Methods 2008 Dec154(1-2)7-13 doi 101016jjviromet200809010 Epub 2008 Oct 30
Validation of a virus neutralization potency test in BHK-21 cells for rabies
immunoglobulins in a two-center study
de Moura WC1 Gallina NM Fuches RM Romijn PC Leite JP
In vitro test (RFFIT) in rabies serum - Replacement
Save 600 mice per batch
Instituto Butantan | 12
Tetanus antitoxin potency by ToBI test - Replacement
Po
ten
cy
(UI
mL
)
Samples
-- In vivo--In vitro
Correl = 094
0
500
1000
1500
2000
2500
3000
1 2 3 4 5 6 7 8 9 10 11 12
Tetanus Antitoxin
Save 330 mice per batch
Instituto Butantan |
Single bleeding for both fractions - ReduceRefinement
Animal reduction proposal bleeding at 6 weeks for both D and T fractions
D for dT
D for DTP
T for dT and DTP
Change Control CMCB-0012418 approved in 07 may 18
Save 6 guinea-pig per batch
Instituto Butantan |
0
2
4
6
8
10
12
1 2 3 4 5 6 7 8 9 10 11
In vivo In vitro
14
dT DT DTP and DTPHB vaccines Diphtheria fraction potency analysis in vitro and in vivo - Replacement
-- In vivo -- In vitro
R=098P
ote
nc
y(U
Im
L)
Correl = 098
Save 88 guinea-pig per batch
Instituto Butantan | 15
dT DT DTP and DTPHB vaccines Tetanus fraction potency analysis in vitro and in vivo - Replacement
0
2
4
6
8
10
12
14
16
0 1 2 3 4 5 6
-- In vivo -- In vitro
Po
ten
cy
(UI
mL
)
Correl = 099
Save 220 mice per batch
Instituto Butantan | 16
LAL method for endotoxin quantification in hyperimmune sera -
Replacement
0 1 2 3 4 5 6 7 800
05
10
15
LPS standard [UEmL]
Tem
pera
ture
[C
els
ius d
eg
ree]
110
120
-100
-50
00
100
200
300
+ 10UEmL
+ 1UEml
+ 01UEml
+ 001UEml
LP
S r
eco
very
[
]
LPS standard curveIn
viv
oIn
vit
ro -
LA
L
Save 6-16 rabbits per batch
Instituto Butantan | 17
Bothrops jararaca sera potency by ToBI test - Replacement
Correl = 093
Save 330 mice per batch
Instituto Butantan | 18
Other 3Rs iniciatives in Butantan InstituteReplacement
On going in developmentinternal validation phase
MAT ndash Monocyte Activation Test (consortium by RENAMA)
Diphteria sera potency by ToBI test
Rabies potency test by ELISA (glycoproteinanti-glycoprotein)
Abnormal toxicity test banishment (already done for Influenza vaccine ndash 70 millions doses per year) on going for other
vaccines already registered (DTP DT dT HepB)
Instituto Butantan | 19
Other 3Rs iniciatives in Butantan Institute Refinement
Previous anesthesia to intracerebral challenge for
rabies and pertussis vaccines testsChange Control CMCB-0013418 approved in 14 ago 18 and
just implemented
End point to tetanus rabies and pertussis tests
Change Control CMCB-0011618 approved in 23 march 18 and
just implemented
Instituto Butantan | 20
Other 3Rs iniciatives in Butantan Institute Refinement
Pool for pyrogen and potency tests in antitoxins bulk
ready-to-fillChange Control CMCB-0013118 approved in 29 june 18 and
just implemented
Previous anesthesia to bleeding guinea-pigs
immunized for dT DT and DTP vaccines
Euthanasia by isofluorane in mice
Instituto Butantan | 21
Av Vital Brasil 1500 ndash Butantatilde - Satildeo Paulo ndash SP - Brazil
Zip code - 05503-900
(+ 55 11) 26279453
wwwbutantangovbr
Instituto Butantan | 22
Diphtheria and Tetanus combined vaccine potency
by ToBI
Alternative methods recommended by Eur Ph and WHO ndash determination of Ab titration (potency)
- T fraction ELISA andor ToBI test
- D fraction ELISA andor Vero cell tests
Our propose
- Both fractions titration by ToBI test
Instituto Butantan | 23
In vitro potency test of vaccines dT DT DTP and DTPHB
+ diphtheria and tetanus toxoid
bull ToBI test (Toxin Binding Inhibition Test)
Hendriksen et al J Biol Stand 1988 The toxin binding inhibition test as areliable in vitro alternative to the toxin neutralization test in mice for theestimation of tetanus antitoxin in human sera
Similar principle of the in vivo potency test
Decrease of 200 mice per batch of each vaccine and 400 mice per batch
of anti-tetanus serum
Instituto Butantan | 24
dT DT DTP and DTPHB vaccines selectivity
Sample + toxoidSample + both (tetanus and
diphteria) toxoid
DTPHB313 UImL 318 UImL
100 1016
DTP497 UImL 514 UImL
100 1034
Tetanus Toxoid801 UImL 724 UImL
100 904
dT1001 UImL 101 UImL
100 1001
DT1381 UImL 1448 UImL
100 1048
Tetanus antitoxin NIBSC1038 UImL 1058 UImL
100 102
All results between 80-120
Instituto Butantan | 25
dT DT DTP and DTPHB vaccines linearity Diphtheria fraction
Parameter SpecificationExperimental
Results
Correlation
coefficient (r)ge 0950 09979
Y-intercept --------- 00816
slope --------- 09753
Coefficient of
determination (r2)ge 0950 09958
Relative Standard
Deviation (RSD)le 20 1 to 6
Instituto Butantan | 26
dT DT DTP and DTPHB vaccines linearity Tetanus fraction
Parameter SpecificationExperimental
Results
Correlation
coefficient (r)ge 0950 09996
Y-intercept --------- - 03059
slope --------- 1059
Coefficient of
determination (r2)ge 0950 09992
Relative Standard
Deviation (RSD)le 20 2 to 8
Instituto Butantan | 27
dT DT DTP and DTPHB vaccines repeatability Diphtheria fraction
dT(n=7)
DT(n=7)
DTPHB(n=9)
Diphtheria Toxoid(n=8)
DTP(n=7)
Mean (UImL) 338 467 657 668 1038
Standard Deviation 043 071 062 085 107
Relative Standard Deviation
(le20)13 15 9 13 10
An
aly
st
I
dT(n=3)
DT(n=3)
DTPHB(n=3)
Diphtheria Toxoid(n=3)
DTP(n=3)
Mean (UImL) 276 399 609 582 927
Standard Deviation 021 015 025 036 068
Relative Standard Deviation
(le20)8 4 4 6 7
An
aly
st
II
Instituto Butantan | 28
dT DT DTP and DTPHB vaccines repeatability Tetanus fraction
DTPHB(n=3)
DTP(n=3)
Tetanus Toxoid(n=3)
dT(n=3)
DT(n=3)
Mean (UImL) 313 497 801 1001 1381
Standard Deviation 027 068 064 014 026
Relative Standard Deviation
(le20)9 14 8 1 2
An
aly
st
I
DTPHB(n=3)
DTP(n=3)
Tetanus Toxoid(n=3)
dT(n=3)
DT(n=3)
Mean (UImL) 321 53 874 1031 1391
Standard Deviation 012 031 099 098 023
Relative Standard Deviation
(le20)4 6 11 10 2
An
aly
st
II
Instituto Butantan | 29
dT DT DTP and DTPHB vaccines intermediate precision Diphtheria fraction
SAMPLES
ANALYSTS I + II | X(An II) ndash X(An I) | x 100
X(An I)
(le20)
Mean(UImL)
SDRSD(le20)
dT 319 047 15 18
DT 446 067 15 15
DTPHB 645 058 9 7
Diphtheria Toxoid 645 084 13 13
DTP 1005 107 11 11
RE 8992003 (ANVISA) RSD le 5)
Instituto Butantan | 30
dT DT DTP and DTPHB vaccines intermediate precision Tetanus fraction
SAMPLES
ANALYSTS I + II | X(An II) ndash X(An I) | x 100
X(An I)
(le20)
Mean(UImL)
SDRSD(le20)
DTPHB 317 019 6 3
DTP 513 051 10 7
Tetanus Toxoid 837 085 10 9
dT 1016 065 6 3
DT 1386 023 2 1
RE 8992003 (ANVISA) RSD le 5)
Instituto Butantan | 31
dT DT DTP and DTPHB vaccines accuracy Diphtheria fraction
SAMPLESX (ToBI)(UImL)
n = 7
Official ResultIn vivo
(UImL)
n = 1
X (ToBI) x 100
Official Result(80 to 120)
dT 338 30 113
DT 467 49 95
DTPHB 657 60 110
Diphtheria
Toxoid668 66 101
DTP 1038 114 91
Instituto Butantan | 32
dT DT DTP and DTPHB vaccines accuracy Tetanus fraction
SAMPLESX (ToBI)(UImL)
n = 3
Official ResultIn vivo
(UImL)
n = 1
X (ToBI) x 100
Official Result(80 to 120)
DTPHB 313 28 112
DTP 497 46 108
Tetanus Toxoid 801 89 90
dT 1001 123 81
DT 1381 152 91
Instituto Butantan | 33
in vivo e in vitro correlation
dT DT DTP and DTPHB vaccines Diphtheria fraction potency analysis
Instituto Butantan | 34
in vivo e in vitro correlation
dT DT DTP and DTPHB vaccines Tetanus fraction potency analysis
Instituto Butantan | 35
Internal validated ToBI tests presented suitable to estimate the potency not only to
tetanus fraction but ALSO to diphtheria fraction in combined vaccines
Our data met all acceptance validation criteria as specificityselectivity linearity
precision (repeatability and intermediate precision) accuracy and in vitro and in vivo
concordance showed strong correlation (R=096) for both D and T components
The high relevance of these data for replacement of animal testing strongly impacts
the routine of Quality Control turning the analyses faster accurate and cheaper and
more importantly saving the lives of hundred of animals per year
Diphtheria and Tetanus combined vaccine potency by ToBI
Conclusion after internal validation
Instituto Butantan | 36
Av Vital Brasil 1500 ndash Butantatilde - Satildeo Paulo ndash SP -
Brazil
Zip code - 05503-900
(+ 55 11) 26279453
Thank you
patriciacarneirobutantangovbr
Biotech QC team
Instituto Butantan | 4
- ANVISA (National Health Surveillance Agency) - NRA
- Butantan has GMP certifications for API (active pharmaceutical input)
for vaccines and sera lines
- Butantan has GMP certifications for two pharmaceutical forms
solutions and suspensions of sterile small volume parenteral
solutions
- Waiting for WHO inspection ndash PQ Influenza Seasonal Vaccine
GMP Certifications ndash ANVISAWHO
Instituto Butantan | 5
Butantan Institute hyperimmune sera portfolio
13 immunoglobulins
400000 vialsyear
Instituto Butantan | 6
Butantan Institute vaccines portfolio
Ongoing
Dengue
Pandemic Influenza
Quadrivalent
Influenza rBCG
DTPHB HPV DTPa
HepA mAbs
6 vaccines of the national calendar
150 million dosesyear
Instituto Butantan |
Human resources team training (multidisciplinary training including
management and innovation) dedicated group to AM and talent setting
(attractive remuneration)
Infrastructure academia-industry interaction (transfer and commercialization
of technologies import process) technological support structures (reference
centers) and technological services (conformity assessment)
Investments financing (irregularity discontinuity) and investment in RampDampI
(tax exemption and import)
Source Agecircncia Brasileira de Desenvolvimento Industrial 2012
Alternative methods - challenges
Instituto Butantan |
Regulatory approval
Alternative methods
Instituto Butantan |
Alternative methods ndash Regulatory proposal
Associated
Labs -
RENAMA
BRACVAM CONCEAANVISA and Br Ph
propose submit recommends
approves recognizesdevelopment
validation
Instituto Butantan | 10
3Rs iniciatives in Butantan Institute
Alternative methods can be defined as any method that can be used to
replace reduce or refine the use of animal in biomedical research
testing or teaching
Instituto Butantan | 11
J Virol Methods 2008 Dec154(1-2)7-13 doi 101016jjviromet200809010 Epub 2008 Oct 30
Validation of a virus neutralization potency test in BHK-21 cells for rabies
immunoglobulins in a two-center study
de Moura WC1 Gallina NM Fuches RM Romijn PC Leite JP
In vitro test (RFFIT) in rabies serum - Replacement
Save 600 mice per batch
Instituto Butantan | 12
Tetanus antitoxin potency by ToBI test - Replacement
Po
ten
cy
(UI
mL
)
Samples
-- In vivo--In vitro
Correl = 094
0
500
1000
1500
2000
2500
3000
1 2 3 4 5 6 7 8 9 10 11 12
Tetanus Antitoxin
Save 330 mice per batch
Instituto Butantan |
Single bleeding for both fractions - ReduceRefinement
Animal reduction proposal bleeding at 6 weeks for both D and T fractions
D for dT
D for DTP
T for dT and DTP
Change Control CMCB-0012418 approved in 07 may 18
Save 6 guinea-pig per batch
Instituto Butantan |
0
2
4
6
8
10
12
1 2 3 4 5 6 7 8 9 10 11
In vivo In vitro
14
dT DT DTP and DTPHB vaccines Diphtheria fraction potency analysis in vitro and in vivo - Replacement
-- In vivo -- In vitro
R=098P
ote
nc
y(U
Im
L)
Correl = 098
Save 88 guinea-pig per batch
Instituto Butantan | 15
dT DT DTP and DTPHB vaccines Tetanus fraction potency analysis in vitro and in vivo - Replacement
0
2
4
6
8
10
12
14
16
0 1 2 3 4 5 6
-- In vivo -- In vitro
Po
ten
cy
(UI
mL
)
Correl = 099
Save 220 mice per batch
Instituto Butantan | 16
LAL method for endotoxin quantification in hyperimmune sera -
Replacement
0 1 2 3 4 5 6 7 800
05
10
15
LPS standard [UEmL]
Tem
pera
ture
[C
els
ius d
eg
ree]
110
120
-100
-50
00
100
200
300
+ 10UEmL
+ 1UEml
+ 01UEml
+ 001UEml
LP
S r
eco
very
[
]
LPS standard curveIn
viv
oIn
vit
ro -
LA
L
Save 6-16 rabbits per batch
Instituto Butantan | 17
Bothrops jararaca sera potency by ToBI test - Replacement
Correl = 093
Save 330 mice per batch
Instituto Butantan | 18
Other 3Rs iniciatives in Butantan InstituteReplacement
On going in developmentinternal validation phase
MAT ndash Monocyte Activation Test (consortium by RENAMA)
Diphteria sera potency by ToBI test
Rabies potency test by ELISA (glycoproteinanti-glycoprotein)
Abnormal toxicity test banishment (already done for Influenza vaccine ndash 70 millions doses per year) on going for other
vaccines already registered (DTP DT dT HepB)
Instituto Butantan | 19
Other 3Rs iniciatives in Butantan Institute Refinement
Previous anesthesia to intracerebral challenge for
rabies and pertussis vaccines testsChange Control CMCB-0013418 approved in 14 ago 18 and
just implemented
End point to tetanus rabies and pertussis tests
Change Control CMCB-0011618 approved in 23 march 18 and
just implemented
Instituto Butantan | 20
Other 3Rs iniciatives in Butantan Institute Refinement
Pool for pyrogen and potency tests in antitoxins bulk
ready-to-fillChange Control CMCB-0013118 approved in 29 june 18 and
just implemented
Previous anesthesia to bleeding guinea-pigs
immunized for dT DT and DTP vaccines
Euthanasia by isofluorane in mice
Instituto Butantan | 21
Av Vital Brasil 1500 ndash Butantatilde - Satildeo Paulo ndash SP - Brazil
Zip code - 05503-900
(+ 55 11) 26279453
wwwbutantangovbr
Instituto Butantan | 22
Diphtheria and Tetanus combined vaccine potency
by ToBI
Alternative methods recommended by Eur Ph and WHO ndash determination of Ab titration (potency)
- T fraction ELISA andor ToBI test
- D fraction ELISA andor Vero cell tests
Our propose
- Both fractions titration by ToBI test
Instituto Butantan | 23
In vitro potency test of vaccines dT DT DTP and DTPHB
+ diphtheria and tetanus toxoid
bull ToBI test (Toxin Binding Inhibition Test)
Hendriksen et al J Biol Stand 1988 The toxin binding inhibition test as areliable in vitro alternative to the toxin neutralization test in mice for theestimation of tetanus antitoxin in human sera
Similar principle of the in vivo potency test
Decrease of 200 mice per batch of each vaccine and 400 mice per batch
of anti-tetanus serum
Instituto Butantan | 24
dT DT DTP and DTPHB vaccines selectivity
Sample + toxoidSample + both (tetanus and
diphteria) toxoid
DTPHB313 UImL 318 UImL
100 1016
DTP497 UImL 514 UImL
100 1034
Tetanus Toxoid801 UImL 724 UImL
100 904
dT1001 UImL 101 UImL
100 1001
DT1381 UImL 1448 UImL
100 1048
Tetanus antitoxin NIBSC1038 UImL 1058 UImL
100 102
All results between 80-120
Instituto Butantan | 25
dT DT DTP and DTPHB vaccines linearity Diphtheria fraction
Parameter SpecificationExperimental
Results
Correlation
coefficient (r)ge 0950 09979
Y-intercept --------- 00816
slope --------- 09753
Coefficient of
determination (r2)ge 0950 09958
Relative Standard
Deviation (RSD)le 20 1 to 6
Instituto Butantan | 26
dT DT DTP and DTPHB vaccines linearity Tetanus fraction
Parameter SpecificationExperimental
Results
Correlation
coefficient (r)ge 0950 09996
Y-intercept --------- - 03059
slope --------- 1059
Coefficient of
determination (r2)ge 0950 09992
Relative Standard
Deviation (RSD)le 20 2 to 8
Instituto Butantan | 27
dT DT DTP and DTPHB vaccines repeatability Diphtheria fraction
dT(n=7)
DT(n=7)
DTPHB(n=9)
Diphtheria Toxoid(n=8)
DTP(n=7)
Mean (UImL) 338 467 657 668 1038
Standard Deviation 043 071 062 085 107
Relative Standard Deviation
(le20)13 15 9 13 10
An
aly
st
I
dT(n=3)
DT(n=3)
DTPHB(n=3)
Diphtheria Toxoid(n=3)
DTP(n=3)
Mean (UImL) 276 399 609 582 927
Standard Deviation 021 015 025 036 068
Relative Standard Deviation
(le20)8 4 4 6 7
An
aly
st
II
Instituto Butantan | 28
dT DT DTP and DTPHB vaccines repeatability Tetanus fraction
DTPHB(n=3)
DTP(n=3)
Tetanus Toxoid(n=3)
dT(n=3)
DT(n=3)
Mean (UImL) 313 497 801 1001 1381
Standard Deviation 027 068 064 014 026
Relative Standard Deviation
(le20)9 14 8 1 2
An
aly
st
I
DTPHB(n=3)
DTP(n=3)
Tetanus Toxoid(n=3)
dT(n=3)
DT(n=3)
Mean (UImL) 321 53 874 1031 1391
Standard Deviation 012 031 099 098 023
Relative Standard Deviation
(le20)4 6 11 10 2
An
aly
st
II
Instituto Butantan | 29
dT DT DTP and DTPHB vaccines intermediate precision Diphtheria fraction
SAMPLES
ANALYSTS I + II | X(An II) ndash X(An I) | x 100
X(An I)
(le20)
Mean(UImL)
SDRSD(le20)
dT 319 047 15 18
DT 446 067 15 15
DTPHB 645 058 9 7
Diphtheria Toxoid 645 084 13 13
DTP 1005 107 11 11
RE 8992003 (ANVISA) RSD le 5)
Instituto Butantan | 30
dT DT DTP and DTPHB vaccines intermediate precision Tetanus fraction
SAMPLES
ANALYSTS I + II | X(An II) ndash X(An I) | x 100
X(An I)
(le20)
Mean(UImL)
SDRSD(le20)
DTPHB 317 019 6 3
DTP 513 051 10 7
Tetanus Toxoid 837 085 10 9
dT 1016 065 6 3
DT 1386 023 2 1
RE 8992003 (ANVISA) RSD le 5)
Instituto Butantan | 31
dT DT DTP and DTPHB vaccines accuracy Diphtheria fraction
SAMPLESX (ToBI)(UImL)
n = 7
Official ResultIn vivo
(UImL)
n = 1
X (ToBI) x 100
Official Result(80 to 120)
dT 338 30 113
DT 467 49 95
DTPHB 657 60 110
Diphtheria
Toxoid668 66 101
DTP 1038 114 91
Instituto Butantan | 32
dT DT DTP and DTPHB vaccines accuracy Tetanus fraction
SAMPLESX (ToBI)(UImL)
n = 3
Official ResultIn vivo
(UImL)
n = 1
X (ToBI) x 100
Official Result(80 to 120)
DTPHB 313 28 112
DTP 497 46 108
Tetanus Toxoid 801 89 90
dT 1001 123 81
DT 1381 152 91
Instituto Butantan | 33
in vivo e in vitro correlation
dT DT DTP and DTPHB vaccines Diphtheria fraction potency analysis
Instituto Butantan | 34
in vivo e in vitro correlation
dT DT DTP and DTPHB vaccines Tetanus fraction potency analysis
Instituto Butantan | 35
Internal validated ToBI tests presented suitable to estimate the potency not only to
tetanus fraction but ALSO to diphtheria fraction in combined vaccines
Our data met all acceptance validation criteria as specificityselectivity linearity
precision (repeatability and intermediate precision) accuracy and in vitro and in vivo
concordance showed strong correlation (R=096) for both D and T components
The high relevance of these data for replacement of animal testing strongly impacts
the routine of Quality Control turning the analyses faster accurate and cheaper and
more importantly saving the lives of hundred of animals per year
Diphtheria and Tetanus combined vaccine potency by ToBI
Conclusion after internal validation
Instituto Butantan | 36
Av Vital Brasil 1500 ndash Butantatilde - Satildeo Paulo ndash SP -
Brazil
Zip code - 05503-900
(+ 55 11) 26279453
Thank you
patriciacarneirobutantangovbr
Biotech QC team
Instituto Butantan | 5
Butantan Institute hyperimmune sera portfolio
13 immunoglobulins
400000 vialsyear
Instituto Butantan | 6
Butantan Institute vaccines portfolio
Ongoing
Dengue
Pandemic Influenza
Quadrivalent
Influenza rBCG
DTPHB HPV DTPa
HepA mAbs
6 vaccines of the national calendar
150 million dosesyear
Instituto Butantan |
Human resources team training (multidisciplinary training including
management and innovation) dedicated group to AM and talent setting
(attractive remuneration)
Infrastructure academia-industry interaction (transfer and commercialization
of technologies import process) technological support structures (reference
centers) and technological services (conformity assessment)
Investments financing (irregularity discontinuity) and investment in RampDampI
(tax exemption and import)
Source Agecircncia Brasileira de Desenvolvimento Industrial 2012
Alternative methods - challenges
Instituto Butantan |
Regulatory approval
Alternative methods
Instituto Butantan |
Alternative methods ndash Regulatory proposal
Associated
Labs -
RENAMA
BRACVAM CONCEAANVISA and Br Ph
propose submit recommends
approves recognizesdevelopment
validation
Instituto Butantan | 10
3Rs iniciatives in Butantan Institute
Alternative methods can be defined as any method that can be used to
replace reduce or refine the use of animal in biomedical research
testing or teaching
Instituto Butantan | 11
J Virol Methods 2008 Dec154(1-2)7-13 doi 101016jjviromet200809010 Epub 2008 Oct 30
Validation of a virus neutralization potency test in BHK-21 cells for rabies
immunoglobulins in a two-center study
de Moura WC1 Gallina NM Fuches RM Romijn PC Leite JP
In vitro test (RFFIT) in rabies serum - Replacement
Save 600 mice per batch
Instituto Butantan | 12
Tetanus antitoxin potency by ToBI test - Replacement
Po
ten
cy
(UI
mL
)
Samples
-- In vivo--In vitro
Correl = 094
0
500
1000
1500
2000
2500
3000
1 2 3 4 5 6 7 8 9 10 11 12
Tetanus Antitoxin
Save 330 mice per batch
Instituto Butantan |
Single bleeding for both fractions - ReduceRefinement
Animal reduction proposal bleeding at 6 weeks for both D and T fractions
D for dT
D for DTP
T for dT and DTP
Change Control CMCB-0012418 approved in 07 may 18
Save 6 guinea-pig per batch
Instituto Butantan |
0
2
4
6
8
10
12
1 2 3 4 5 6 7 8 9 10 11
In vivo In vitro
14
dT DT DTP and DTPHB vaccines Diphtheria fraction potency analysis in vitro and in vivo - Replacement
-- In vivo -- In vitro
R=098P
ote
nc
y(U
Im
L)
Correl = 098
Save 88 guinea-pig per batch
Instituto Butantan | 15
dT DT DTP and DTPHB vaccines Tetanus fraction potency analysis in vitro and in vivo - Replacement
0
2
4
6
8
10
12
14
16
0 1 2 3 4 5 6
-- In vivo -- In vitro
Po
ten
cy
(UI
mL
)
Correl = 099
Save 220 mice per batch
Instituto Butantan | 16
LAL method for endotoxin quantification in hyperimmune sera -
Replacement
0 1 2 3 4 5 6 7 800
05
10
15
LPS standard [UEmL]
Tem
pera
ture
[C
els
ius d
eg
ree]
110
120
-100
-50
00
100
200
300
+ 10UEmL
+ 1UEml
+ 01UEml
+ 001UEml
LP
S r
eco
very
[
]
LPS standard curveIn
viv
oIn
vit
ro -
LA
L
Save 6-16 rabbits per batch
Instituto Butantan | 17
Bothrops jararaca sera potency by ToBI test - Replacement
Correl = 093
Save 330 mice per batch
Instituto Butantan | 18
Other 3Rs iniciatives in Butantan InstituteReplacement
On going in developmentinternal validation phase
MAT ndash Monocyte Activation Test (consortium by RENAMA)
Diphteria sera potency by ToBI test
Rabies potency test by ELISA (glycoproteinanti-glycoprotein)
Abnormal toxicity test banishment (already done for Influenza vaccine ndash 70 millions doses per year) on going for other
vaccines already registered (DTP DT dT HepB)
Instituto Butantan | 19
Other 3Rs iniciatives in Butantan Institute Refinement
Previous anesthesia to intracerebral challenge for
rabies and pertussis vaccines testsChange Control CMCB-0013418 approved in 14 ago 18 and
just implemented
End point to tetanus rabies and pertussis tests
Change Control CMCB-0011618 approved in 23 march 18 and
just implemented
Instituto Butantan | 20
Other 3Rs iniciatives in Butantan Institute Refinement
Pool for pyrogen and potency tests in antitoxins bulk
ready-to-fillChange Control CMCB-0013118 approved in 29 june 18 and
just implemented
Previous anesthesia to bleeding guinea-pigs
immunized for dT DT and DTP vaccines
Euthanasia by isofluorane in mice
Instituto Butantan | 21
Av Vital Brasil 1500 ndash Butantatilde - Satildeo Paulo ndash SP - Brazil
Zip code - 05503-900
(+ 55 11) 26279453
wwwbutantangovbr
Instituto Butantan | 22
Diphtheria and Tetanus combined vaccine potency
by ToBI
Alternative methods recommended by Eur Ph and WHO ndash determination of Ab titration (potency)
- T fraction ELISA andor ToBI test
- D fraction ELISA andor Vero cell tests
Our propose
- Both fractions titration by ToBI test
Instituto Butantan | 23
In vitro potency test of vaccines dT DT DTP and DTPHB
+ diphtheria and tetanus toxoid
bull ToBI test (Toxin Binding Inhibition Test)
Hendriksen et al J Biol Stand 1988 The toxin binding inhibition test as areliable in vitro alternative to the toxin neutralization test in mice for theestimation of tetanus antitoxin in human sera
Similar principle of the in vivo potency test
Decrease of 200 mice per batch of each vaccine and 400 mice per batch
of anti-tetanus serum
Instituto Butantan | 24
dT DT DTP and DTPHB vaccines selectivity
Sample + toxoidSample + both (tetanus and
diphteria) toxoid
DTPHB313 UImL 318 UImL
100 1016
DTP497 UImL 514 UImL
100 1034
Tetanus Toxoid801 UImL 724 UImL
100 904
dT1001 UImL 101 UImL
100 1001
DT1381 UImL 1448 UImL
100 1048
Tetanus antitoxin NIBSC1038 UImL 1058 UImL
100 102
All results between 80-120
Instituto Butantan | 25
dT DT DTP and DTPHB vaccines linearity Diphtheria fraction
Parameter SpecificationExperimental
Results
Correlation
coefficient (r)ge 0950 09979
Y-intercept --------- 00816
slope --------- 09753
Coefficient of
determination (r2)ge 0950 09958
Relative Standard
Deviation (RSD)le 20 1 to 6
Instituto Butantan | 26
dT DT DTP and DTPHB vaccines linearity Tetanus fraction
Parameter SpecificationExperimental
Results
Correlation
coefficient (r)ge 0950 09996
Y-intercept --------- - 03059
slope --------- 1059
Coefficient of
determination (r2)ge 0950 09992
Relative Standard
Deviation (RSD)le 20 2 to 8
Instituto Butantan | 27
dT DT DTP and DTPHB vaccines repeatability Diphtheria fraction
dT(n=7)
DT(n=7)
DTPHB(n=9)
Diphtheria Toxoid(n=8)
DTP(n=7)
Mean (UImL) 338 467 657 668 1038
Standard Deviation 043 071 062 085 107
Relative Standard Deviation
(le20)13 15 9 13 10
An
aly
st
I
dT(n=3)
DT(n=3)
DTPHB(n=3)
Diphtheria Toxoid(n=3)
DTP(n=3)
Mean (UImL) 276 399 609 582 927
Standard Deviation 021 015 025 036 068
Relative Standard Deviation
(le20)8 4 4 6 7
An
aly
st
II
Instituto Butantan | 28
dT DT DTP and DTPHB vaccines repeatability Tetanus fraction
DTPHB(n=3)
DTP(n=3)
Tetanus Toxoid(n=3)
dT(n=3)
DT(n=3)
Mean (UImL) 313 497 801 1001 1381
Standard Deviation 027 068 064 014 026
Relative Standard Deviation
(le20)9 14 8 1 2
An
aly
st
I
DTPHB(n=3)
DTP(n=3)
Tetanus Toxoid(n=3)
dT(n=3)
DT(n=3)
Mean (UImL) 321 53 874 1031 1391
Standard Deviation 012 031 099 098 023
Relative Standard Deviation
(le20)4 6 11 10 2
An
aly
st
II
Instituto Butantan | 29
dT DT DTP and DTPHB vaccines intermediate precision Diphtheria fraction
SAMPLES
ANALYSTS I + II | X(An II) ndash X(An I) | x 100
X(An I)
(le20)
Mean(UImL)
SDRSD(le20)
dT 319 047 15 18
DT 446 067 15 15
DTPHB 645 058 9 7
Diphtheria Toxoid 645 084 13 13
DTP 1005 107 11 11
RE 8992003 (ANVISA) RSD le 5)
Instituto Butantan | 30
dT DT DTP and DTPHB vaccines intermediate precision Tetanus fraction
SAMPLES
ANALYSTS I + II | X(An II) ndash X(An I) | x 100
X(An I)
(le20)
Mean(UImL)
SDRSD(le20)
DTPHB 317 019 6 3
DTP 513 051 10 7
Tetanus Toxoid 837 085 10 9
dT 1016 065 6 3
DT 1386 023 2 1
RE 8992003 (ANVISA) RSD le 5)
Instituto Butantan | 31
dT DT DTP and DTPHB vaccines accuracy Diphtheria fraction
SAMPLESX (ToBI)(UImL)
n = 7
Official ResultIn vivo
(UImL)
n = 1
X (ToBI) x 100
Official Result(80 to 120)
dT 338 30 113
DT 467 49 95
DTPHB 657 60 110
Diphtheria
Toxoid668 66 101
DTP 1038 114 91
Instituto Butantan | 32
dT DT DTP and DTPHB vaccines accuracy Tetanus fraction
SAMPLESX (ToBI)(UImL)
n = 3
Official ResultIn vivo
(UImL)
n = 1
X (ToBI) x 100
Official Result(80 to 120)
DTPHB 313 28 112
DTP 497 46 108
Tetanus Toxoid 801 89 90
dT 1001 123 81
DT 1381 152 91
Instituto Butantan | 33
in vivo e in vitro correlation
dT DT DTP and DTPHB vaccines Diphtheria fraction potency analysis
Instituto Butantan | 34
in vivo e in vitro correlation
dT DT DTP and DTPHB vaccines Tetanus fraction potency analysis
Instituto Butantan | 35
Internal validated ToBI tests presented suitable to estimate the potency not only to
tetanus fraction but ALSO to diphtheria fraction in combined vaccines
Our data met all acceptance validation criteria as specificityselectivity linearity
precision (repeatability and intermediate precision) accuracy and in vitro and in vivo
concordance showed strong correlation (R=096) for both D and T components
The high relevance of these data for replacement of animal testing strongly impacts
the routine of Quality Control turning the analyses faster accurate and cheaper and
more importantly saving the lives of hundred of animals per year
Diphtheria and Tetanus combined vaccine potency by ToBI
Conclusion after internal validation
Instituto Butantan | 36
Av Vital Brasil 1500 ndash Butantatilde - Satildeo Paulo ndash SP -
Brazil
Zip code - 05503-900
(+ 55 11) 26279453
Thank you
patriciacarneirobutantangovbr
Biotech QC team
Instituto Butantan | 6
Butantan Institute vaccines portfolio
Ongoing
Dengue
Pandemic Influenza
Quadrivalent
Influenza rBCG
DTPHB HPV DTPa
HepA mAbs
6 vaccines of the national calendar
150 million dosesyear
Instituto Butantan |
Human resources team training (multidisciplinary training including
management and innovation) dedicated group to AM and talent setting
(attractive remuneration)
Infrastructure academia-industry interaction (transfer and commercialization
of technologies import process) technological support structures (reference
centers) and technological services (conformity assessment)
Investments financing (irregularity discontinuity) and investment in RampDampI
(tax exemption and import)
Source Agecircncia Brasileira de Desenvolvimento Industrial 2012
Alternative methods - challenges
Instituto Butantan |
Regulatory approval
Alternative methods
Instituto Butantan |
Alternative methods ndash Regulatory proposal
Associated
Labs -
RENAMA
BRACVAM CONCEAANVISA and Br Ph
propose submit recommends
approves recognizesdevelopment
validation
Instituto Butantan | 10
3Rs iniciatives in Butantan Institute
Alternative methods can be defined as any method that can be used to
replace reduce or refine the use of animal in biomedical research
testing or teaching
Instituto Butantan | 11
J Virol Methods 2008 Dec154(1-2)7-13 doi 101016jjviromet200809010 Epub 2008 Oct 30
Validation of a virus neutralization potency test in BHK-21 cells for rabies
immunoglobulins in a two-center study
de Moura WC1 Gallina NM Fuches RM Romijn PC Leite JP
In vitro test (RFFIT) in rabies serum - Replacement
Save 600 mice per batch
Instituto Butantan | 12
Tetanus antitoxin potency by ToBI test - Replacement
Po
ten
cy
(UI
mL
)
Samples
-- In vivo--In vitro
Correl = 094
0
500
1000
1500
2000
2500
3000
1 2 3 4 5 6 7 8 9 10 11 12
Tetanus Antitoxin
Save 330 mice per batch
Instituto Butantan |
Single bleeding for both fractions - ReduceRefinement
Animal reduction proposal bleeding at 6 weeks for both D and T fractions
D for dT
D for DTP
T for dT and DTP
Change Control CMCB-0012418 approved in 07 may 18
Save 6 guinea-pig per batch
Instituto Butantan |
0
2
4
6
8
10
12
1 2 3 4 5 6 7 8 9 10 11
In vivo In vitro
14
dT DT DTP and DTPHB vaccines Diphtheria fraction potency analysis in vitro and in vivo - Replacement
-- In vivo -- In vitro
R=098P
ote
nc
y(U
Im
L)
Correl = 098
Save 88 guinea-pig per batch
Instituto Butantan | 15
dT DT DTP and DTPHB vaccines Tetanus fraction potency analysis in vitro and in vivo - Replacement
0
2
4
6
8
10
12
14
16
0 1 2 3 4 5 6
-- In vivo -- In vitro
Po
ten
cy
(UI
mL
)
Correl = 099
Save 220 mice per batch
Instituto Butantan | 16
LAL method for endotoxin quantification in hyperimmune sera -
Replacement
0 1 2 3 4 5 6 7 800
05
10
15
LPS standard [UEmL]
Tem
pera
ture
[C
els
ius d
eg
ree]
110
120
-100
-50
00
100
200
300
+ 10UEmL
+ 1UEml
+ 01UEml
+ 001UEml
LP
S r
eco
very
[
]
LPS standard curveIn
viv
oIn
vit
ro -
LA
L
Save 6-16 rabbits per batch
Instituto Butantan | 17
Bothrops jararaca sera potency by ToBI test - Replacement
Correl = 093
Save 330 mice per batch
Instituto Butantan | 18
Other 3Rs iniciatives in Butantan InstituteReplacement
On going in developmentinternal validation phase
MAT ndash Monocyte Activation Test (consortium by RENAMA)
Diphteria sera potency by ToBI test
Rabies potency test by ELISA (glycoproteinanti-glycoprotein)
Abnormal toxicity test banishment (already done for Influenza vaccine ndash 70 millions doses per year) on going for other
vaccines already registered (DTP DT dT HepB)
Instituto Butantan | 19
Other 3Rs iniciatives in Butantan Institute Refinement
Previous anesthesia to intracerebral challenge for
rabies and pertussis vaccines testsChange Control CMCB-0013418 approved in 14 ago 18 and
just implemented
End point to tetanus rabies and pertussis tests
Change Control CMCB-0011618 approved in 23 march 18 and
just implemented
Instituto Butantan | 20
Other 3Rs iniciatives in Butantan Institute Refinement
Pool for pyrogen and potency tests in antitoxins bulk
ready-to-fillChange Control CMCB-0013118 approved in 29 june 18 and
just implemented
Previous anesthesia to bleeding guinea-pigs
immunized for dT DT and DTP vaccines
Euthanasia by isofluorane in mice
Instituto Butantan | 21
Av Vital Brasil 1500 ndash Butantatilde - Satildeo Paulo ndash SP - Brazil
Zip code - 05503-900
(+ 55 11) 26279453
wwwbutantangovbr
Instituto Butantan | 22
Diphtheria and Tetanus combined vaccine potency
by ToBI
Alternative methods recommended by Eur Ph and WHO ndash determination of Ab titration (potency)
- T fraction ELISA andor ToBI test
- D fraction ELISA andor Vero cell tests
Our propose
- Both fractions titration by ToBI test
Instituto Butantan | 23
In vitro potency test of vaccines dT DT DTP and DTPHB
+ diphtheria and tetanus toxoid
bull ToBI test (Toxin Binding Inhibition Test)
Hendriksen et al J Biol Stand 1988 The toxin binding inhibition test as areliable in vitro alternative to the toxin neutralization test in mice for theestimation of tetanus antitoxin in human sera
Similar principle of the in vivo potency test
Decrease of 200 mice per batch of each vaccine and 400 mice per batch
of anti-tetanus serum
Instituto Butantan | 24
dT DT DTP and DTPHB vaccines selectivity
Sample + toxoidSample + both (tetanus and
diphteria) toxoid
DTPHB313 UImL 318 UImL
100 1016
DTP497 UImL 514 UImL
100 1034
Tetanus Toxoid801 UImL 724 UImL
100 904
dT1001 UImL 101 UImL
100 1001
DT1381 UImL 1448 UImL
100 1048
Tetanus antitoxin NIBSC1038 UImL 1058 UImL
100 102
All results between 80-120
Instituto Butantan | 25
dT DT DTP and DTPHB vaccines linearity Diphtheria fraction
Parameter SpecificationExperimental
Results
Correlation
coefficient (r)ge 0950 09979
Y-intercept --------- 00816
slope --------- 09753
Coefficient of
determination (r2)ge 0950 09958
Relative Standard
Deviation (RSD)le 20 1 to 6
Instituto Butantan | 26
dT DT DTP and DTPHB vaccines linearity Tetanus fraction
Parameter SpecificationExperimental
Results
Correlation
coefficient (r)ge 0950 09996
Y-intercept --------- - 03059
slope --------- 1059
Coefficient of
determination (r2)ge 0950 09992
Relative Standard
Deviation (RSD)le 20 2 to 8
Instituto Butantan | 27
dT DT DTP and DTPHB vaccines repeatability Diphtheria fraction
dT(n=7)
DT(n=7)
DTPHB(n=9)
Diphtheria Toxoid(n=8)
DTP(n=7)
Mean (UImL) 338 467 657 668 1038
Standard Deviation 043 071 062 085 107
Relative Standard Deviation
(le20)13 15 9 13 10
An
aly
st
I
dT(n=3)
DT(n=3)
DTPHB(n=3)
Diphtheria Toxoid(n=3)
DTP(n=3)
Mean (UImL) 276 399 609 582 927
Standard Deviation 021 015 025 036 068
Relative Standard Deviation
(le20)8 4 4 6 7
An
aly
st
II
Instituto Butantan | 28
dT DT DTP and DTPHB vaccines repeatability Tetanus fraction
DTPHB(n=3)
DTP(n=3)
Tetanus Toxoid(n=3)
dT(n=3)
DT(n=3)
Mean (UImL) 313 497 801 1001 1381
Standard Deviation 027 068 064 014 026
Relative Standard Deviation
(le20)9 14 8 1 2
An
aly
st
I
DTPHB(n=3)
DTP(n=3)
Tetanus Toxoid(n=3)
dT(n=3)
DT(n=3)
Mean (UImL) 321 53 874 1031 1391
Standard Deviation 012 031 099 098 023
Relative Standard Deviation
(le20)4 6 11 10 2
An
aly
st
II
Instituto Butantan | 29
dT DT DTP and DTPHB vaccines intermediate precision Diphtheria fraction
SAMPLES
ANALYSTS I + II | X(An II) ndash X(An I) | x 100
X(An I)
(le20)
Mean(UImL)
SDRSD(le20)
dT 319 047 15 18
DT 446 067 15 15
DTPHB 645 058 9 7
Diphtheria Toxoid 645 084 13 13
DTP 1005 107 11 11
RE 8992003 (ANVISA) RSD le 5)
Instituto Butantan | 30
dT DT DTP and DTPHB vaccines intermediate precision Tetanus fraction
SAMPLES
ANALYSTS I + II | X(An II) ndash X(An I) | x 100
X(An I)
(le20)
Mean(UImL)
SDRSD(le20)
DTPHB 317 019 6 3
DTP 513 051 10 7
Tetanus Toxoid 837 085 10 9
dT 1016 065 6 3
DT 1386 023 2 1
RE 8992003 (ANVISA) RSD le 5)
Instituto Butantan | 31
dT DT DTP and DTPHB vaccines accuracy Diphtheria fraction
SAMPLESX (ToBI)(UImL)
n = 7
Official ResultIn vivo
(UImL)
n = 1
X (ToBI) x 100
Official Result(80 to 120)
dT 338 30 113
DT 467 49 95
DTPHB 657 60 110
Diphtheria
Toxoid668 66 101
DTP 1038 114 91
Instituto Butantan | 32
dT DT DTP and DTPHB vaccines accuracy Tetanus fraction
SAMPLESX (ToBI)(UImL)
n = 3
Official ResultIn vivo
(UImL)
n = 1
X (ToBI) x 100
Official Result(80 to 120)
DTPHB 313 28 112
DTP 497 46 108
Tetanus Toxoid 801 89 90
dT 1001 123 81
DT 1381 152 91
Instituto Butantan | 33
in vivo e in vitro correlation
dT DT DTP and DTPHB vaccines Diphtheria fraction potency analysis
Instituto Butantan | 34
in vivo e in vitro correlation
dT DT DTP and DTPHB vaccines Tetanus fraction potency analysis
Instituto Butantan | 35
Internal validated ToBI tests presented suitable to estimate the potency not only to
tetanus fraction but ALSO to diphtheria fraction in combined vaccines
Our data met all acceptance validation criteria as specificityselectivity linearity
precision (repeatability and intermediate precision) accuracy and in vitro and in vivo
concordance showed strong correlation (R=096) for both D and T components
The high relevance of these data for replacement of animal testing strongly impacts
the routine of Quality Control turning the analyses faster accurate and cheaper and
more importantly saving the lives of hundred of animals per year
Diphtheria and Tetanus combined vaccine potency by ToBI
Conclusion after internal validation
Instituto Butantan | 36
Av Vital Brasil 1500 ndash Butantatilde - Satildeo Paulo ndash SP -
Brazil
Zip code - 05503-900
(+ 55 11) 26279453
Thank you
patriciacarneirobutantangovbr
Biotech QC team
Instituto Butantan |
Human resources team training (multidisciplinary training including
management and innovation) dedicated group to AM and talent setting
(attractive remuneration)
Infrastructure academia-industry interaction (transfer and commercialization
of technologies import process) technological support structures (reference
centers) and technological services (conformity assessment)
Investments financing (irregularity discontinuity) and investment in RampDampI
(tax exemption and import)
Source Agecircncia Brasileira de Desenvolvimento Industrial 2012
Alternative methods - challenges
Instituto Butantan |
Regulatory approval
Alternative methods
Instituto Butantan |
Alternative methods ndash Regulatory proposal
Associated
Labs -
RENAMA
BRACVAM CONCEAANVISA and Br Ph
propose submit recommends
approves recognizesdevelopment
validation
Instituto Butantan | 10
3Rs iniciatives in Butantan Institute
Alternative methods can be defined as any method that can be used to
replace reduce or refine the use of animal in biomedical research
testing or teaching
Instituto Butantan | 11
J Virol Methods 2008 Dec154(1-2)7-13 doi 101016jjviromet200809010 Epub 2008 Oct 30
Validation of a virus neutralization potency test in BHK-21 cells for rabies
immunoglobulins in a two-center study
de Moura WC1 Gallina NM Fuches RM Romijn PC Leite JP
In vitro test (RFFIT) in rabies serum - Replacement
Save 600 mice per batch
Instituto Butantan | 12
Tetanus antitoxin potency by ToBI test - Replacement
Po
ten
cy
(UI
mL
)
Samples
-- In vivo--In vitro
Correl = 094
0
500
1000
1500
2000
2500
3000
1 2 3 4 5 6 7 8 9 10 11 12
Tetanus Antitoxin
Save 330 mice per batch
Instituto Butantan |
Single bleeding for both fractions - ReduceRefinement
Animal reduction proposal bleeding at 6 weeks for both D and T fractions
D for dT
D for DTP
T for dT and DTP
Change Control CMCB-0012418 approved in 07 may 18
Save 6 guinea-pig per batch
Instituto Butantan |
0
2
4
6
8
10
12
1 2 3 4 5 6 7 8 9 10 11
In vivo In vitro
14
dT DT DTP and DTPHB vaccines Diphtheria fraction potency analysis in vitro and in vivo - Replacement
-- In vivo -- In vitro
R=098P
ote
nc
y(U
Im
L)
Correl = 098
Save 88 guinea-pig per batch
Instituto Butantan | 15
dT DT DTP and DTPHB vaccines Tetanus fraction potency analysis in vitro and in vivo - Replacement
0
2
4
6
8
10
12
14
16
0 1 2 3 4 5 6
-- In vivo -- In vitro
Po
ten
cy
(UI
mL
)
Correl = 099
Save 220 mice per batch
Instituto Butantan | 16
LAL method for endotoxin quantification in hyperimmune sera -
Replacement
0 1 2 3 4 5 6 7 800
05
10
15
LPS standard [UEmL]
Tem
pera
ture
[C
els
ius d
eg
ree]
110
120
-100
-50
00
100
200
300
+ 10UEmL
+ 1UEml
+ 01UEml
+ 001UEml
LP
S r
eco
very
[
]
LPS standard curveIn
viv
oIn
vit
ro -
LA
L
Save 6-16 rabbits per batch
Instituto Butantan | 17
Bothrops jararaca sera potency by ToBI test - Replacement
Correl = 093
Save 330 mice per batch
Instituto Butantan | 18
Other 3Rs iniciatives in Butantan InstituteReplacement
On going in developmentinternal validation phase
MAT ndash Monocyte Activation Test (consortium by RENAMA)
Diphteria sera potency by ToBI test
Rabies potency test by ELISA (glycoproteinanti-glycoprotein)
Abnormal toxicity test banishment (already done for Influenza vaccine ndash 70 millions doses per year) on going for other
vaccines already registered (DTP DT dT HepB)
Instituto Butantan | 19
Other 3Rs iniciatives in Butantan Institute Refinement
Previous anesthesia to intracerebral challenge for
rabies and pertussis vaccines testsChange Control CMCB-0013418 approved in 14 ago 18 and
just implemented
End point to tetanus rabies and pertussis tests
Change Control CMCB-0011618 approved in 23 march 18 and
just implemented
Instituto Butantan | 20
Other 3Rs iniciatives in Butantan Institute Refinement
Pool for pyrogen and potency tests in antitoxins bulk
ready-to-fillChange Control CMCB-0013118 approved in 29 june 18 and
just implemented
Previous anesthesia to bleeding guinea-pigs
immunized for dT DT and DTP vaccines
Euthanasia by isofluorane in mice
Instituto Butantan | 21
Av Vital Brasil 1500 ndash Butantatilde - Satildeo Paulo ndash SP - Brazil
Zip code - 05503-900
(+ 55 11) 26279453
wwwbutantangovbr
Instituto Butantan | 22
Diphtheria and Tetanus combined vaccine potency
by ToBI
Alternative methods recommended by Eur Ph and WHO ndash determination of Ab titration (potency)
- T fraction ELISA andor ToBI test
- D fraction ELISA andor Vero cell tests
Our propose
- Both fractions titration by ToBI test
Instituto Butantan | 23
In vitro potency test of vaccines dT DT DTP and DTPHB
+ diphtheria and tetanus toxoid
bull ToBI test (Toxin Binding Inhibition Test)
Hendriksen et al J Biol Stand 1988 The toxin binding inhibition test as areliable in vitro alternative to the toxin neutralization test in mice for theestimation of tetanus antitoxin in human sera
Similar principle of the in vivo potency test
Decrease of 200 mice per batch of each vaccine and 400 mice per batch
of anti-tetanus serum
Instituto Butantan | 24
dT DT DTP and DTPHB vaccines selectivity
Sample + toxoidSample + both (tetanus and
diphteria) toxoid
DTPHB313 UImL 318 UImL
100 1016
DTP497 UImL 514 UImL
100 1034
Tetanus Toxoid801 UImL 724 UImL
100 904
dT1001 UImL 101 UImL
100 1001
DT1381 UImL 1448 UImL
100 1048
Tetanus antitoxin NIBSC1038 UImL 1058 UImL
100 102
All results between 80-120
Instituto Butantan | 25
dT DT DTP and DTPHB vaccines linearity Diphtheria fraction
Parameter SpecificationExperimental
Results
Correlation
coefficient (r)ge 0950 09979
Y-intercept --------- 00816
slope --------- 09753
Coefficient of
determination (r2)ge 0950 09958
Relative Standard
Deviation (RSD)le 20 1 to 6
Instituto Butantan | 26
dT DT DTP and DTPHB vaccines linearity Tetanus fraction
Parameter SpecificationExperimental
Results
Correlation
coefficient (r)ge 0950 09996
Y-intercept --------- - 03059
slope --------- 1059
Coefficient of
determination (r2)ge 0950 09992
Relative Standard
Deviation (RSD)le 20 2 to 8
Instituto Butantan | 27
dT DT DTP and DTPHB vaccines repeatability Diphtheria fraction
dT(n=7)
DT(n=7)
DTPHB(n=9)
Diphtheria Toxoid(n=8)
DTP(n=7)
Mean (UImL) 338 467 657 668 1038
Standard Deviation 043 071 062 085 107
Relative Standard Deviation
(le20)13 15 9 13 10
An
aly
st
I
dT(n=3)
DT(n=3)
DTPHB(n=3)
Diphtheria Toxoid(n=3)
DTP(n=3)
Mean (UImL) 276 399 609 582 927
Standard Deviation 021 015 025 036 068
Relative Standard Deviation
(le20)8 4 4 6 7
An
aly
st
II
Instituto Butantan | 28
dT DT DTP and DTPHB vaccines repeatability Tetanus fraction
DTPHB(n=3)
DTP(n=3)
Tetanus Toxoid(n=3)
dT(n=3)
DT(n=3)
Mean (UImL) 313 497 801 1001 1381
Standard Deviation 027 068 064 014 026
Relative Standard Deviation
(le20)9 14 8 1 2
An
aly
st
I
DTPHB(n=3)
DTP(n=3)
Tetanus Toxoid(n=3)
dT(n=3)
DT(n=3)
Mean (UImL) 321 53 874 1031 1391
Standard Deviation 012 031 099 098 023
Relative Standard Deviation
(le20)4 6 11 10 2
An
aly
st
II
Instituto Butantan | 29
dT DT DTP and DTPHB vaccines intermediate precision Diphtheria fraction
SAMPLES
ANALYSTS I + II | X(An II) ndash X(An I) | x 100
X(An I)
(le20)
Mean(UImL)
SDRSD(le20)
dT 319 047 15 18
DT 446 067 15 15
DTPHB 645 058 9 7
Diphtheria Toxoid 645 084 13 13
DTP 1005 107 11 11
RE 8992003 (ANVISA) RSD le 5)
Instituto Butantan | 30
dT DT DTP and DTPHB vaccines intermediate precision Tetanus fraction
SAMPLES
ANALYSTS I + II | X(An II) ndash X(An I) | x 100
X(An I)
(le20)
Mean(UImL)
SDRSD(le20)
DTPHB 317 019 6 3
DTP 513 051 10 7
Tetanus Toxoid 837 085 10 9
dT 1016 065 6 3
DT 1386 023 2 1
RE 8992003 (ANVISA) RSD le 5)
Instituto Butantan | 31
dT DT DTP and DTPHB vaccines accuracy Diphtheria fraction
SAMPLESX (ToBI)(UImL)
n = 7
Official ResultIn vivo
(UImL)
n = 1
X (ToBI) x 100
Official Result(80 to 120)
dT 338 30 113
DT 467 49 95
DTPHB 657 60 110
Diphtheria
Toxoid668 66 101
DTP 1038 114 91
Instituto Butantan | 32
dT DT DTP and DTPHB vaccines accuracy Tetanus fraction
SAMPLESX (ToBI)(UImL)
n = 3
Official ResultIn vivo
(UImL)
n = 1
X (ToBI) x 100
Official Result(80 to 120)
DTPHB 313 28 112
DTP 497 46 108
Tetanus Toxoid 801 89 90
dT 1001 123 81
DT 1381 152 91
Instituto Butantan | 33
in vivo e in vitro correlation
dT DT DTP and DTPHB vaccines Diphtheria fraction potency analysis
Instituto Butantan | 34
in vivo e in vitro correlation
dT DT DTP and DTPHB vaccines Tetanus fraction potency analysis
Instituto Butantan | 35
Internal validated ToBI tests presented suitable to estimate the potency not only to
tetanus fraction but ALSO to diphtheria fraction in combined vaccines
Our data met all acceptance validation criteria as specificityselectivity linearity
precision (repeatability and intermediate precision) accuracy and in vitro and in vivo
concordance showed strong correlation (R=096) for both D and T components
The high relevance of these data for replacement of animal testing strongly impacts
the routine of Quality Control turning the analyses faster accurate and cheaper and
more importantly saving the lives of hundred of animals per year
Diphtheria and Tetanus combined vaccine potency by ToBI
Conclusion after internal validation
Instituto Butantan | 36
Av Vital Brasil 1500 ndash Butantatilde - Satildeo Paulo ndash SP -
Brazil
Zip code - 05503-900
(+ 55 11) 26279453
Thank you
patriciacarneirobutantangovbr
Biotech QC team
Instituto Butantan |
Regulatory approval
Alternative methods
Instituto Butantan |
Alternative methods ndash Regulatory proposal
Associated
Labs -
RENAMA
BRACVAM CONCEAANVISA and Br Ph
propose submit recommends
approves recognizesdevelopment
validation
Instituto Butantan | 10
3Rs iniciatives in Butantan Institute
Alternative methods can be defined as any method that can be used to
replace reduce or refine the use of animal in biomedical research
testing or teaching
Instituto Butantan | 11
J Virol Methods 2008 Dec154(1-2)7-13 doi 101016jjviromet200809010 Epub 2008 Oct 30
Validation of a virus neutralization potency test in BHK-21 cells for rabies
immunoglobulins in a two-center study
de Moura WC1 Gallina NM Fuches RM Romijn PC Leite JP
In vitro test (RFFIT) in rabies serum - Replacement
Save 600 mice per batch
Instituto Butantan | 12
Tetanus antitoxin potency by ToBI test - Replacement
Po
ten
cy
(UI
mL
)
Samples
-- In vivo--In vitro
Correl = 094
0
500
1000
1500
2000
2500
3000
1 2 3 4 5 6 7 8 9 10 11 12
Tetanus Antitoxin
Save 330 mice per batch
Instituto Butantan |
Single bleeding for both fractions - ReduceRefinement
Animal reduction proposal bleeding at 6 weeks for both D and T fractions
D for dT
D for DTP
T for dT and DTP
Change Control CMCB-0012418 approved in 07 may 18
Save 6 guinea-pig per batch
Instituto Butantan |
0
2
4
6
8
10
12
1 2 3 4 5 6 7 8 9 10 11
In vivo In vitro
14
dT DT DTP and DTPHB vaccines Diphtheria fraction potency analysis in vitro and in vivo - Replacement
-- In vivo -- In vitro
R=098P
ote
nc
y(U
Im
L)
Correl = 098
Save 88 guinea-pig per batch
Instituto Butantan | 15
dT DT DTP and DTPHB vaccines Tetanus fraction potency analysis in vitro and in vivo - Replacement
0
2
4
6
8
10
12
14
16
0 1 2 3 4 5 6
-- In vivo -- In vitro
Po
ten
cy
(UI
mL
)
Correl = 099
Save 220 mice per batch
Instituto Butantan | 16
LAL method for endotoxin quantification in hyperimmune sera -
Replacement
0 1 2 3 4 5 6 7 800
05
10
15
LPS standard [UEmL]
Tem
pera
ture
[C
els
ius d
eg
ree]
110
120
-100
-50
00
100
200
300
+ 10UEmL
+ 1UEml
+ 01UEml
+ 001UEml
LP
S r
eco
very
[
]
LPS standard curveIn
viv
oIn
vit
ro -
LA
L
Save 6-16 rabbits per batch
Instituto Butantan | 17
Bothrops jararaca sera potency by ToBI test - Replacement
Correl = 093
Save 330 mice per batch
Instituto Butantan | 18
Other 3Rs iniciatives in Butantan InstituteReplacement
On going in developmentinternal validation phase
MAT ndash Monocyte Activation Test (consortium by RENAMA)
Diphteria sera potency by ToBI test
Rabies potency test by ELISA (glycoproteinanti-glycoprotein)
Abnormal toxicity test banishment (already done for Influenza vaccine ndash 70 millions doses per year) on going for other
vaccines already registered (DTP DT dT HepB)
Instituto Butantan | 19
Other 3Rs iniciatives in Butantan Institute Refinement
Previous anesthesia to intracerebral challenge for
rabies and pertussis vaccines testsChange Control CMCB-0013418 approved in 14 ago 18 and
just implemented
End point to tetanus rabies and pertussis tests
Change Control CMCB-0011618 approved in 23 march 18 and
just implemented
Instituto Butantan | 20
Other 3Rs iniciatives in Butantan Institute Refinement
Pool for pyrogen and potency tests in antitoxins bulk
ready-to-fillChange Control CMCB-0013118 approved in 29 june 18 and
just implemented
Previous anesthesia to bleeding guinea-pigs
immunized for dT DT and DTP vaccines
Euthanasia by isofluorane in mice
Instituto Butantan | 21
Av Vital Brasil 1500 ndash Butantatilde - Satildeo Paulo ndash SP - Brazil
Zip code - 05503-900
(+ 55 11) 26279453
wwwbutantangovbr
Instituto Butantan | 22
Diphtheria and Tetanus combined vaccine potency
by ToBI
Alternative methods recommended by Eur Ph and WHO ndash determination of Ab titration (potency)
- T fraction ELISA andor ToBI test
- D fraction ELISA andor Vero cell tests
Our propose
- Both fractions titration by ToBI test
Instituto Butantan | 23
In vitro potency test of vaccines dT DT DTP and DTPHB
+ diphtheria and tetanus toxoid
bull ToBI test (Toxin Binding Inhibition Test)
Hendriksen et al J Biol Stand 1988 The toxin binding inhibition test as areliable in vitro alternative to the toxin neutralization test in mice for theestimation of tetanus antitoxin in human sera
Similar principle of the in vivo potency test
Decrease of 200 mice per batch of each vaccine and 400 mice per batch
of anti-tetanus serum
Instituto Butantan | 24
dT DT DTP and DTPHB vaccines selectivity
Sample + toxoidSample + both (tetanus and
diphteria) toxoid
DTPHB313 UImL 318 UImL
100 1016
DTP497 UImL 514 UImL
100 1034
Tetanus Toxoid801 UImL 724 UImL
100 904
dT1001 UImL 101 UImL
100 1001
DT1381 UImL 1448 UImL
100 1048
Tetanus antitoxin NIBSC1038 UImL 1058 UImL
100 102
All results between 80-120
Instituto Butantan | 25
dT DT DTP and DTPHB vaccines linearity Diphtheria fraction
Parameter SpecificationExperimental
Results
Correlation
coefficient (r)ge 0950 09979
Y-intercept --------- 00816
slope --------- 09753
Coefficient of
determination (r2)ge 0950 09958
Relative Standard
Deviation (RSD)le 20 1 to 6
Instituto Butantan | 26
dT DT DTP and DTPHB vaccines linearity Tetanus fraction
Parameter SpecificationExperimental
Results
Correlation
coefficient (r)ge 0950 09996
Y-intercept --------- - 03059
slope --------- 1059
Coefficient of
determination (r2)ge 0950 09992
Relative Standard
Deviation (RSD)le 20 2 to 8
Instituto Butantan | 27
dT DT DTP and DTPHB vaccines repeatability Diphtheria fraction
dT(n=7)
DT(n=7)
DTPHB(n=9)
Diphtheria Toxoid(n=8)
DTP(n=7)
Mean (UImL) 338 467 657 668 1038
Standard Deviation 043 071 062 085 107
Relative Standard Deviation
(le20)13 15 9 13 10
An
aly
st
I
dT(n=3)
DT(n=3)
DTPHB(n=3)
Diphtheria Toxoid(n=3)
DTP(n=3)
Mean (UImL) 276 399 609 582 927
Standard Deviation 021 015 025 036 068
Relative Standard Deviation
(le20)8 4 4 6 7
An
aly
st
II
Instituto Butantan | 28
dT DT DTP and DTPHB vaccines repeatability Tetanus fraction
DTPHB(n=3)
DTP(n=3)
Tetanus Toxoid(n=3)
dT(n=3)
DT(n=3)
Mean (UImL) 313 497 801 1001 1381
Standard Deviation 027 068 064 014 026
Relative Standard Deviation
(le20)9 14 8 1 2
An
aly
st
I
DTPHB(n=3)
DTP(n=3)
Tetanus Toxoid(n=3)
dT(n=3)
DT(n=3)
Mean (UImL) 321 53 874 1031 1391
Standard Deviation 012 031 099 098 023
Relative Standard Deviation
(le20)4 6 11 10 2
An
aly
st
II
Instituto Butantan | 29
dT DT DTP and DTPHB vaccines intermediate precision Diphtheria fraction
SAMPLES
ANALYSTS I + II | X(An II) ndash X(An I) | x 100
X(An I)
(le20)
Mean(UImL)
SDRSD(le20)
dT 319 047 15 18
DT 446 067 15 15
DTPHB 645 058 9 7
Diphtheria Toxoid 645 084 13 13
DTP 1005 107 11 11
RE 8992003 (ANVISA) RSD le 5)
Instituto Butantan | 30
dT DT DTP and DTPHB vaccines intermediate precision Tetanus fraction
SAMPLES
ANALYSTS I + II | X(An II) ndash X(An I) | x 100
X(An I)
(le20)
Mean(UImL)
SDRSD(le20)
DTPHB 317 019 6 3
DTP 513 051 10 7
Tetanus Toxoid 837 085 10 9
dT 1016 065 6 3
DT 1386 023 2 1
RE 8992003 (ANVISA) RSD le 5)
Instituto Butantan | 31
dT DT DTP and DTPHB vaccines accuracy Diphtheria fraction
SAMPLESX (ToBI)(UImL)
n = 7
Official ResultIn vivo
(UImL)
n = 1
X (ToBI) x 100
Official Result(80 to 120)
dT 338 30 113
DT 467 49 95
DTPHB 657 60 110
Diphtheria
Toxoid668 66 101
DTP 1038 114 91
Instituto Butantan | 32
dT DT DTP and DTPHB vaccines accuracy Tetanus fraction
SAMPLESX (ToBI)(UImL)
n = 3
Official ResultIn vivo
(UImL)
n = 1
X (ToBI) x 100
Official Result(80 to 120)
DTPHB 313 28 112
DTP 497 46 108
Tetanus Toxoid 801 89 90
dT 1001 123 81
DT 1381 152 91
Instituto Butantan | 33
in vivo e in vitro correlation
dT DT DTP and DTPHB vaccines Diphtheria fraction potency analysis
Instituto Butantan | 34
in vivo e in vitro correlation
dT DT DTP and DTPHB vaccines Tetanus fraction potency analysis
Instituto Butantan | 35
Internal validated ToBI tests presented suitable to estimate the potency not only to
tetanus fraction but ALSO to diphtheria fraction in combined vaccines
Our data met all acceptance validation criteria as specificityselectivity linearity
precision (repeatability and intermediate precision) accuracy and in vitro and in vivo
concordance showed strong correlation (R=096) for both D and T components
The high relevance of these data for replacement of animal testing strongly impacts
the routine of Quality Control turning the analyses faster accurate and cheaper and
more importantly saving the lives of hundred of animals per year
Diphtheria and Tetanus combined vaccine potency by ToBI
Conclusion after internal validation
Instituto Butantan | 36
Av Vital Brasil 1500 ndash Butantatilde - Satildeo Paulo ndash SP -
Brazil
Zip code - 05503-900
(+ 55 11) 26279453
Thank you
patriciacarneirobutantangovbr
Biotech QC team
Instituto Butantan |
Alternative methods ndash Regulatory proposal
Associated
Labs -
RENAMA
BRACVAM CONCEAANVISA and Br Ph
propose submit recommends
approves recognizesdevelopment
validation
Instituto Butantan | 10
3Rs iniciatives in Butantan Institute
Alternative methods can be defined as any method that can be used to
replace reduce or refine the use of animal in biomedical research
testing or teaching
Instituto Butantan | 11
J Virol Methods 2008 Dec154(1-2)7-13 doi 101016jjviromet200809010 Epub 2008 Oct 30
Validation of a virus neutralization potency test in BHK-21 cells for rabies
immunoglobulins in a two-center study
de Moura WC1 Gallina NM Fuches RM Romijn PC Leite JP
In vitro test (RFFIT) in rabies serum - Replacement
Save 600 mice per batch
Instituto Butantan | 12
Tetanus antitoxin potency by ToBI test - Replacement
Po
ten
cy
(UI
mL
)
Samples
-- In vivo--In vitro
Correl = 094
0
500
1000
1500
2000
2500
3000
1 2 3 4 5 6 7 8 9 10 11 12
Tetanus Antitoxin
Save 330 mice per batch
Instituto Butantan |
Single bleeding for both fractions - ReduceRefinement
Animal reduction proposal bleeding at 6 weeks for both D and T fractions
D for dT
D for DTP
T for dT and DTP
Change Control CMCB-0012418 approved in 07 may 18
Save 6 guinea-pig per batch
Instituto Butantan |
0
2
4
6
8
10
12
1 2 3 4 5 6 7 8 9 10 11
In vivo In vitro
14
dT DT DTP and DTPHB vaccines Diphtheria fraction potency analysis in vitro and in vivo - Replacement
-- In vivo -- In vitro
R=098P
ote
nc
y(U
Im
L)
Correl = 098
Save 88 guinea-pig per batch
Instituto Butantan | 15
dT DT DTP and DTPHB vaccines Tetanus fraction potency analysis in vitro and in vivo - Replacement
0
2
4
6
8
10
12
14
16
0 1 2 3 4 5 6
-- In vivo -- In vitro
Po
ten
cy
(UI
mL
)
Correl = 099
Save 220 mice per batch
Instituto Butantan | 16
LAL method for endotoxin quantification in hyperimmune sera -
Replacement
0 1 2 3 4 5 6 7 800
05
10
15
LPS standard [UEmL]
Tem
pera
ture
[C
els
ius d
eg
ree]
110
120
-100
-50
00
100
200
300
+ 10UEmL
+ 1UEml
+ 01UEml
+ 001UEml
LP
S r
eco
very
[
]
LPS standard curveIn
viv
oIn
vit
ro -
LA
L
Save 6-16 rabbits per batch
Instituto Butantan | 17
Bothrops jararaca sera potency by ToBI test - Replacement
Correl = 093
Save 330 mice per batch
Instituto Butantan | 18
Other 3Rs iniciatives in Butantan InstituteReplacement
On going in developmentinternal validation phase
MAT ndash Monocyte Activation Test (consortium by RENAMA)
Diphteria sera potency by ToBI test
Rabies potency test by ELISA (glycoproteinanti-glycoprotein)
Abnormal toxicity test banishment (already done for Influenza vaccine ndash 70 millions doses per year) on going for other
vaccines already registered (DTP DT dT HepB)
Instituto Butantan | 19
Other 3Rs iniciatives in Butantan Institute Refinement
Previous anesthesia to intracerebral challenge for
rabies and pertussis vaccines testsChange Control CMCB-0013418 approved in 14 ago 18 and
just implemented
End point to tetanus rabies and pertussis tests
Change Control CMCB-0011618 approved in 23 march 18 and
just implemented
Instituto Butantan | 20
Other 3Rs iniciatives in Butantan Institute Refinement
Pool for pyrogen and potency tests in antitoxins bulk
ready-to-fillChange Control CMCB-0013118 approved in 29 june 18 and
just implemented
Previous anesthesia to bleeding guinea-pigs
immunized for dT DT and DTP vaccines
Euthanasia by isofluorane in mice
Instituto Butantan | 21
Av Vital Brasil 1500 ndash Butantatilde - Satildeo Paulo ndash SP - Brazil
Zip code - 05503-900
(+ 55 11) 26279453
wwwbutantangovbr
Instituto Butantan | 22
Diphtheria and Tetanus combined vaccine potency
by ToBI
Alternative methods recommended by Eur Ph and WHO ndash determination of Ab titration (potency)
- T fraction ELISA andor ToBI test
- D fraction ELISA andor Vero cell tests
Our propose
- Both fractions titration by ToBI test
Instituto Butantan | 23
In vitro potency test of vaccines dT DT DTP and DTPHB
+ diphtheria and tetanus toxoid
bull ToBI test (Toxin Binding Inhibition Test)
Hendriksen et al J Biol Stand 1988 The toxin binding inhibition test as areliable in vitro alternative to the toxin neutralization test in mice for theestimation of tetanus antitoxin in human sera
Similar principle of the in vivo potency test
Decrease of 200 mice per batch of each vaccine and 400 mice per batch
of anti-tetanus serum
Instituto Butantan | 24
dT DT DTP and DTPHB vaccines selectivity
Sample + toxoidSample + both (tetanus and
diphteria) toxoid
DTPHB313 UImL 318 UImL
100 1016
DTP497 UImL 514 UImL
100 1034
Tetanus Toxoid801 UImL 724 UImL
100 904
dT1001 UImL 101 UImL
100 1001
DT1381 UImL 1448 UImL
100 1048
Tetanus antitoxin NIBSC1038 UImL 1058 UImL
100 102
All results between 80-120
Instituto Butantan | 25
dT DT DTP and DTPHB vaccines linearity Diphtheria fraction
Parameter SpecificationExperimental
Results
Correlation
coefficient (r)ge 0950 09979
Y-intercept --------- 00816
slope --------- 09753
Coefficient of
determination (r2)ge 0950 09958
Relative Standard
Deviation (RSD)le 20 1 to 6
Instituto Butantan | 26
dT DT DTP and DTPHB vaccines linearity Tetanus fraction
Parameter SpecificationExperimental
Results
Correlation
coefficient (r)ge 0950 09996
Y-intercept --------- - 03059
slope --------- 1059
Coefficient of
determination (r2)ge 0950 09992
Relative Standard
Deviation (RSD)le 20 2 to 8
Instituto Butantan | 27
dT DT DTP and DTPHB vaccines repeatability Diphtheria fraction
dT(n=7)
DT(n=7)
DTPHB(n=9)
Diphtheria Toxoid(n=8)
DTP(n=7)
Mean (UImL) 338 467 657 668 1038
Standard Deviation 043 071 062 085 107
Relative Standard Deviation
(le20)13 15 9 13 10
An
aly
st
I
dT(n=3)
DT(n=3)
DTPHB(n=3)
Diphtheria Toxoid(n=3)
DTP(n=3)
Mean (UImL) 276 399 609 582 927
Standard Deviation 021 015 025 036 068
Relative Standard Deviation
(le20)8 4 4 6 7
An
aly
st
II
Instituto Butantan | 28
dT DT DTP and DTPHB vaccines repeatability Tetanus fraction
DTPHB(n=3)
DTP(n=3)
Tetanus Toxoid(n=3)
dT(n=3)
DT(n=3)
Mean (UImL) 313 497 801 1001 1381
Standard Deviation 027 068 064 014 026
Relative Standard Deviation
(le20)9 14 8 1 2
An
aly
st
I
DTPHB(n=3)
DTP(n=3)
Tetanus Toxoid(n=3)
dT(n=3)
DT(n=3)
Mean (UImL) 321 53 874 1031 1391
Standard Deviation 012 031 099 098 023
Relative Standard Deviation
(le20)4 6 11 10 2
An
aly
st
II
Instituto Butantan | 29
dT DT DTP and DTPHB vaccines intermediate precision Diphtheria fraction
SAMPLES
ANALYSTS I + II | X(An II) ndash X(An I) | x 100
X(An I)
(le20)
Mean(UImL)
SDRSD(le20)
dT 319 047 15 18
DT 446 067 15 15
DTPHB 645 058 9 7
Diphtheria Toxoid 645 084 13 13
DTP 1005 107 11 11
RE 8992003 (ANVISA) RSD le 5)
Instituto Butantan | 30
dT DT DTP and DTPHB vaccines intermediate precision Tetanus fraction
SAMPLES
ANALYSTS I + II | X(An II) ndash X(An I) | x 100
X(An I)
(le20)
Mean(UImL)
SDRSD(le20)
DTPHB 317 019 6 3
DTP 513 051 10 7
Tetanus Toxoid 837 085 10 9
dT 1016 065 6 3
DT 1386 023 2 1
RE 8992003 (ANVISA) RSD le 5)
Instituto Butantan | 31
dT DT DTP and DTPHB vaccines accuracy Diphtheria fraction
SAMPLESX (ToBI)(UImL)
n = 7
Official ResultIn vivo
(UImL)
n = 1
X (ToBI) x 100
Official Result(80 to 120)
dT 338 30 113
DT 467 49 95
DTPHB 657 60 110
Diphtheria
Toxoid668 66 101
DTP 1038 114 91
Instituto Butantan | 32
dT DT DTP and DTPHB vaccines accuracy Tetanus fraction
SAMPLESX (ToBI)(UImL)
n = 3
Official ResultIn vivo
(UImL)
n = 1
X (ToBI) x 100
Official Result(80 to 120)
DTPHB 313 28 112
DTP 497 46 108
Tetanus Toxoid 801 89 90
dT 1001 123 81
DT 1381 152 91
Instituto Butantan | 33
in vivo e in vitro correlation
dT DT DTP and DTPHB vaccines Diphtheria fraction potency analysis
Instituto Butantan | 34
in vivo e in vitro correlation
dT DT DTP and DTPHB vaccines Tetanus fraction potency analysis
Instituto Butantan | 35
Internal validated ToBI tests presented suitable to estimate the potency not only to
tetanus fraction but ALSO to diphtheria fraction in combined vaccines
Our data met all acceptance validation criteria as specificityselectivity linearity
precision (repeatability and intermediate precision) accuracy and in vitro and in vivo
concordance showed strong correlation (R=096) for both D and T components
The high relevance of these data for replacement of animal testing strongly impacts
the routine of Quality Control turning the analyses faster accurate and cheaper and
more importantly saving the lives of hundred of animals per year
Diphtheria and Tetanus combined vaccine potency by ToBI
Conclusion after internal validation
Instituto Butantan | 36
Av Vital Brasil 1500 ndash Butantatilde - Satildeo Paulo ndash SP -
Brazil
Zip code - 05503-900
(+ 55 11) 26279453
Thank you
patriciacarneirobutantangovbr
Biotech QC team
Instituto Butantan | 10
3Rs iniciatives in Butantan Institute
Alternative methods can be defined as any method that can be used to
replace reduce or refine the use of animal in biomedical research
testing or teaching
Instituto Butantan | 11
J Virol Methods 2008 Dec154(1-2)7-13 doi 101016jjviromet200809010 Epub 2008 Oct 30
Validation of a virus neutralization potency test in BHK-21 cells for rabies
immunoglobulins in a two-center study
de Moura WC1 Gallina NM Fuches RM Romijn PC Leite JP
In vitro test (RFFIT) in rabies serum - Replacement
Save 600 mice per batch
Instituto Butantan | 12
Tetanus antitoxin potency by ToBI test - Replacement
Po
ten
cy
(UI
mL
)
Samples
-- In vivo--In vitro
Correl = 094
0
500
1000
1500
2000
2500
3000
1 2 3 4 5 6 7 8 9 10 11 12
Tetanus Antitoxin
Save 330 mice per batch
Instituto Butantan |
Single bleeding for both fractions - ReduceRefinement
Animal reduction proposal bleeding at 6 weeks for both D and T fractions
D for dT
D for DTP
T for dT and DTP
Change Control CMCB-0012418 approved in 07 may 18
Save 6 guinea-pig per batch
Instituto Butantan |
0
2
4
6
8
10
12
1 2 3 4 5 6 7 8 9 10 11
In vivo In vitro
14
dT DT DTP and DTPHB vaccines Diphtheria fraction potency analysis in vitro and in vivo - Replacement
-- In vivo -- In vitro
R=098P
ote
nc
y(U
Im
L)
Correl = 098
Save 88 guinea-pig per batch
Instituto Butantan | 15
dT DT DTP and DTPHB vaccines Tetanus fraction potency analysis in vitro and in vivo - Replacement
0
2
4
6
8
10
12
14
16
0 1 2 3 4 5 6
-- In vivo -- In vitro
Po
ten
cy
(UI
mL
)
Correl = 099
Save 220 mice per batch
Instituto Butantan | 16
LAL method for endotoxin quantification in hyperimmune sera -
Replacement
0 1 2 3 4 5 6 7 800
05
10
15
LPS standard [UEmL]
Tem
pera
ture
[C
els
ius d
eg
ree]
110
120
-100
-50
00
100
200
300
+ 10UEmL
+ 1UEml
+ 01UEml
+ 001UEml
LP
S r
eco
very
[
]
LPS standard curveIn
viv
oIn
vit
ro -
LA
L
Save 6-16 rabbits per batch
Instituto Butantan | 17
Bothrops jararaca sera potency by ToBI test - Replacement
Correl = 093
Save 330 mice per batch
Instituto Butantan | 18
Other 3Rs iniciatives in Butantan InstituteReplacement
On going in developmentinternal validation phase
MAT ndash Monocyte Activation Test (consortium by RENAMA)
Diphteria sera potency by ToBI test
Rabies potency test by ELISA (glycoproteinanti-glycoprotein)
Abnormal toxicity test banishment (already done for Influenza vaccine ndash 70 millions doses per year) on going for other
vaccines already registered (DTP DT dT HepB)
Instituto Butantan | 19
Other 3Rs iniciatives in Butantan Institute Refinement
Previous anesthesia to intracerebral challenge for
rabies and pertussis vaccines testsChange Control CMCB-0013418 approved in 14 ago 18 and
just implemented
End point to tetanus rabies and pertussis tests
Change Control CMCB-0011618 approved in 23 march 18 and
just implemented
Instituto Butantan | 20
Other 3Rs iniciatives in Butantan Institute Refinement
Pool for pyrogen and potency tests in antitoxins bulk
ready-to-fillChange Control CMCB-0013118 approved in 29 june 18 and
just implemented
Previous anesthesia to bleeding guinea-pigs
immunized for dT DT and DTP vaccines
Euthanasia by isofluorane in mice
Instituto Butantan | 21
Av Vital Brasil 1500 ndash Butantatilde - Satildeo Paulo ndash SP - Brazil
Zip code - 05503-900
(+ 55 11) 26279453
wwwbutantangovbr
Instituto Butantan | 22
Diphtheria and Tetanus combined vaccine potency
by ToBI
Alternative methods recommended by Eur Ph and WHO ndash determination of Ab titration (potency)
- T fraction ELISA andor ToBI test
- D fraction ELISA andor Vero cell tests
Our propose
- Both fractions titration by ToBI test
Instituto Butantan | 23
In vitro potency test of vaccines dT DT DTP and DTPHB
+ diphtheria and tetanus toxoid
bull ToBI test (Toxin Binding Inhibition Test)
Hendriksen et al J Biol Stand 1988 The toxin binding inhibition test as areliable in vitro alternative to the toxin neutralization test in mice for theestimation of tetanus antitoxin in human sera
Similar principle of the in vivo potency test
Decrease of 200 mice per batch of each vaccine and 400 mice per batch
of anti-tetanus serum
Instituto Butantan | 24
dT DT DTP and DTPHB vaccines selectivity
Sample + toxoidSample + both (tetanus and
diphteria) toxoid
DTPHB313 UImL 318 UImL
100 1016
DTP497 UImL 514 UImL
100 1034
Tetanus Toxoid801 UImL 724 UImL
100 904
dT1001 UImL 101 UImL
100 1001
DT1381 UImL 1448 UImL
100 1048
Tetanus antitoxin NIBSC1038 UImL 1058 UImL
100 102
All results between 80-120
Instituto Butantan | 25
dT DT DTP and DTPHB vaccines linearity Diphtheria fraction
Parameter SpecificationExperimental
Results
Correlation
coefficient (r)ge 0950 09979
Y-intercept --------- 00816
slope --------- 09753
Coefficient of
determination (r2)ge 0950 09958
Relative Standard
Deviation (RSD)le 20 1 to 6
Instituto Butantan | 26
dT DT DTP and DTPHB vaccines linearity Tetanus fraction
Parameter SpecificationExperimental
Results
Correlation
coefficient (r)ge 0950 09996
Y-intercept --------- - 03059
slope --------- 1059
Coefficient of
determination (r2)ge 0950 09992
Relative Standard
Deviation (RSD)le 20 2 to 8
Instituto Butantan | 27
dT DT DTP and DTPHB vaccines repeatability Diphtheria fraction
dT(n=7)
DT(n=7)
DTPHB(n=9)
Diphtheria Toxoid(n=8)
DTP(n=7)
Mean (UImL) 338 467 657 668 1038
Standard Deviation 043 071 062 085 107
Relative Standard Deviation
(le20)13 15 9 13 10
An
aly
st
I
dT(n=3)
DT(n=3)
DTPHB(n=3)
Diphtheria Toxoid(n=3)
DTP(n=3)
Mean (UImL) 276 399 609 582 927
Standard Deviation 021 015 025 036 068
Relative Standard Deviation
(le20)8 4 4 6 7
An
aly
st
II
Instituto Butantan | 28
dT DT DTP and DTPHB vaccines repeatability Tetanus fraction
DTPHB(n=3)
DTP(n=3)
Tetanus Toxoid(n=3)
dT(n=3)
DT(n=3)
Mean (UImL) 313 497 801 1001 1381
Standard Deviation 027 068 064 014 026
Relative Standard Deviation
(le20)9 14 8 1 2
An
aly
st
I
DTPHB(n=3)
DTP(n=3)
Tetanus Toxoid(n=3)
dT(n=3)
DT(n=3)
Mean (UImL) 321 53 874 1031 1391
Standard Deviation 012 031 099 098 023
Relative Standard Deviation
(le20)4 6 11 10 2
An
aly
st
II
Instituto Butantan | 29
dT DT DTP and DTPHB vaccines intermediate precision Diphtheria fraction
SAMPLES
ANALYSTS I + II | X(An II) ndash X(An I) | x 100
X(An I)
(le20)
Mean(UImL)
SDRSD(le20)
dT 319 047 15 18
DT 446 067 15 15
DTPHB 645 058 9 7
Diphtheria Toxoid 645 084 13 13
DTP 1005 107 11 11
RE 8992003 (ANVISA) RSD le 5)
Instituto Butantan | 30
dT DT DTP and DTPHB vaccines intermediate precision Tetanus fraction
SAMPLES
ANALYSTS I + II | X(An II) ndash X(An I) | x 100
X(An I)
(le20)
Mean(UImL)
SDRSD(le20)
DTPHB 317 019 6 3
DTP 513 051 10 7
Tetanus Toxoid 837 085 10 9
dT 1016 065 6 3
DT 1386 023 2 1
RE 8992003 (ANVISA) RSD le 5)
Instituto Butantan | 31
dT DT DTP and DTPHB vaccines accuracy Diphtheria fraction
SAMPLESX (ToBI)(UImL)
n = 7
Official ResultIn vivo
(UImL)
n = 1
X (ToBI) x 100
Official Result(80 to 120)
dT 338 30 113
DT 467 49 95
DTPHB 657 60 110
Diphtheria
Toxoid668 66 101
DTP 1038 114 91
Instituto Butantan | 32
dT DT DTP and DTPHB vaccines accuracy Tetanus fraction
SAMPLESX (ToBI)(UImL)
n = 3
Official ResultIn vivo
(UImL)
n = 1
X (ToBI) x 100
Official Result(80 to 120)
DTPHB 313 28 112
DTP 497 46 108
Tetanus Toxoid 801 89 90
dT 1001 123 81
DT 1381 152 91
Instituto Butantan | 33
in vivo e in vitro correlation
dT DT DTP and DTPHB vaccines Diphtheria fraction potency analysis
Instituto Butantan | 34
in vivo e in vitro correlation
dT DT DTP and DTPHB vaccines Tetanus fraction potency analysis
Instituto Butantan | 35
Internal validated ToBI tests presented suitable to estimate the potency not only to
tetanus fraction but ALSO to diphtheria fraction in combined vaccines
Our data met all acceptance validation criteria as specificityselectivity linearity
precision (repeatability and intermediate precision) accuracy and in vitro and in vivo
concordance showed strong correlation (R=096) for both D and T components
The high relevance of these data for replacement of animal testing strongly impacts
the routine of Quality Control turning the analyses faster accurate and cheaper and
more importantly saving the lives of hundred of animals per year
Diphtheria and Tetanus combined vaccine potency by ToBI
Conclusion after internal validation
Instituto Butantan | 36
Av Vital Brasil 1500 ndash Butantatilde - Satildeo Paulo ndash SP -
Brazil
Zip code - 05503-900
(+ 55 11) 26279453
Thank you
patriciacarneirobutantangovbr
Biotech QC team
Instituto Butantan | 11
J Virol Methods 2008 Dec154(1-2)7-13 doi 101016jjviromet200809010 Epub 2008 Oct 30
Validation of a virus neutralization potency test in BHK-21 cells for rabies
immunoglobulins in a two-center study
de Moura WC1 Gallina NM Fuches RM Romijn PC Leite JP
In vitro test (RFFIT) in rabies serum - Replacement
Save 600 mice per batch
Instituto Butantan | 12
Tetanus antitoxin potency by ToBI test - Replacement
Po
ten
cy
(UI
mL
)
Samples
-- In vivo--In vitro
Correl = 094
0
500
1000
1500
2000
2500
3000
1 2 3 4 5 6 7 8 9 10 11 12
Tetanus Antitoxin
Save 330 mice per batch
Instituto Butantan |
Single bleeding for both fractions - ReduceRefinement
Animal reduction proposal bleeding at 6 weeks for both D and T fractions
D for dT
D for DTP
T for dT and DTP
Change Control CMCB-0012418 approved in 07 may 18
Save 6 guinea-pig per batch
Instituto Butantan |
0
2
4
6
8
10
12
1 2 3 4 5 6 7 8 9 10 11
In vivo In vitro
14
dT DT DTP and DTPHB vaccines Diphtheria fraction potency analysis in vitro and in vivo - Replacement
-- In vivo -- In vitro
R=098P
ote
nc
y(U
Im
L)
Correl = 098
Save 88 guinea-pig per batch
Instituto Butantan | 15
dT DT DTP and DTPHB vaccines Tetanus fraction potency analysis in vitro and in vivo - Replacement
0
2
4
6
8
10
12
14
16
0 1 2 3 4 5 6
-- In vivo -- In vitro
Po
ten
cy
(UI
mL
)
Correl = 099
Save 220 mice per batch
Instituto Butantan | 16
LAL method for endotoxin quantification in hyperimmune sera -
Replacement
0 1 2 3 4 5 6 7 800
05
10
15
LPS standard [UEmL]
Tem
pera
ture
[C
els
ius d
eg
ree]
110
120
-100
-50
00
100
200
300
+ 10UEmL
+ 1UEml
+ 01UEml
+ 001UEml
LP
S r
eco
very
[
]
LPS standard curveIn
viv
oIn
vit
ro -
LA
L
Save 6-16 rabbits per batch
Instituto Butantan | 17
Bothrops jararaca sera potency by ToBI test - Replacement
Correl = 093
Save 330 mice per batch
Instituto Butantan | 18
Other 3Rs iniciatives in Butantan InstituteReplacement
On going in developmentinternal validation phase
MAT ndash Monocyte Activation Test (consortium by RENAMA)
Diphteria sera potency by ToBI test
Rabies potency test by ELISA (glycoproteinanti-glycoprotein)
Abnormal toxicity test banishment (already done for Influenza vaccine ndash 70 millions doses per year) on going for other
vaccines already registered (DTP DT dT HepB)
Instituto Butantan | 19
Other 3Rs iniciatives in Butantan Institute Refinement
Previous anesthesia to intracerebral challenge for
rabies and pertussis vaccines testsChange Control CMCB-0013418 approved in 14 ago 18 and
just implemented
End point to tetanus rabies and pertussis tests
Change Control CMCB-0011618 approved in 23 march 18 and
just implemented
Instituto Butantan | 20
Other 3Rs iniciatives in Butantan Institute Refinement
Pool for pyrogen and potency tests in antitoxins bulk
ready-to-fillChange Control CMCB-0013118 approved in 29 june 18 and
just implemented
Previous anesthesia to bleeding guinea-pigs
immunized for dT DT and DTP vaccines
Euthanasia by isofluorane in mice
Instituto Butantan | 21
Av Vital Brasil 1500 ndash Butantatilde - Satildeo Paulo ndash SP - Brazil
Zip code - 05503-900
(+ 55 11) 26279453
wwwbutantangovbr
Instituto Butantan | 22
Diphtheria and Tetanus combined vaccine potency
by ToBI
Alternative methods recommended by Eur Ph and WHO ndash determination of Ab titration (potency)
- T fraction ELISA andor ToBI test
- D fraction ELISA andor Vero cell tests
Our propose
- Both fractions titration by ToBI test
Instituto Butantan | 23
In vitro potency test of vaccines dT DT DTP and DTPHB
+ diphtheria and tetanus toxoid
bull ToBI test (Toxin Binding Inhibition Test)
Hendriksen et al J Biol Stand 1988 The toxin binding inhibition test as areliable in vitro alternative to the toxin neutralization test in mice for theestimation of tetanus antitoxin in human sera
Similar principle of the in vivo potency test
Decrease of 200 mice per batch of each vaccine and 400 mice per batch
of anti-tetanus serum
Instituto Butantan | 24
dT DT DTP and DTPHB vaccines selectivity
Sample + toxoidSample + both (tetanus and
diphteria) toxoid
DTPHB313 UImL 318 UImL
100 1016
DTP497 UImL 514 UImL
100 1034
Tetanus Toxoid801 UImL 724 UImL
100 904
dT1001 UImL 101 UImL
100 1001
DT1381 UImL 1448 UImL
100 1048
Tetanus antitoxin NIBSC1038 UImL 1058 UImL
100 102
All results between 80-120
Instituto Butantan | 25
dT DT DTP and DTPHB vaccines linearity Diphtheria fraction
Parameter SpecificationExperimental
Results
Correlation
coefficient (r)ge 0950 09979
Y-intercept --------- 00816
slope --------- 09753
Coefficient of
determination (r2)ge 0950 09958
Relative Standard
Deviation (RSD)le 20 1 to 6
Instituto Butantan | 26
dT DT DTP and DTPHB vaccines linearity Tetanus fraction
Parameter SpecificationExperimental
Results
Correlation
coefficient (r)ge 0950 09996
Y-intercept --------- - 03059
slope --------- 1059
Coefficient of
determination (r2)ge 0950 09992
Relative Standard
Deviation (RSD)le 20 2 to 8
Instituto Butantan | 27
dT DT DTP and DTPHB vaccines repeatability Diphtheria fraction
dT(n=7)
DT(n=7)
DTPHB(n=9)
Diphtheria Toxoid(n=8)
DTP(n=7)
Mean (UImL) 338 467 657 668 1038
Standard Deviation 043 071 062 085 107
Relative Standard Deviation
(le20)13 15 9 13 10
An
aly
st
I
dT(n=3)
DT(n=3)
DTPHB(n=3)
Diphtheria Toxoid(n=3)
DTP(n=3)
Mean (UImL) 276 399 609 582 927
Standard Deviation 021 015 025 036 068
Relative Standard Deviation
(le20)8 4 4 6 7
An
aly
st
II
Instituto Butantan | 28
dT DT DTP and DTPHB vaccines repeatability Tetanus fraction
DTPHB(n=3)
DTP(n=3)
Tetanus Toxoid(n=3)
dT(n=3)
DT(n=3)
Mean (UImL) 313 497 801 1001 1381
Standard Deviation 027 068 064 014 026
Relative Standard Deviation
(le20)9 14 8 1 2
An
aly
st
I
DTPHB(n=3)
DTP(n=3)
Tetanus Toxoid(n=3)
dT(n=3)
DT(n=3)
Mean (UImL) 321 53 874 1031 1391
Standard Deviation 012 031 099 098 023
Relative Standard Deviation
(le20)4 6 11 10 2
An
aly
st
II
Instituto Butantan | 29
dT DT DTP and DTPHB vaccines intermediate precision Diphtheria fraction
SAMPLES
ANALYSTS I + II | X(An II) ndash X(An I) | x 100
X(An I)
(le20)
Mean(UImL)
SDRSD(le20)
dT 319 047 15 18
DT 446 067 15 15
DTPHB 645 058 9 7
Diphtheria Toxoid 645 084 13 13
DTP 1005 107 11 11
RE 8992003 (ANVISA) RSD le 5)
Instituto Butantan | 30
dT DT DTP and DTPHB vaccines intermediate precision Tetanus fraction
SAMPLES
ANALYSTS I + II | X(An II) ndash X(An I) | x 100
X(An I)
(le20)
Mean(UImL)
SDRSD(le20)
DTPHB 317 019 6 3
DTP 513 051 10 7
Tetanus Toxoid 837 085 10 9
dT 1016 065 6 3
DT 1386 023 2 1
RE 8992003 (ANVISA) RSD le 5)
Instituto Butantan | 31
dT DT DTP and DTPHB vaccines accuracy Diphtheria fraction
SAMPLESX (ToBI)(UImL)
n = 7
Official ResultIn vivo
(UImL)
n = 1
X (ToBI) x 100
Official Result(80 to 120)
dT 338 30 113
DT 467 49 95
DTPHB 657 60 110
Diphtheria
Toxoid668 66 101
DTP 1038 114 91
Instituto Butantan | 32
dT DT DTP and DTPHB vaccines accuracy Tetanus fraction
SAMPLESX (ToBI)(UImL)
n = 3
Official ResultIn vivo
(UImL)
n = 1
X (ToBI) x 100
Official Result(80 to 120)
DTPHB 313 28 112
DTP 497 46 108
Tetanus Toxoid 801 89 90
dT 1001 123 81
DT 1381 152 91
Instituto Butantan | 33
in vivo e in vitro correlation
dT DT DTP and DTPHB vaccines Diphtheria fraction potency analysis
Instituto Butantan | 34
in vivo e in vitro correlation
dT DT DTP and DTPHB vaccines Tetanus fraction potency analysis
Instituto Butantan | 35
Internal validated ToBI tests presented suitable to estimate the potency not only to
tetanus fraction but ALSO to diphtheria fraction in combined vaccines
Our data met all acceptance validation criteria as specificityselectivity linearity
precision (repeatability and intermediate precision) accuracy and in vitro and in vivo
concordance showed strong correlation (R=096) for both D and T components
The high relevance of these data for replacement of animal testing strongly impacts
the routine of Quality Control turning the analyses faster accurate and cheaper and
more importantly saving the lives of hundred of animals per year
Diphtheria and Tetanus combined vaccine potency by ToBI
Conclusion after internal validation
Instituto Butantan | 36
Av Vital Brasil 1500 ndash Butantatilde - Satildeo Paulo ndash SP -
Brazil
Zip code - 05503-900
(+ 55 11) 26279453
Thank you
patriciacarneirobutantangovbr
Biotech QC team
Instituto Butantan | 12
Tetanus antitoxin potency by ToBI test - Replacement
Po
ten
cy
(UI
mL
)
Samples
-- In vivo--In vitro
Correl = 094
0
500
1000
1500
2000
2500
3000
1 2 3 4 5 6 7 8 9 10 11 12
Tetanus Antitoxin
Save 330 mice per batch
Instituto Butantan |
Single bleeding for both fractions - ReduceRefinement
Animal reduction proposal bleeding at 6 weeks for both D and T fractions
D for dT
D for DTP
T for dT and DTP
Change Control CMCB-0012418 approved in 07 may 18
Save 6 guinea-pig per batch
Instituto Butantan |
0
2
4
6
8
10
12
1 2 3 4 5 6 7 8 9 10 11
In vivo In vitro
14
dT DT DTP and DTPHB vaccines Diphtheria fraction potency analysis in vitro and in vivo - Replacement
-- In vivo -- In vitro
R=098P
ote
nc
y(U
Im
L)
Correl = 098
Save 88 guinea-pig per batch
Instituto Butantan | 15
dT DT DTP and DTPHB vaccines Tetanus fraction potency analysis in vitro and in vivo - Replacement
0
2
4
6
8
10
12
14
16
0 1 2 3 4 5 6
-- In vivo -- In vitro
Po
ten
cy
(UI
mL
)
Correl = 099
Save 220 mice per batch
Instituto Butantan | 16
LAL method for endotoxin quantification in hyperimmune sera -
Replacement
0 1 2 3 4 5 6 7 800
05
10
15
LPS standard [UEmL]
Tem
pera
ture
[C
els
ius d
eg
ree]
110
120
-100
-50
00
100
200
300
+ 10UEmL
+ 1UEml
+ 01UEml
+ 001UEml
LP
S r
eco
very
[
]
LPS standard curveIn
viv
oIn
vit
ro -
LA
L
Save 6-16 rabbits per batch
Instituto Butantan | 17
Bothrops jararaca sera potency by ToBI test - Replacement
Correl = 093
Save 330 mice per batch
Instituto Butantan | 18
Other 3Rs iniciatives in Butantan InstituteReplacement
On going in developmentinternal validation phase
MAT ndash Monocyte Activation Test (consortium by RENAMA)
Diphteria sera potency by ToBI test
Rabies potency test by ELISA (glycoproteinanti-glycoprotein)
Abnormal toxicity test banishment (already done for Influenza vaccine ndash 70 millions doses per year) on going for other
vaccines already registered (DTP DT dT HepB)
Instituto Butantan | 19
Other 3Rs iniciatives in Butantan Institute Refinement
Previous anesthesia to intracerebral challenge for
rabies and pertussis vaccines testsChange Control CMCB-0013418 approved in 14 ago 18 and
just implemented
End point to tetanus rabies and pertussis tests
Change Control CMCB-0011618 approved in 23 march 18 and
just implemented
Instituto Butantan | 20
Other 3Rs iniciatives in Butantan Institute Refinement
Pool for pyrogen and potency tests in antitoxins bulk
ready-to-fillChange Control CMCB-0013118 approved in 29 june 18 and
just implemented
Previous anesthesia to bleeding guinea-pigs
immunized for dT DT and DTP vaccines
Euthanasia by isofluorane in mice
Instituto Butantan | 21
Av Vital Brasil 1500 ndash Butantatilde - Satildeo Paulo ndash SP - Brazil
Zip code - 05503-900
(+ 55 11) 26279453
wwwbutantangovbr
Instituto Butantan | 22
Diphtheria and Tetanus combined vaccine potency
by ToBI
Alternative methods recommended by Eur Ph and WHO ndash determination of Ab titration (potency)
- T fraction ELISA andor ToBI test
- D fraction ELISA andor Vero cell tests
Our propose
- Both fractions titration by ToBI test
Instituto Butantan | 23
In vitro potency test of vaccines dT DT DTP and DTPHB
+ diphtheria and tetanus toxoid
bull ToBI test (Toxin Binding Inhibition Test)
Hendriksen et al J Biol Stand 1988 The toxin binding inhibition test as areliable in vitro alternative to the toxin neutralization test in mice for theestimation of tetanus antitoxin in human sera
Similar principle of the in vivo potency test
Decrease of 200 mice per batch of each vaccine and 400 mice per batch
of anti-tetanus serum
Instituto Butantan | 24
dT DT DTP and DTPHB vaccines selectivity
Sample + toxoidSample + both (tetanus and
diphteria) toxoid
DTPHB313 UImL 318 UImL
100 1016
DTP497 UImL 514 UImL
100 1034
Tetanus Toxoid801 UImL 724 UImL
100 904
dT1001 UImL 101 UImL
100 1001
DT1381 UImL 1448 UImL
100 1048
Tetanus antitoxin NIBSC1038 UImL 1058 UImL
100 102
All results between 80-120
Instituto Butantan | 25
dT DT DTP and DTPHB vaccines linearity Diphtheria fraction
Parameter SpecificationExperimental
Results
Correlation
coefficient (r)ge 0950 09979
Y-intercept --------- 00816
slope --------- 09753
Coefficient of
determination (r2)ge 0950 09958
Relative Standard
Deviation (RSD)le 20 1 to 6
Instituto Butantan | 26
dT DT DTP and DTPHB vaccines linearity Tetanus fraction
Parameter SpecificationExperimental
Results
Correlation
coefficient (r)ge 0950 09996
Y-intercept --------- - 03059
slope --------- 1059
Coefficient of
determination (r2)ge 0950 09992
Relative Standard
Deviation (RSD)le 20 2 to 8
Instituto Butantan | 27
dT DT DTP and DTPHB vaccines repeatability Diphtheria fraction
dT(n=7)
DT(n=7)
DTPHB(n=9)
Diphtheria Toxoid(n=8)
DTP(n=7)
Mean (UImL) 338 467 657 668 1038
Standard Deviation 043 071 062 085 107
Relative Standard Deviation
(le20)13 15 9 13 10
An
aly
st
I
dT(n=3)
DT(n=3)
DTPHB(n=3)
Diphtheria Toxoid(n=3)
DTP(n=3)
Mean (UImL) 276 399 609 582 927
Standard Deviation 021 015 025 036 068
Relative Standard Deviation
(le20)8 4 4 6 7
An
aly
st
II
Instituto Butantan | 28
dT DT DTP and DTPHB vaccines repeatability Tetanus fraction
DTPHB(n=3)
DTP(n=3)
Tetanus Toxoid(n=3)
dT(n=3)
DT(n=3)
Mean (UImL) 313 497 801 1001 1381
Standard Deviation 027 068 064 014 026
Relative Standard Deviation
(le20)9 14 8 1 2
An
aly
st
I
DTPHB(n=3)
DTP(n=3)
Tetanus Toxoid(n=3)
dT(n=3)
DT(n=3)
Mean (UImL) 321 53 874 1031 1391
Standard Deviation 012 031 099 098 023
Relative Standard Deviation
(le20)4 6 11 10 2
An
aly
st
II
Instituto Butantan | 29
dT DT DTP and DTPHB vaccines intermediate precision Diphtheria fraction
SAMPLES
ANALYSTS I + II | X(An II) ndash X(An I) | x 100
X(An I)
(le20)
Mean(UImL)
SDRSD(le20)
dT 319 047 15 18
DT 446 067 15 15
DTPHB 645 058 9 7
Diphtheria Toxoid 645 084 13 13
DTP 1005 107 11 11
RE 8992003 (ANVISA) RSD le 5)
Instituto Butantan | 30
dT DT DTP and DTPHB vaccines intermediate precision Tetanus fraction
SAMPLES
ANALYSTS I + II | X(An II) ndash X(An I) | x 100
X(An I)
(le20)
Mean(UImL)
SDRSD(le20)
DTPHB 317 019 6 3
DTP 513 051 10 7
Tetanus Toxoid 837 085 10 9
dT 1016 065 6 3
DT 1386 023 2 1
RE 8992003 (ANVISA) RSD le 5)
Instituto Butantan | 31
dT DT DTP and DTPHB vaccines accuracy Diphtheria fraction
SAMPLESX (ToBI)(UImL)
n = 7
Official ResultIn vivo
(UImL)
n = 1
X (ToBI) x 100
Official Result(80 to 120)
dT 338 30 113
DT 467 49 95
DTPHB 657 60 110
Diphtheria
Toxoid668 66 101
DTP 1038 114 91
Instituto Butantan | 32
dT DT DTP and DTPHB vaccines accuracy Tetanus fraction
SAMPLESX (ToBI)(UImL)
n = 3
Official ResultIn vivo
(UImL)
n = 1
X (ToBI) x 100
Official Result(80 to 120)
DTPHB 313 28 112
DTP 497 46 108
Tetanus Toxoid 801 89 90
dT 1001 123 81
DT 1381 152 91
Instituto Butantan | 33
in vivo e in vitro correlation
dT DT DTP and DTPHB vaccines Diphtheria fraction potency analysis
Instituto Butantan | 34
in vivo e in vitro correlation
dT DT DTP and DTPHB vaccines Tetanus fraction potency analysis
Instituto Butantan | 35
Internal validated ToBI tests presented suitable to estimate the potency not only to
tetanus fraction but ALSO to diphtheria fraction in combined vaccines
Our data met all acceptance validation criteria as specificityselectivity linearity
precision (repeatability and intermediate precision) accuracy and in vitro and in vivo
concordance showed strong correlation (R=096) for both D and T components
The high relevance of these data for replacement of animal testing strongly impacts
the routine of Quality Control turning the analyses faster accurate and cheaper and
more importantly saving the lives of hundred of animals per year
Diphtheria and Tetanus combined vaccine potency by ToBI
Conclusion after internal validation
Instituto Butantan | 36
Av Vital Brasil 1500 ndash Butantatilde - Satildeo Paulo ndash SP -
Brazil
Zip code - 05503-900
(+ 55 11) 26279453
Thank you
patriciacarneirobutantangovbr
Biotech QC team
Instituto Butantan |
Single bleeding for both fractions - ReduceRefinement
Animal reduction proposal bleeding at 6 weeks for both D and T fractions
D for dT
D for DTP
T for dT and DTP
Change Control CMCB-0012418 approved in 07 may 18
Save 6 guinea-pig per batch
Instituto Butantan |
0
2
4
6
8
10
12
1 2 3 4 5 6 7 8 9 10 11
In vivo In vitro
14
dT DT DTP and DTPHB vaccines Diphtheria fraction potency analysis in vitro and in vivo - Replacement
-- In vivo -- In vitro
R=098P
ote
nc
y(U
Im
L)
Correl = 098
Save 88 guinea-pig per batch
Instituto Butantan | 15
dT DT DTP and DTPHB vaccines Tetanus fraction potency analysis in vitro and in vivo - Replacement
0
2
4
6
8
10
12
14
16
0 1 2 3 4 5 6
-- In vivo -- In vitro
Po
ten
cy
(UI
mL
)
Correl = 099
Save 220 mice per batch
Instituto Butantan | 16
LAL method for endotoxin quantification in hyperimmune sera -
Replacement
0 1 2 3 4 5 6 7 800
05
10
15
LPS standard [UEmL]
Tem
pera
ture
[C
els
ius d
eg
ree]
110
120
-100
-50
00
100
200
300
+ 10UEmL
+ 1UEml
+ 01UEml
+ 001UEml
LP
S r
eco
very
[
]
LPS standard curveIn
viv
oIn
vit
ro -
LA
L
Save 6-16 rabbits per batch
Instituto Butantan | 17
Bothrops jararaca sera potency by ToBI test - Replacement
Correl = 093
Save 330 mice per batch
Instituto Butantan | 18
Other 3Rs iniciatives in Butantan InstituteReplacement
On going in developmentinternal validation phase
MAT ndash Monocyte Activation Test (consortium by RENAMA)
Diphteria sera potency by ToBI test
Rabies potency test by ELISA (glycoproteinanti-glycoprotein)
Abnormal toxicity test banishment (already done for Influenza vaccine ndash 70 millions doses per year) on going for other
vaccines already registered (DTP DT dT HepB)
Instituto Butantan | 19
Other 3Rs iniciatives in Butantan Institute Refinement
Previous anesthesia to intracerebral challenge for
rabies and pertussis vaccines testsChange Control CMCB-0013418 approved in 14 ago 18 and
just implemented
End point to tetanus rabies and pertussis tests
Change Control CMCB-0011618 approved in 23 march 18 and
just implemented
Instituto Butantan | 20
Other 3Rs iniciatives in Butantan Institute Refinement
Pool for pyrogen and potency tests in antitoxins bulk
ready-to-fillChange Control CMCB-0013118 approved in 29 june 18 and
just implemented
Previous anesthesia to bleeding guinea-pigs
immunized for dT DT and DTP vaccines
Euthanasia by isofluorane in mice
Instituto Butantan | 21
Av Vital Brasil 1500 ndash Butantatilde - Satildeo Paulo ndash SP - Brazil
Zip code - 05503-900
(+ 55 11) 26279453
wwwbutantangovbr
Instituto Butantan | 22
Diphtheria and Tetanus combined vaccine potency
by ToBI
Alternative methods recommended by Eur Ph and WHO ndash determination of Ab titration (potency)
- T fraction ELISA andor ToBI test
- D fraction ELISA andor Vero cell tests
Our propose
- Both fractions titration by ToBI test
Instituto Butantan | 23
In vitro potency test of vaccines dT DT DTP and DTPHB
+ diphtheria and tetanus toxoid
bull ToBI test (Toxin Binding Inhibition Test)
Hendriksen et al J Biol Stand 1988 The toxin binding inhibition test as areliable in vitro alternative to the toxin neutralization test in mice for theestimation of tetanus antitoxin in human sera
Similar principle of the in vivo potency test
Decrease of 200 mice per batch of each vaccine and 400 mice per batch
of anti-tetanus serum
Instituto Butantan | 24
dT DT DTP and DTPHB vaccines selectivity
Sample + toxoidSample + both (tetanus and
diphteria) toxoid
DTPHB313 UImL 318 UImL
100 1016
DTP497 UImL 514 UImL
100 1034
Tetanus Toxoid801 UImL 724 UImL
100 904
dT1001 UImL 101 UImL
100 1001
DT1381 UImL 1448 UImL
100 1048
Tetanus antitoxin NIBSC1038 UImL 1058 UImL
100 102
All results between 80-120
Instituto Butantan | 25
dT DT DTP and DTPHB vaccines linearity Diphtheria fraction
Parameter SpecificationExperimental
Results
Correlation
coefficient (r)ge 0950 09979
Y-intercept --------- 00816
slope --------- 09753
Coefficient of
determination (r2)ge 0950 09958
Relative Standard
Deviation (RSD)le 20 1 to 6
Instituto Butantan | 26
dT DT DTP and DTPHB vaccines linearity Tetanus fraction
Parameter SpecificationExperimental
Results
Correlation
coefficient (r)ge 0950 09996
Y-intercept --------- - 03059
slope --------- 1059
Coefficient of
determination (r2)ge 0950 09992
Relative Standard
Deviation (RSD)le 20 2 to 8
Instituto Butantan | 27
dT DT DTP and DTPHB vaccines repeatability Diphtheria fraction
dT(n=7)
DT(n=7)
DTPHB(n=9)
Diphtheria Toxoid(n=8)
DTP(n=7)
Mean (UImL) 338 467 657 668 1038
Standard Deviation 043 071 062 085 107
Relative Standard Deviation
(le20)13 15 9 13 10
An
aly
st
I
dT(n=3)
DT(n=3)
DTPHB(n=3)
Diphtheria Toxoid(n=3)
DTP(n=3)
Mean (UImL) 276 399 609 582 927
Standard Deviation 021 015 025 036 068
Relative Standard Deviation
(le20)8 4 4 6 7
An
aly
st
II
Instituto Butantan | 28
dT DT DTP and DTPHB vaccines repeatability Tetanus fraction
DTPHB(n=3)
DTP(n=3)
Tetanus Toxoid(n=3)
dT(n=3)
DT(n=3)
Mean (UImL) 313 497 801 1001 1381
Standard Deviation 027 068 064 014 026
Relative Standard Deviation
(le20)9 14 8 1 2
An
aly
st
I
DTPHB(n=3)
DTP(n=3)
Tetanus Toxoid(n=3)
dT(n=3)
DT(n=3)
Mean (UImL) 321 53 874 1031 1391
Standard Deviation 012 031 099 098 023
Relative Standard Deviation
(le20)4 6 11 10 2
An
aly
st
II
Instituto Butantan | 29
dT DT DTP and DTPHB vaccines intermediate precision Diphtheria fraction
SAMPLES
ANALYSTS I + II | X(An II) ndash X(An I) | x 100
X(An I)
(le20)
Mean(UImL)
SDRSD(le20)
dT 319 047 15 18
DT 446 067 15 15
DTPHB 645 058 9 7
Diphtheria Toxoid 645 084 13 13
DTP 1005 107 11 11
RE 8992003 (ANVISA) RSD le 5)
Instituto Butantan | 30
dT DT DTP and DTPHB vaccines intermediate precision Tetanus fraction
SAMPLES
ANALYSTS I + II | X(An II) ndash X(An I) | x 100
X(An I)
(le20)
Mean(UImL)
SDRSD(le20)
DTPHB 317 019 6 3
DTP 513 051 10 7
Tetanus Toxoid 837 085 10 9
dT 1016 065 6 3
DT 1386 023 2 1
RE 8992003 (ANVISA) RSD le 5)
Instituto Butantan | 31
dT DT DTP and DTPHB vaccines accuracy Diphtheria fraction
SAMPLESX (ToBI)(UImL)
n = 7
Official ResultIn vivo
(UImL)
n = 1
X (ToBI) x 100
Official Result(80 to 120)
dT 338 30 113
DT 467 49 95
DTPHB 657 60 110
Diphtheria
Toxoid668 66 101
DTP 1038 114 91
Instituto Butantan | 32
dT DT DTP and DTPHB vaccines accuracy Tetanus fraction
SAMPLESX (ToBI)(UImL)
n = 3
Official ResultIn vivo
(UImL)
n = 1
X (ToBI) x 100
Official Result(80 to 120)
DTPHB 313 28 112
DTP 497 46 108
Tetanus Toxoid 801 89 90
dT 1001 123 81
DT 1381 152 91
Instituto Butantan | 33
in vivo e in vitro correlation
dT DT DTP and DTPHB vaccines Diphtheria fraction potency analysis
Instituto Butantan | 34
in vivo e in vitro correlation
dT DT DTP and DTPHB vaccines Tetanus fraction potency analysis
Instituto Butantan | 35
Internal validated ToBI tests presented suitable to estimate the potency not only to
tetanus fraction but ALSO to diphtheria fraction in combined vaccines
Our data met all acceptance validation criteria as specificityselectivity linearity
precision (repeatability and intermediate precision) accuracy and in vitro and in vivo
concordance showed strong correlation (R=096) for both D and T components
The high relevance of these data for replacement of animal testing strongly impacts
the routine of Quality Control turning the analyses faster accurate and cheaper and
more importantly saving the lives of hundred of animals per year
Diphtheria and Tetanus combined vaccine potency by ToBI
Conclusion after internal validation
Instituto Butantan | 36
Av Vital Brasil 1500 ndash Butantatilde - Satildeo Paulo ndash SP -
Brazil
Zip code - 05503-900
(+ 55 11) 26279453
Thank you
patriciacarneirobutantangovbr
Biotech QC team
Instituto Butantan |
0
2
4
6
8
10
12
1 2 3 4 5 6 7 8 9 10 11
In vivo In vitro
14
dT DT DTP and DTPHB vaccines Diphtheria fraction potency analysis in vitro and in vivo - Replacement
-- In vivo -- In vitro
R=098P
ote
nc
y(U
Im
L)
Correl = 098
Save 88 guinea-pig per batch
Instituto Butantan | 15
dT DT DTP and DTPHB vaccines Tetanus fraction potency analysis in vitro and in vivo - Replacement
0
2
4
6
8
10
12
14
16
0 1 2 3 4 5 6
-- In vivo -- In vitro
Po
ten
cy
(UI
mL
)
Correl = 099
Save 220 mice per batch
Instituto Butantan | 16
LAL method for endotoxin quantification in hyperimmune sera -
Replacement
0 1 2 3 4 5 6 7 800
05
10
15
LPS standard [UEmL]
Tem
pera
ture
[C
els
ius d
eg
ree]
110
120
-100
-50
00
100
200
300
+ 10UEmL
+ 1UEml
+ 01UEml
+ 001UEml
LP
S r
eco
very
[
]
LPS standard curveIn
viv
oIn
vit
ro -
LA
L
Save 6-16 rabbits per batch
Instituto Butantan | 17
Bothrops jararaca sera potency by ToBI test - Replacement
Correl = 093
Save 330 mice per batch
Instituto Butantan | 18
Other 3Rs iniciatives in Butantan InstituteReplacement
On going in developmentinternal validation phase
MAT ndash Monocyte Activation Test (consortium by RENAMA)
Diphteria sera potency by ToBI test
Rabies potency test by ELISA (glycoproteinanti-glycoprotein)
Abnormal toxicity test banishment (already done for Influenza vaccine ndash 70 millions doses per year) on going for other
vaccines already registered (DTP DT dT HepB)
Instituto Butantan | 19
Other 3Rs iniciatives in Butantan Institute Refinement
Previous anesthesia to intracerebral challenge for
rabies and pertussis vaccines testsChange Control CMCB-0013418 approved in 14 ago 18 and
just implemented
End point to tetanus rabies and pertussis tests
Change Control CMCB-0011618 approved in 23 march 18 and
just implemented
Instituto Butantan | 20
Other 3Rs iniciatives in Butantan Institute Refinement
Pool for pyrogen and potency tests in antitoxins bulk
ready-to-fillChange Control CMCB-0013118 approved in 29 june 18 and
just implemented
Previous anesthesia to bleeding guinea-pigs
immunized for dT DT and DTP vaccines
Euthanasia by isofluorane in mice
Instituto Butantan | 21
Av Vital Brasil 1500 ndash Butantatilde - Satildeo Paulo ndash SP - Brazil
Zip code - 05503-900
(+ 55 11) 26279453
wwwbutantangovbr
Instituto Butantan | 22
Diphtheria and Tetanus combined vaccine potency
by ToBI
Alternative methods recommended by Eur Ph and WHO ndash determination of Ab titration (potency)
- T fraction ELISA andor ToBI test
- D fraction ELISA andor Vero cell tests
Our propose
- Both fractions titration by ToBI test
Instituto Butantan | 23
In vitro potency test of vaccines dT DT DTP and DTPHB
+ diphtheria and tetanus toxoid
bull ToBI test (Toxin Binding Inhibition Test)
Hendriksen et al J Biol Stand 1988 The toxin binding inhibition test as areliable in vitro alternative to the toxin neutralization test in mice for theestimation of tetanus antitoxin in human sera
Similar principle of the in vivo potency test
Decrease of 200 mice per batch of each vaccine and 400 mice per batch
of anti-tetanus serum
Instituto Butantan | 24
dT DT DTP and DTPHB vaccines selectivity
Sample + toxoidSample + both (tetanus and
diphteria) toxoid
DTPHB313 UImL 318 UImL
100 1016
DTP497 UImL 514 UImL
100 1034
Tetanus Toxoid801 UImL 724 UImL
100 904
dT1001 UImL 101 UImL
100 1001
DT1381 UImL 1448 UImL
100 1048
Tetanus antitoxin NIBSC1038 UImL 1058 UImL
100 102
All results between 80-120
Instituto Butantan | 25
dT DT DTP and DTPHB vaccines linearity Diphtheria fraction
Parameter SpecificationExperimental
Results
Correlation
coefficient (r)ge 0950 09979
Y-intercept --------- 00816
slope --------- 09753
Coefficient of
determination (r2)ge 0950 09958
Relative Standard
Deviation (RSD)le 20 1 to 6
Instituto Butantan | 26
dT DT DTP and DTPHB vaccines linearity Tetanus fraction
Parameter SpecificationExperimental
Results
Correlation
coefficient (r)ge 0950 09996
Y-intercept --------- - 03059
slope --------- 1059
Coefficient of
determination (r2)ge 0950 09992
Relative Standard
Deviation (RSD)le 20 2 to 8
Instituto Butantan | 27
dT DT DTP and DTPHB vaccines repeatability Diphtheria fraction
dT(n=7)
DT(n=7)
DTPHB(n=9)
Diphtheria Toxoid(n=8)
DTP(n=7)
Mean (UImL) 338 467 657 668 1038
Standard Deviation 043 071 062 085 107
Relative Standard Deviation
(le20)13 15 9 13 10
An
aly
st
I
dT(n=3)
DT(n=3)
DTPHB(n=3)
Diphtheria Toxoid(n=3)
DTP(n=3)
Mean (UImL) 276 399 609 582 927
Standard Deviation 021 015 025 036 068
Relative Standard Deviation
(le20)8 4 4 6 7
An
aly
st
II
Instituto Butantan | 28
dT DT DTP and DTPHB vaccines repeatability Tetanus fraction
DTPHB(n=3)
DTP(n=3)
Tetanus Toxoid(n=3)
dT(n=3)
DT(n=3)
Mean (UImL) 313 497 801 1001 1381
Standard Deviation 027 068 064 014 026
Relative Standard Deviation
(le20)9 14 8 1 2
An
aly
st
I
DTPHB(n=3)
DTP(n=3)
Tetanus Toxoid(n=3)
dT(n=3)
DT(n=3)
Mean (UImL) 321 53 874 1031 1391
Standard Deviation 012 031 099 098 023
Relative Standard Deviation
(le20)4 6 11 10 2
An
aly
st
II
Instituto Butantan | 29
dT DT DTP and DTPHB vaccines intermediate precision Diphtheria fraction
SAMPLES
ANALYSTS I + II | X(An II) ndash X(An I) | x 100
X(An I)
(le20)
Mean(UImL)
SDRSD(le20)
dT 319 047 15 18
DT 446 067 15 15
DTPHB 645 058 9 7
Diphtheria Toxoid 645 084 13 13
DTP 1005 107 11 11
RE 8992003 (ANVISA) RSD le 5)
Instituto Butantan | 30
dT DT DTP and DTPHB vaccines intermediate precision Tetanus fraction
SAMPLES
ANALYSTS I + II | X(An II) ndash X(An I) | x 100
X(An I)
(le20)
Mean(UImL)
SDRSD(le20)
DTPHB 317 019 6 3
DTP 513 051 10 7
Tetanus Toxoid 837 085 10 9
dT 1016 065 6 3
DT 1386 023 2 1
RE 8992003 (ANVISA) RSD le 5)
Instituto Butantan | 31
dT DT DTP and DTPHB vaccines accuracy Diphtheria fraction
SAMPLESX (ToBI)(UImL)
n = 7
Official ResultIn vivo
(UImL)
n = 1
X (ToBI) x 100
Official Result(80 to 120)
dT 338 30 113
DT 467 49 95
DTPHB 657 60 110
Diphtheria
Toxoid668 66 101
DTP 1038 114 91
Instituto Butantan | 32
dT DT DTP and DTPHB vaccines accuracy Tetanus fraction
SAMPLESX (ToBI)(UImL)
n = 3
Official ResultIn vivo
(UImL)
n = 1
X (ToBI) x 100
Official Result(80 to 120)
DTPHB 313 28 112
DTP 497 46 108
Tetanus Toxoid 801 89 90
dT 1001 123 81
DT 1381 152 91
Instituto Butantan | 33
in vivo e in vitro correlation
dT DT DTP and DTPHB vaccines Diphtheria fraction potency analysis
Instituto Butantan | 34
in vivo e in vitro correlation
dT DT DTP and DTPHB vaccines Tetanus fraction potency analysis
Instituto Butantan | 35
Internal validated ToBI tests presented suitable to estimate the potency not only to
tetanus fraction but ALSO to diphtheria fraction in combined vaccines
Our data met all acceptance validation criteria as specificityselectivity linearity
precision (repeatability and intermediate precision) accuracy and in vitro and in vivo
concordance showed strong correlation (R=096) for both D and T components
The high relevance of these data for replacement of animal testing strongly impacts
the routine of Quality Control turning the analyses faster accurate and cheaper and
more importantly saving the lives of hundred of animals per year
Diphtheria and Tetanus combined vaccine potency by ToBI
Conclusion after internal validation
Instituto Butantan | 36
Av Vital Brasil 1500 ndash Butantatilde - Satildeo Paulo ndash SP -
Brazil
Zip code - 05503-900
(+ 55 11) 26279453
Thank you
patriciacarneirobutantangovbr
Biotech QC team
Instituto Butantan | 15
dT DT DTP and DTPHB vaccines Tetanus fraction potency analysis in vitro and in vivo - Replacement
0
2
4
6
8
10
12
14
16
0 1 2 3 4 5 6
-- In vivo -- In vitro
Po
ten
cy
(UI
mL
)
Correl = 099
Save 220 mice per batch
Instituto Butantan | 16
LAL method for endotoxin quantification in hyperimmune sera -
Replacement
0 1 2 3 4 5 6 7 800
05
10
15
LPS standard [UEmL]
Tem
pera
ture
[C
els
ius d
eg
ree]
110
120
-100
-50
00
100
200
300
+ 10UEmL
+ 1UEml
+ 01UEml
+ 001UEml
LP
S r
eco
very
[
]
LPS standard curveIn
viv
oIn
vit
ro -
LA
L
Save 6-16 rabbits per batch
Instituto Butantan | 17
Bothrops jararaca sera potency by ToBI test - Replacement
Correl = 093
Save 330 mice per batch
Instituto Butantan | 18
Other 3Rs iniciatives in Butantan InstituteReplacement
On going in developmentinternal validation phase
MAT ndash Monocyte Activation Test (consortium by RENAMA)
Diphteria sera potency by ToBI test
Rabies potency test by ELISA (glycoproteinanti-glycoprotein)
Abnormal toxicity test banishment (already done for Influenza vaccine ndash 70 millions doses per year) on going for other
vaccines already registered (DTP DT dT HepB)
Instituto Butantan | 19
Other 3Rs iniciatives in Butantan Institute Refinement
Previous anesthesia to intracerebral challenge for
rabies and pertussis vaccines testsChange Control CMCB-0013418 approved in 14 ago 18 and
just implemented
End point to tetanus rabies and pertussis tests
Change Control CMCB-0011618 approved in 23 march 18 and
just implemented
Instituto Butantan | 20
Other 3Rs iniciatives in Butantan Institute Refinement
Pool for pyrogen and potency tests in antitoxins bulk
ready-to-fillChange Control CMCB-0013118 approved in 29 june 18 and
just implemented
Previous anesthesia to bleeding guinea-pigs
immunized for dT DT and DTP vaccines
Euthanasia by isofluorane in mice
Instituto Butantan | 21
Av Vital Brasil 1500 ndash Butantatilde - Satildeo Paulo ndash SP - Brazil
Zip code - 05503-900
(+ 55 11) 26279453
wwwbutantangovbr
Instituto Butantan | 22
Diphtheria and Tetanus combined vaccine potency
by ToBI
Alternative methods recommended by Eur Ph and WHO ndash determination of Ab titration (potency)
- T fraction ELISA andor ToBI test
- D fraction ELISA andor Vero cell tests
Our propose
- Both fractions titration by ToBI test
Instituto Butantan | 23
In vitro potency test of vaccines dT DT DTP and DTPHB
+ diphtheria and tetanus toxoid
bull ToBI test (Toxin Binding Inhibition Test)
Hendriksen et al J Biol Stand 1988 The toxin binding inhibition test as areliable in vitro alternative to the toxin neutralization test in mice for theestimation of tetanus antitoxin in human sera
Similar principle of the in vivo potency test
Decrease of 200 mice per batch of each vaccine and 400 mice per batch
of anti-tetanus serum
Instituto Butantan | 24
dT DT DTP and DTPHB vaccines selectivity
Sample + toxoidSample + both (tetanus and
diphteria) toxoid
DTPHB313 UImL 318 UImL
100 1016
DTP497 UImL 514 UImL
100 1034
Tetanus Toxoid801 UImL 724 UImL
100 904
dT1001 UImL 101 UImL
100 1001
DT1381 UImL 1448 UImL
100 1048
Tetanus antitoxin NIBSC1038 UImL 1058 UImL
100 102
All results between 80-120
Instituto Butantan | 25
dT DT DTP and DTPHB vaccines linearity Diphtheria fraction
Parameter SpecificationExperimental
Results
Correlation
coefficient (r)ge 0950 09979
Y-intercept --------- 00816
slope --------- 09753
Coefficient of
determination (r2)ge 0950 09958
Relative Standard
Deviation (RSD)le 20 1 to 6
Instituto Butantan | 26
dT DT DTP and DTPHB vaccines linearity Tetanus fraction
Parameter SpecificationExperimental
Results
Correlation
coefficient (r)ge 0950 09996
Y-intercept --------- - 03059
slope --------- 1059
Coefficient of
determination (r2)ge 0950 09992
Relative Standard
Deviation (RSD)le 20 2 to 8
Instituto Butantan | 27
dT DT DTP and DTPHB vaccines repeatability Diphtheria fraction
dT(n=7)
DT(n=7)
DTPHB(n=9)
Diphtheria Toxoid(n=8)
DTP(n=7)
Mean (UImL) 338 467 657 668 1038
Standard Deviation 043 071 062 085 107
Relative Standard Deviation
(le20)13 15 9 13 10
An
aly
st
I
dT(n=3)
DT(n=3)
DTPHB(n=3)
Diphtheria Toxoid(n=3)
DTP(n=3)
Mean (UImL) 276 399 609 582 927
Standard Deviation 021 015 025 036 068
Relative Standard Deviation
(le20)8 4 4 6 7
An
aly
st
II
Instituto Butantan | 28
dT DT DTP and DTPHB vaccines repeatability Tetanus fraction
DTPHB(n=3)
DTP(n=3)
Tetanus Toxoid(n=3)
dT(n=3)
DT(n=3)
Mean (UImL) 313 497 801 1001 1381
Standard Deviation 027 068 064 014 026
Relative Standard Deviation
(le20)9 14 8 1 2
An
aly
st
I
DTPHB(n=3)
DTP(n=3)
Tetanus Toxoid(n=3)
dT(n=3)
DT(n=3)
Mean (UImL) 321 53 874 1031 1391
Standard Deviation 012 031 099 098 023
Relative Standard Deviation
(le20)4 6 11 10 2
An
aly
st
II
Instituto Butantan | 29
dT DT DTP and DTPHB vaccines intermediate precision Diphtheria fraction
SAMPLES
ANALYSTS I + II | X(An II) ndash X(An I) | x 100
X(An I)
(le20)
Mean(UImL)
SDRSD(le20)
dT 319 047 15 18
DT 446 067 15 15
DTPHB 645 058 9 7
Diphtheria Toxoid 645 084 13 13
DTP 1005 107 11 11
RE 8992003 (ANVISA) RSD le 5)
Instituto Butantan | 30
dT DT DTP and DTPHB vaccines intermediate precision Tetanus fraction
SAMPLES
ANALYSTS I + II | X(An II) ndash X(An I) | x 100
X(An I)
(le20)
Mean(UImL)
SDRSD(le20)
DTPHB 317 019 6 3
DTP 513 051 10 7
Tetanus Toxoid 837 085 10 9
dT 1016 065 6 3
DT 1386 023 2 1
RE 8992003 (ANVISA) RSD le 5)
Instituto Butantan | 31
dT DT DTP and DTPHB vaccines accuracy Diphtheria fraction
SAMPLESX (ToBI)(UImL)
n = 7
Official ResultIn vivo
(UImL)
n = 1
X (ToBI) x 100
Official Result(80 to 120)
dT 338 30 113
DT 467 49 95
DTPHB 657 60 110
Diphtheria
Toxoid668 66 101
DTP 1038 114 91
Instituto Butantan | 32
dT DT DTP and DTPHB vaccines accuracy Tetanus fraction
SAMPLESX (ToBI)(UImL)
n = 3
Official ResultIn vivo
(UImL)
n = 1
X (ToBI) x 100
Official Result(80 to 120)
DTPHB 313 28 112
DTP 497 46 108
Tetanus Toxoid 801 89 90
dT 1001 123 81
DT 1381 152 91
Instituto Butantan | 33
in vivo e in vitro correlation
dT DT DTP and DTPHB vaccines Diphtheria fraction potency analysis
Instituto Butantan | 34
in vivo e in vitro correlation
dT DT DTP and DTPHB vaccines Tetanus fraction potency analysis
Instituto Butantan | 35
Internal validated ToBI tests presented suitable to estimate the potency not only to
tetanus fraction but ALSO to diphtheria fraction in combined vaccines
Our data met all acceptance validation criteria as specificityselectivity linearity
precision (repeatability and intermediate precision) accuracy and in vitro and in vivo
concordance showed strong correlation (R=096) for both D and T components
The high relevance of these data for replacement of animal testing strongly impacts
the routine of Quality Control turning the analyses faster accurate and cheaper and
more importantly saving the lives of hundred of animals per year
Diphtheria and Tetanus combined vaccine potency by ToBI
Conclusion after internal validation
Instituto Butantan | 36
Av Vital Brasil 1500 ndash Butantatilde - Satildeo Paulo ndash SP -
Brazil
Zip code - 05503-900
(+ 55 11) 26279453
Thank you
patriciacarneirobutantangovbr
Biotech QC team
Instituto Butantan | 16
LAL method for endotoxin quantification in hyperimmune sera -
Replacement
0 1 2 3 4 5 6 7 800
05
10
15
LPS standard [UEmL]
Tem
pera
ture
[C
els
ius d
eg
ree]
110
120
-100
-50
00
100
200
300
+ 10UEmL
+ 1UEml
+ 01UEml
+ 001UEml
LP
S r
eco
very
[
]
LPS standard curveIn
viv
oIn
vit
ro -
LA
L
Save 6-16 rabbits per batch
Instituto Butantan | 17
Bothrops jararaca sera potency by ToBI test - Replacement
Correl = 093
Save 330 mice per batch
Instituto Butantan | 18
Other 3Rs iniciatives in Butantan InstituteReplacement
On going in developmentinternal validation phase
MAT ndash Monocyte Activation Test (consortium by RENAMA)
Diphteria sera potency by ToBI test
Rabies potency test by ELISA (glycoproteinanti-glycoprotein)
Abnormal toxicity test banishment (already done for Influenza vaccine ndash 70 millions doses per year) on going for other
vaccines already registered (DTP DT dT HepB)
Instituto Butantan | 19
Other 3Rs iniciatives in Butantan Institute Refinement
Previous anesthesia to intracerebral challenge for
rabies and pertussis vaccines testsChange Control CMCB-0013418 approved in 14 ago 18 and
just implemented
End point to tetanus rabies and pertussis tests
Change Control CMCB-0011618 approved in 23 march 18 and
just implemented
Instituto Butantan | 20
Other 3Rs iniciatives in Butantan Institute Refinement
Pool for pyrogen and potency tests in antitoxins bulk
ready-to-fillChange Control CMCB-0013118 approved in 29 june 18 and
just implemented
Previous anesthesia to bleeding guinea-pigs
immunized for dT DT and DTP vaccines
Euthanasia by isofluorane in mice
Instituto Butantan | 21
Av Vital Brasil 1500 ndash Butantatilde - Satildeo Paulo ndash SP - Brazil
Zip code - 05503-900
(+ 55 11) 26279453
wwwbutantangovbr
Instituto Butantan | 22
Diphtheria and Tetanus combined vaccine potency
by ToBI
Alternative methods recommended by Eur Ph and WHO ndash determination of Ab titration (potency)
- T fraction ELISA andor ToBI test
- D fraction ELISA andor Vero cell tests
Our propose
- Both fractions titration by ToBI test
Instituto Butantan | 23
In vitro potency test of vaccines dT DT DTP and DTPHB
+ diphtheria and tetanus toxoid
bull ToBI test (Toxin Binding Inhibition Test)
Hendriksen et al J Biol Stand 1988 The toxin binding inhibition test as areliable in vitro alternative to the toxin neutralization test in mice for theestimation of tetanus antitoxin in human sera
Similar principle of the in vivo potency test
Decrease of 200 mice per batch of each vaccine and 400 mice per batch
of anti-tetanus serum
Instituto Butantan | 24
dT DT DTP and DTPHB vaccines selectivity
Sample + toxoidSample + both (tetanus and
diphteria) toxoid
DTPHB313 UImL 318 UImL
100 1016
DTP497 UImL 514 UImL
100 1034
Tetanus Toxoid801 UImL 724 UImL
100 904
dT1001 UImL 101 UImL
100 1001
DT1381 UImL 1448 UImL
100 1048
Tetanus antitoxin NIBSC1038 UImL 1058 UImL
100 102
All results between 80-120
Instituto Butantan | 25
dT DT DTP and DTPHB vaccines linearity Diphtheria fraction
Parameter SpecificationExperimental
Results
Correlation
coefficient (r)ge 0950 09979
Y-intercept --------- 00816
slope --------- 09753
Coefficient of
determination (r2)ge 0950 09958
Relative Standard
Deviation (RSD)le 20 1 to 6
Instituto Butantan | 26
dT DT DTP and DTPHB vaccines linearity Tetanus fraction
Parameter SpecificationExperimental
Results
Correlation
coefficient (r)ge 0950 09996
Y-intercept --------- - 03059
slope --------- 1059
Coefficient of
determination (r2)ge 0950 09992
Relative Standard
Deviation (RSD)le 20 2 to 8
Instituto Butantan | 27
dT DT DTP and DTPHB vaccines repeatability Diphtheria fraction
dT(n=7)
DT(n=7)
DTPHB(n=9)
Diphtheria Toxoid(n=8)
DTP(n=7)
Mean (UImL) 338 467 657 668 1038
Standard Deviation 043 071 062 085 107
Relative Standard Deviation
(le20)13 15 9 13 10
An
aly
st
I
dT(n=3)
DT(n=3)
DTPHB(n=3)
Diphtheria Toxoid(n=3)
DTP(n=3)
Mean (UImL) 276 399 609 582 927
Standard Deviation 021 015 025 036 068
Relative Standard Deviation
(le20)8 4 4 6 7
An
aly
st
II
Instituto Butantan | 28
dT DT DTP and DTPHB vaccines repeatability Tetanus fraction
DTPHB(n=3)
DTP(n=3)
Tetanus Toxoid(n=3)
dT(n=3)
DT(n=3)
Mean (UImL) 313 497 801 1001 1381
Standard Deviation 027 068 064 014 026
Relative Standard Deviation
(le20)9 14 8 1 2
An
aly
st
I
DTPHB(n=3)
DTP(n=3)
Tetanus Toxoid(n=3)
dT(n=3)
DT(n=3)
Mean (UImL) 321 53 874 1031 1391
Standard Deviation 012 031 099 098 023
Relative Standard Deviation
(le20)4 6 11 10 2
An
aly
st
II
Instituto Butantan | 29
dT DT DTP and DTPHB vaccines intermediate precision Diphtheria fraction
SAMPLES
ANALYSTS I + II | X(An II) ndash X(An I) | x 100
X(An I)
(le20)
Mean(UImL)
SDRSD(le20)
dT 319 047 15 18
DT 446 067 15 15
DTPHB 645 058 9 7
Diphtheria Toxoid 645 084 13 13
DTP 1005 107 11 11
RE 8992003 (ANVISA) RSD le 5)
Instituto Butantan | 30
dT DT DTP and DTPHB vaccines intermediate precision Tetanus fraction
SAMPLES
ANALYSTS I + II | X(An II) ndash X(An I) | x 100
X(An I)
(le20)
Mean(UImL)
SDRSD(le20)
DTPHB 317 019 6 3
DTP 513 051 10 7
Tetanus Toxoid 837 085 10 9
dT 1016 065 6 3
DT 1386 023 2 1
RE 8992003 (ANVISA) RSD le 5)
Instituto Butantan | 31
dT DT DTP and DTPHB vaccines accuracy Diphtheria fraction
SAMPLESX (ToBI)(UImL)
n = 7
Official ResultIn vivo
(UImL)
n = 1
X (ToBI) x 100
Official Result(80 to 120)
dT 338 30 113
DT 467 49 95
DTPHB 657 60 110
Diphtheria
Toxoid668 66 101
DTP 1038 114 91
Instituto Butantan | 32
dT DT DTP and DTPHB vaccines accuracy Tetanus fraction
SAMPLESX (ToBI)(UImL)
n = 3
Official ResultIn vivo
(UImL)
n = 1
X (ToBI) x 100
Official Result(80 to 120)
DTPHB 313 28 112
DTP 497 46 108
Tetanus Toxoid 801 89 90
dT 1001 123 81
DT 1381 152 91
Instituto Butantan | 33
in vivo e in vitro correlation
dT DT DTP and DTPHB vaccines Diphtheria fraction potency analysis
Instituto Butantan | 34
in vivo e in vitro correlation
dT DT DTP and DTPHB vaccines Tetanus fraction potency analysis
Instituto Butantan | 35
Internal validated ToBI tests presented suitable to estimate the potency not only to
tetanus fraction but ALSO to diphtheria fraction in combined vaccines
Our data met all acceptance validation criteria as specificityselectivity linearity
precision (repeatability and intermediate precision) accuracy and in vitro and in vivo
concordance showed strong correlation (R=096) for both D and T components
The high relevance of these data for replacement of animal testing strongly impacts
the routine of Quality Control turning the analyses faster accurate and cheaper and
more importantly saving the lives of hundred of animals per year
Diphtheria and Tetanus combined vaccine potency by ToBI
Conclusion after internal validation
Instituto Butantan | 36
Av Vital Brasil 1500 ndash Butantatilde - Satildeo Paulo ndash SP -
Brazil
Zip code - 05503-900
(+ 55 11) 26279453
Thank you
patriciacarneirobutantangovbr
Biotech QC team
Instituto Butantan | 17
Bothrops jararaca sera potency by ToBI test - Replacement
Correl = 093
Save 330 mice per batch
Instituto Butantan | 18
Other 3Rs iniciatives in Butantan InstituteReplacement
On going in developmentinternal validation phase
MAT ndash Monocyte Activation Test (consortium by RENAMA)
Diphteria sera potency by ToBI test
Rabies potency test by ELISA (glycoproteinanti-glycoprotein)
Abnormal toxicity test banishment (already done for Influenza vaccine ndash 70 millions doses per year) on going for other
vaccines already registered (DTP DT dT HepB)
Instituto Butantan | 19
Other 3Rs iniciatives in Butantan Institute Refinement
Previous anesthesia to intracerebral challenge for
rabies and pertussis vaccines testsChange Control CMCB-0013418 approved in 14 ago 18 and
just implemented
End point to tetanus rabies and pertussis tests
Change Control CMCB-0011618 approved in 23 march 18 and
just implemented
Instituto Butantan | 20
Other 3Rs iniciatives in Butantan Institute Refinement
Pool for pyrogen and potency tests in antitoxins bulk
ready-to-fillChange Control CMCB-0013118 approved in 29 june 18 and
just implemented
Previous anesthesia to bleeding guinea-pigs
immunized for dT DT and DTP vaccines
Euthanasia by isofluorane in mice
Instituto Butantan | 21
Av Vital Brasil 1500 ndash Butantatilde - Satildeo Paulo ndash SP - Brazil
Zip code - 05503-900
(+ 55 11) 26279453
wwwbutantangovbr
Instituto Butantan | 22
Diphtheria and Tetanus combined vaccine potency
by ToBI
Alternative methods recommended by Eur Ph and WHO ndash determination of Ab titration (potency)
- T fraction ELISA andor ToBI test
- D fraction ELISA andor Vero cell tests
Our propose
- Both fractions titration by ToBI test
Instituto Butantan | 23
In vitro potency test of vaccines dT DT DTP and DTPHB
+ diphtheria and tetanus toxoid
bull ToBI test (Toxin Binding Inhibition Test)
Hendriksen et al J Biol Stand 1988 The toxin binding inhibition test as areliable in vitro alternative to the toxin neutralization test in mice for theestimation of tetanus antitoxin in human sera
Similar principle of the in vivo potency test
Decrease of 200 mice per batch of each vaccine and 400 mice per batch
of anti-tetanus serum
Instituto Butantan | 24
dT DT DTP and DTPHB vaccines selectivity
Sample + toxoidSample + both (tetanus and
diphteria) toxoid
DTPHB313 UImL 318 UImL
100 1016
DTP497 UImL 514 UImL
100 1034
Tetanus Toxoid801 UImL 724 UImL
100 904
dT1001 UImL 101 UImL
100 1001
DT1381 UImL 1448 UImL
100 1048
Tetanus antitoxin NIBSC1038 UImL 1058 UImL
100 102
All results between 80-120
Instituto Butantan | 25
dT DT DTP and DTPHB vaccines linearity Diphtheria fraction
Parameter SpecificationExperimental
Results
Correlation
coefficient (r)ge 0950 09979
Y-intercept --------- 00816
slope --------- 09753
Coefficient of
determination (r2)ge 0950 09958
Relative Standard
Deviation (RSD)le 20 1 to 6
Instituto Butantan | 26
dT DT DTP and DTPHB vaccines linearity Tetanus fraction
Parameter SpecificationExperimental
Results
Correlation
coefficient (r)ge 0950 09996
Y-intercept --------- - 03059
slope --------- 1059
Coefficient of
determination (r2)ge 0950 09992
Relative Standard
Deviation (RSD)le 20 2 to 8
Instituto Butantan | 27
dT DT DTP and DTPHB vaccines repeatability Diphtheria fraction
dT(n=7)
DT(n=7)
DTPHB(n=9)
Diphtheria Toxoid(n=8)
DTP(n=7)
Mean (UImL) 338 467 657 668 1038
Standard Deviation 043 071 062 085 107
Relative Standard Deviation
(le20)13 15 9 13 10
An
aly
st
I
dT(n=3)
DT(n=3)
DTPHB(n=3)
Diphtheria Toxoid(n=3)
DTP(n=3)
Mean (UImL) 276 399 609 582 927
Standard Deviation 021 015 025 036 068
Relative Standard Deviation
(le20)8 4 4 6 7
An
aly
st
II
Instituto Butantan | 28
dT DT DTP and DTPHB vaccines repeatability Tetanus fraction
DTPHB(n=3)
DTP(n=3)
Tetanus Toxoid(n=3)
dT(n=3)
DT(n=3)
Mean (UImL) 313 497 801 1001 1381
Standard Deviation 027 068 064 014 026
Relative Standard Deviation
(le20)9 14 8 1 2
An
aly
st
I
DTPHB(n=3)
DTP(n=3)
Tetanus Toxoid(n=3)
dT(n=3)
DT(n=3)
Mean (UImL) 321 53 874 1031 1391
Standard Deviation 012 031 099 098 023
Relative Standard Deviation
(le20)4 6 11 10 2
An
aly
st
II
Instituto Butantan | 29
dT DT DTP and DTPHB vaccines intermediate precision Diphtheria fraction
SAMPLES
ANALYSTS I + II | X(An II) ndash X(An I) | x 100
X(An I)
(le20)
Mean(UImL)
SDRSD(le20)
dT 319 047 15 18
DT 446 067 15 15
DTPHB 645 058 9 7
Diphtheria Toxoid 645 084 13 13
DTP 1005 107 11 11
RE 8992003 (ANVISA) RSD le 5)
Instituto Butantan | 30
dT DT DTP and DTPHB vaccines intermediate precision Tetanus fraction
SAMPLES
ANALYSTS I + II | X(An II) ndash X(An I) | x 100
X(An I)
(le20)
Mean(UImL)
SDRSD(le20)
DTPHB 317 019 6 3
DTP 513 051 10 7
Tetanus Toxoid 837 085 10 9
dT 1016 065 6 3
DT 1386 023 2 1
RE 8992003 (ANVISA) RSD le 5)
Instituto Butantan | 31
dT DT DTP and DTPHB vaccines accuracy Diphtheria fraction
SAMPLESX (ToBI)(UImL)
n = 7
Official ResultIn vivo
(UImL)
n = 1
X (ToBI) x 100
Official Result(80 to 120)
dT 338 30 113
DT 467 49 95
DTPHB 657 60 110
Diphtheria
Toxoid668 66 101
DTP 1038 114 91
Instituto Butantan | 32
dT DT DTP and DTPHB vaccines accuracy Tetanus fraction
SAMPLESX (ToBI)(UImL)
n = 3
Official ResultIn vivo
(UImL)
n = 1
X (ToBI) x 100
Official Result(80 to 120)
DTPHB 313 28 112
DTP 497 46 108
Tetanus Toxoid 801 89 90
dT 1001 123 81
DT 1381 152 91
Instituto Butantan | 33
in vivo e in vitro correlation
dT DT DTP and DTPHB vaccines Diphtheria fraction potency analysis
Instituto Butantan | 34
in vivo e in vitro correlation
dT DT DTP and DTPHB vaccines Tetanus fraction potency analysis
Instituto Butantan | 35
Internal validated ToBI tests presented suitable to estimate the potency not only to
tetanus fraction but ALSO to diphtheria fraction in combined vaccines
Our data met all acceptance validation criteria as specificityselectivity linearity
precision (repeatability and intermediate precision) accuracy and in vitro and in vivo
concordance showed strong correlation (R=096) for both D and T components
The high relevance of these data for replacement of animal testing strongly impacts
the routine of Quality Control turning the analyses faster accurate and cheaper and
more importantly saving the lives of hundred of animals per year
Diphtheria and Tetanus combined vaccine potency by ToBI
Conclusion after internal validation
Instituto Butantan | 36
Av Vital Brasil 1500 ndash Butantatilde - Satildeo Paulo ndash SP -
Brazil
Zip code - 05503-900
(+ 55 11) 26279453
Thank you
patriciacarneirobutantangovbr
Biotech QC team
Instituto Butantan | 18
Other 3Rs iniciatives in Butantan InstituteReplacement
On going in developmentinternal validation phase
MAT ndash Monocyte Activation Test (consortium by RENAMA)
Diphteria sera potency by ToBI test
Rabies potency test by ELISA (glycoproteinanti-glycoprotein)
Abnormal toxicity test banishment (already done for Influenza vaccine ndash 70 millions doses per year) on going for other
vaccines already registered (DTP DT dT HepB)
Instituto Butantan | 19
Other 3Rs iniciatives in Butantan Institute Refinement
Previous anesthesia to intracerebral challenge for
rabies and pertussis vaccines testsChange Control CMCB-0013418 approved in 14 ago 18 and
just implemented
End point to tetanus rabies and pertussis tests
Change Control CMCB-0011618 approved in 23 march 18 and
just implemented
Instituto Butantan | 20
Other 3Rs iniciatives in Butantan Institute Refinement
Pool for pyrogen and potency tests in antitoxins bulk
ready-to-fillChange Control CMCB-0013118 approved in 29 june 18 and
just implemented
Previous anesthesia to bleeding guinea-pigs
immunized for dT DT and DTP vaccines
Euthanasia by isofluorane in mice
Instituto Butantan | 21
Av Vital Brasil 1500 ndash Butantatilde - Satildeo Paulo ndash SP - Brazil
Zip code - 05503-900
(+ 55 11) 26279453
wwwbutantangovbr
Instituto Butantan | 22
Diphtheria and Tetanus combined vaccine potency
by ToBI
Alternative methods recommended by Eur Ph and WHO ndash determination of Ab titration (potency)
- T fraction ELISA andor ToBI test
- D fraction ELISA andor Vero cell tests
Our propose
- Both fractions titration by ToBI test
Instituto Butantan | 23
In vitro potency test of vaccines dT DT DTP and DTPHB
+ diphtheria and tetanus toxoid
bull ToBI test (Toxin Binding Inhibition Test)
Hendriksen et al J Biol Stand 1988 The toxin binding inhibition test as areliable in vitro alternative to the toxin neutralization test in mice for theestimation of tetanus antitoxin in human sera
Similar principle of the in vivo potency test
Decrease of 200 mice per batch of each vaccine and 400 mice per batch
of anti-tetanus serum
Instituto Butantan | 24
dT DT DTP and DTPHB vaccines selectivity
Sample + toxoidSample + both (tetanus and
diphteria) toxoid
DTPHB313 UImL 318 UImL
100 1016
DTP497 UImL 514 UImL
100 1034
Tetanus Toxoid801 UImL 724 UImL
100 904
dT1001 UImL 101 UImL
100 1001
DT1381 UImL 1448 UImL
100 1048
Tetanus antitoxin NIBSC1038 UImL 1058 UImL
100 102
All results between 80-120
Instituto Butantan | 25
dT DT DTP and DTPHB vaccines linearity Diphtheria fraction
Parameter SpecificationExperimental
Results
Correlation
coefficient (r)ge 0950 09979
Y-intercept --------- 00816
slope --------- 09753
Coefficient of
determination (r2)ge 0950 09958
Relative Standard
Deviation (RSD)le 20 1 to 6
Instituto Butantan | 26
dT DT DTP and DTPHB vaccines linearity Tetanus fraction
Parameter SpecificationExperimental
Results
Correlation
coefficient (r)ge 0950 09996
Y-intercept --------- - 03059
slope --------- 1059
Coefficient of
determination (r2)ge 0950 09992
Relative Standard
Deviation (RSD)le 20 2 to 8
Instituto Butantan | 27
dT DT DTP and DTPHB vaccines repeatability Diphtheria fraction
dT(n=7)
DT(n=7)
DTPHB(n=9)
Diphtheria Toxoid(n=8)
DTP(n=7)
Mean (UImL) 338 467 657 668 1038
Standard Deviation 043 071 062 085 107
Relative Standard Deviation
(le20)13 15 9 13 10
An
aly
st
I
dT(n=3)
DT(n=3)
DTPHB(n=3)
Diphtheria Toxoid(n=3)
DTP(n=3)
Mean (UImL) 276 399 609 582 927
Standard Deviation 021 015 025 036 068
Relative Standard Deviation
(le20)8 4 4 6 7
An
aly
st
II
Instituto Butantan | 28
dT DT DTP and DTPHB vaccines repeatability Tetanus fraction
DTPHB(n=3)
DTP(n=3)
Tetanus Toxoid(n=3)
dT(n=3)
DT(n=3)
Mean (UImL) 313 497 801 1001 1381
Standard Deviation 027 068 064 014 026
Relative Standard Deviation
(le20)9 14 8 1 2
An
aly
st
I
DTPHB(n=3)
DTP(n=3)
Tetanus Toxoid(n=3)
dT(n=3)
DT(n=3)
Mean (UImL) 321 53 874 1031 1391
Standard Deviation 012 031 099 098 023
Relative Standard Deviation
(le20)4 6 11 10 2
An
aly
st
II
Instituto Butantan | 29
dT DT DTP and DTPHB vaccines intermediate precision Diphtheria fraction
SAMPLES
ANALYSTS I + II | X(An II) ndash X(An I) | x 100
X(An I)
(le20)
Mean(UImL)
SDRSD(le20)
dT 319 047 15 18
DT 446 067 15 15
DTPHB 645 058 9 7
Diphtheria Toxoid 645 084 13 13
DTP 1005 107 11 11
RE 8992003 (ANVISA) RSD le 5)
Instituto Butantan | 30
dT DT DTP and DTPHB vaccines intermediate precision Tetanus fraction
SAMPLES
ANALYSTS I + II | X(An II) ndash X(An I) | x 100
X(An I)
(le20)
Mean(UImL)
SDRSD(le20)
DTPHB 317 019 6 3
DTP 513 051 10 7
Tetanus Toxoid 837 085 10 9
dT 1016 065 6 3
DT 1386 023 2 1
RE 8992003 (ANVISA) RSD le 5)
Instituto Butantan | 31
dT DT DTP and DTPHB vaccines accuracy Diphtheria fraction
SAMPLESX (ToBI)(UImL)
n = 7
Official ResultIn vivo
(UImL)
n = 1
X (ToBI) x 100
Official Result(80 to 120)
dT 338 30 113
DT 467 49 95
DTPHB 657 60 110
Diphtheria
Toxoid668 66 101
DTP 1038 114 91
Instituto Butantan | 32
dT DT DTP and DTPHB vaccines accuracy Tetanus fraction
SAMPLESX (ToBI)(UImL)
n = 3
Official ResultIn vivo
(UImL)
n = 1
X (ToBI) x 100
Official Result(80 to 120)
DTPHB 313 28 112
DTP 497 46 108
Tetanus Toxoid 801 89 90
dT 1001 123 81
DT 1381 152 91
Instituto Butantan | 33
in vivo e in vitro correlation
dT DT DTP and DTPHB vaccines Diphtheria fraction potency analysis
Instituto Butantan | 34
in vivo e in vitro correlation
dT DT DTP and DTPHB vaccines Tetanus fraction potency analysis
Instituto Butantan | 35
Internal validated ToBI tests presented suitable to estimate the potency not only to
tetanus fraction but ALSO to diphtheria fraction in combined vaccines
Our data met all acceptance validation criteria as specificityselectivity linearity
precision (repeatability and intermediate precision) accuracy and in vitro and in vivo
concordance showed strong correlation (R=096) for both D and T components
The high relevance of these data for replacement of animal testing strongly impacts
the routine of Quality Control turning the analyses faster accurate and cheaper and
more importantly saving the lives of hundred of animals per year
Diphtheria and Tetanus combined vaccine potency by ToBI
Conclusion after internal validation
Instituto Butantan | 36
Av Vital Brasil 1500 ndash Butantatilde - Satildeo Paulo ndash SP -
Brazil
Zip code - 05503-900
(+ 55 11) 26279453
Thank you
patriciacarneirobutantangovbr
Biotech QC team
Instituto Butantan | 19
Other 3Rs iniciatives in Butantan Institute Refinement
Previous anesthesia to intracerebral challenge for
rabies and pertussis vaccines testsChange Control CMCB-0013418 approved in 14 ago 18 and
just implemented
End point to tetanus rabies and pertussis tests
Change Control CMCB-0011618 approved in 23 march 18 and
just implemented
Instituto Butantan | 20
Other 3Rs iniciatives in Butantan Institute Refinement
Pool for pyrogen and potency tests in antitoxins bulk
ready-to-fillChange Control CMCB-0013118 approved in 29 june 18 and
just implemented
Previous anesthesia to bleeding guinea-pigs
immunized for dT DT and DTP vaccines
Euthanasia by isofluorane in mice
Instituto Butantan | 21
Av Vital Brasil 1500 ndash Butantatilde - Satildeo Paulo ndash SP - Brazil
Zip code - 05503-900
(+ 55 11) 26279453
wwwbutantangovbr
Instituto Butantan | 22
Diphtheria and Tetanus combined vaccine potency
by ToBI
Alternative methods recommended by Eur Ph and WHO ndash determination of Ab titration (potency)
- T fraction ELISA andor ToBI test
- D fraction ELISA andor Vero cell tests
Our propose
- Both fractions titration by ToBI test
Instituto Butantan | 23
In vitro potency test of vaccines dT DT DTP and DTPHB
+ diphtheria and tetanus toxoid
bull ToBI test (Toxin Binding Inhibition Test)
Hendriksen et al J Biol Stand 1988 The toxin binding inhibition test as areliable in vitro alternative to the toxin neutralization test in mice for theestimation of tetanus antitoxin in human sera
Similar principle of the in vivo potency test
Decrease of 200 mice per batch of each vaccine and 400 mice per batch
of anti-tetanus serum
Instituto Butantan | 24
dT DT DTP and DTPHB vaccines selectivity
Sample + toxoidSample + both (tetanus and
diphteria) toxoid
DTPHB313 UImL 318 UImL
100 1016
DTP497 UImL 514 UImL
100 1034
Tetanus Toxoid801 UImL 724 UImL
100 904
dT1001 UImL 101 UImL
100 1001
DT1381 UImL 1448 UImL
100 1048
Tetanus antitoxin NIBSC1038 UImL 1058 UImL
100 102
All results between 80-120
Instituto Butantan | 25
dT DT DTP and DTPHB vaccines linearity Diphtheria fraction
Parameter SpecificationExperimental
Results
Correlation
coefficient (r)ge 0950 09979
Y-intercept --------- 00816
slope --------- 09753
Coefficient of
determination (r2)ge 0950 09958
Relative Standard
Deviation (RSD)le 20 1 to 6
Instituto Butantan | 26
dT DT DTP and DTPHB vaccines linearity Tetanus fraction
Parameter SpecificationExperimental
Results
Correlation
coefficient (r)ge 0950 09996
Y-intercept --------- - 03059
slope --------- 1059
Coefficient of
determination (r2)ge 0950 09992
Relative Standard
Deviation (RSD)le 20 2 to 8
Instituto Butantan | 27
dT DT DTP and DTPHB vaccines repeatability Diphtheria fraction
dT(n=7)
DT(n=7)
DTPHB(n=9)
Diphtheria Toxoid(n=8)
DTP(n=7)
Mean (UImL) 338 467 657 668 1038
Standard Deviation 043 071 062 085 107
Relative Standard Deviation
(le20)13 15 9 13 10
An
aly
st
I
dT(n=3)
DT(n=3)
DTPHB(n=3)
Diphtheria Toxoid(n=3)
DTP(n=3)
Mean (UImL) 276 399 609 582 927
Standard Deviation 021 015 025 036 068
Relative Standard Deviation
(le20)8 4 4 6 7
An
aly
st
II
Instituto Butantan | 28
dT DT DTP and DTPHB vaccines repeatability Tetanus fraction
DTPHB(n=3)
DTP(n=3)
Tetanus Toxoid(n=3)
dT(n=3)
DT(n=3)
Mean (UImL) 313 497 801 1001 1381
Standard Deviation 027 068 064 014 026
Relative Standard Deviation
(le20)9 14 8 1 2
An
aly
st
I
DTPHB(n=3)
DTP(n=3)
Tetanus Toxoid(n=3)
dT(n=3)
DT(n=3)
Mean (UImL) 321 53 874 1031 1391
Standard Deviation 012 031 099 098 023
Relative Standard Deviation
(le20)4 6 11 10 2
An
aly
st
II
Instituto Butantan | 29
dT DT DTP and DTPHB vaccines intermediate precision Diphtheria fraction
SAMPLES
ANALYSTS I + II | X(An II) ndash X(An I) | x 100
X(An I)
(le20)
Mean(UImL)
SDRSD(le20)
dT 319 047 15 18
DT 446 067 15 15
DTPHB 645 058 9 7
Diphtheria Toxoid 645 084 13 13
DTP 1005 107 11 11
RE 8992003 (ANVISA) RSD le 5)
Instituto Butantan | 30
dT DT DTP and DTPHB vaccines intermediate precision Tetanus fraction
SAMPLES
ANALYSTS I + II | X(An II) ndash X(An I) | x 100
X(An I)
(le20)
Mean(UImL)
SDRSD(le20)
DTPHB 317 019 6 3
DTP 513 051 10 7
Tetanus Toxoid 837 085 10 9
dT 1016 065 6 3
DT 1386 023 2 1
RE 8992003 (ANVISA) RSD le 5)
Instituto Butantan | 31
dT DT DTP and DTPHB vaccines accuracy Diphtheria fraction
SAMPLESX (ToBI)(UImL)
n = 7
Official ResultIn vivo
(UImL)
n = 1
X (ToBI) x 100
Official Result(80 to 120)
dT 338 30 113
DT 467 49 95
DTPHB 657 60 110
Diphtheria
Toxoid668 66 101
DTP 1038 114 91
Instituto Butantan | 32
dT DT DTP and DTPHB vaccines accuracy Tetanus fraction
SAMPLESX (ToBI)(UImL)
n = 3
Official ResultIn vivo
(UImL)
n = 1
X (ToBI) x 100
Official Result(80 to 120)
DTPHB 313 28 112
DTP 497 46 108
Tetanus Toxoid 801 89 90
dT 1001 123 81
DT 1381 152 91
Instituto Butantan | 33
in vivo e in vitro correlation
dT DT DTP and DTPHB vaccines Diphtheria fraction potency analysis
Instituto Butantan | 34
in vivo e in vitro correlation
dT DT DTP and DTPHB vaccines Tetanus fraction potency analysis
Instituto Butantan | 35
Internal validated ToBI tests presented suitable to estimate the potency not only to
tetanus fraction but ALSO to diphtheria fraction in combined vaccines
Our data met all acceptance validation criteria as specificityselectivity linearity
precision (repeatability and intermediate precision) accuracy and in vitro and in vivo
concordance showed strong correlation (R=096) for both D and T components
The high relevance of these data for replacement of animal testing strongly impacts
the routine of Quality Control turning the analyses faster accurate and cheaper and
more importantly saving the lives of hundred of animals per year
Diphtheria and Tetanus combined vaccine potency by ToBI
Conclusion after internal validation
Instituto Butantan | 36
Av Vital Brasil 1500 ndash Butantatilde - Satildeo Paulo ndash SP -
Brazil
Zip code - 05503-900
(+ 55 11) 26279453
Thank you
patriciacarneirobutantangovbr
Biotech QC team
Instituto Butantan | 20
Other 3Rs iniciatives in Butantan Institute Refinement
Pool for pyrogen and potency tests in antitoxins bulk
ready-to-fillChange Control CMCB-0013118 approved in 29 june 18 and
just implemented
Previous anesthesia to bleeding guinea-pigs
immunized for dT DT and DTP vaccines
Euthanasia by isofluorane in mice
Instituto Butantan | 21
Av Vital Brasil 1500 ndash Butantatilde - Satildeo Paulo ndash SP - Brazil
Zip code - 05503-900
(+ 55 11) 26279453
wwwbutantangovbr
Instituto Butantan | 22
Diphtheria and Tetanus combined vaccine potency
by ToBI
Alternative methods recommended by Eur Ph and WHO ndash determination of Ab titration (potency)
- T fraction ELISA andor ToBI test
- D fraction ELISA andor Vero cell tests
Our propose
- Both fractions titration by ToBI test
Instituto Butantan | 23
In vitro potency test of vaccines dT DT DTP and DTPHB
+ diphtheria and tetanus toxoid
bull ToBI test (Toxin Binding Inhibition Test)
Hendriksen et al J Biol Stand 1988 The toxin binding inhibition test as areliable in vitro alternative to the toxin neutralization test in mice for theestimation of tetanus antitoxin in human sera
Similar principle of the in vivo potency test
Decrease of 200 mice per batch of each vaccine and 400 mice per batch
of anti-tetanus serum
Instituto Butantan | 24
dT DT DTP and DTPHB vaccines selectivity
Sample + toxoidSample + both (tetanus and
diphteria) toxoid
DTPHB313 UImL 318 UImL
100 1016
DTP497 UImL 514 UImL
100 1034
Tetanus Toxoid801 UImL 724 UImL
100 904
dT1001 UImL 101 UImL
100 1001
DT1381 UImL 1448 UImL
100 1048
Tetanus antitoxin NIBSC1038 UImL 1058 UImL
100 102
All results between 80-120
Instituto Butantan | 25
dT DT DTP and DTPHB vaccines linearity Diphtheria fraction
Parameter SpecificationExperimental
Results
Correlation
coefficient (r)ge 0950 09979
Y-intercept --------- 00816
slope --------- 09753
Coefficient of
determination (r2)ge 0950 09958
Relative Standard
Deviation (RSD)le 20 1 to 6
Instituto Butantan | 26
dT DT DTP and DTPHB vaccines linearity Tetanus fraction
Parameter SpecificationExperimental
Results
Correlation
coefficient (r)ge 0950 09996
Y-intercept --------- - 03059
slope --------- 1059
Coefficient of
determination (r2)ge 0950 09992
Relative Standard
Deviation (RSD)le 20 2 to 8
Instituto Butantan | 27
dT DT DTP and DTPHB vaccines repeatability Diphtheria fraction
dT(n=7)
DT(n=7)
DTPHB(n=9)
Diphtheria Toxoid(n=8)
DTP(n=7)
Mean (UImL) 338 467 657 668 1038
Standard Deviation 043 071 062 085 107
Relative Standard Deviation
(le20)13 15 9 13 10
An
aly
st
I
dT(n=3)
DT(n=3)
DTPHB(n=3)
Diphtheria Toxoid(n=3)
DTP(n=3)
Mean (UImL) 276 399 609 582 927
Standard Deviation 021 015 025 036 068
Relative Standard Deviation
(le20)8 4 4 6 7
An
aly
st
II
Instituto Butantan | 28
dT DT DTP and DTPHB vaccines repeatability Tetanus fraction
DTPHB(n=3)
DTP(n=3)
Tetanus Toxoid(n=3)
dT(n=3)
DT(n=3)
Mean (UImL) 313 497 801 1001 1381
Standard Deviation 027 068 064 014 026
Relative Standard Deviation
(le20)9 14 8 1 2
An
aly
st
I
DTPHB(n=3)
DTP(n=3)
Tetanus Toxoid(n=3)
dT(n=3)
DT(n=3)
Mean (UImL) 321 53 874 1031 1391
Standard Deviation 012 031 099 098 023
Relative Standard Deviation
(le20)4 6 11 10 2
An
aly
st
II
Instituto Butantan | 29
dT DT DTP and DTPHB vaccines intermediate precision Diphtheria fraction
SAMPLES
ANALYSTS I + II | X(An II) ndash X(An I) | x 100
X(An I)
(le20)
Mean(UImL)
SDRSD(le20)
dT 319 047 15 18
DT 446 067 15 15
DTPHB 645 058 9 7
Diphtheria Toxoid 645 084 13 13
DTP 1005 107 11 11
RE 8992003 (ANVISA) RSD le 5)
Instituto Butantan | 30
dT DT DTP and DTPHB vaccines intermediate precision Tetanus fraction
SAMPLES
ANALYSTS I + II | X(An II) ndash X(An I) | x 100
X(An I)
(le20)
Mean(UImL)
SDRSD(le20)
DTPHB 317 019 6 3
DTP 513 051 10 7
Tetanus Toxoid 837 085 10 9
dT 1016 065 6 3
DT 1386 023 2 1
RE 8992003 (ANVISA) RSD le 5)
Instituto Butantan | 31
dT DT DTP and DTPHB vaccines accuracy Diphtheria fraction
SAMPLESX (ToBI)(UImL)
n = 7
Official ResultIn vivo
(UImL)
n = 1
X (ToBI) x 100
Official Result(80 to 120)
dT 338 30 113
DT 467 49 95
DTPHB 657 60 110
Diphtheria
Toxoid668 66 101
DTP 1038 114 91
Instituto Butantan | 32
dT DT DTP and DTPHB vaccines accuracy Tetanus fraction
SAMPLESX (ToBI)(UImL)
n = 3
Official ResultIn vivo
(UImL)
n = 1
X (ToBI) x 100
Official Result(80 to 120)
DTPHB 313 28 112
DTP 497 46 108
Tetanus Toxoid 801 89 90
dT 1001 123 81
DT 1381 152 91
Instituto Butantan | 33
in vivo e in vitro correlation
dT DT DTP and DTPHB vaccines Diphtheria fraction potency analysis
Instituto Butantan | 34
in vivo e in vitro correlation
dT DT DTP and DTPHB vaccines Tetanus fraction potency analysis
Instituto Butantan | 35
Internal validated ToBI tests presented suitable to estimate the potency not only to
tetanus fraction but ALSO to diphtheria fraction in combined vaccines
Our data met all acceptance validation criteria as specificityselectivity linearity
precision (repeatability and intermediate precision) accuracy and in vitro and in vivo
concordance showed strong correlation (R=096) for both D and T components
The high relevance of these data for replacement of animal testing strongly impacts
the routine of Quality Control turning the analyses faster accurate and cheaper and
more importantly saving the lives of hundred of animals per year
Diphtheria and Tetanus combined vaccine potency by ToBI
Conclusion after internal validation
Instituto Butantan | 36
Av Vital Brasil 1500 ndash Butantatilde - Satildeo Paulo ndash SP -
Brazil
Zip code - 05503-900
(+ 55 11) 26279453
Thank you
patriciacarneirobutantangovbr
Biotech QC team
Instituto Butantan | 21
Av Vital Brasil 1500 ndash Butantatilde - Satildeo Paulo ndash SP - Brazil
Zip code - 05503-900
(+ 55 11) 26279453
wwwbutantangovbr
Instituto Butantan | 22
Diphtheria and Tetanus combined vaccine potency
by ToBI
Alternative methods recommended by Eur Ph and WHO ndash determination of Ab titration (potency)
- T fraction ELISA andor ToBI test
- D fraction ELISA andor Vero cell tests
Our propose
- Both fractions titration by ToBI test
Instituto Butantan | 23
In vitro potency test of vaccines dT DT DTP and DTPHB
+ diphtheria and tetanus toxoid
bull ToBI test (Toxin Binding Inhibition Test)
Hendriksen et al J Biol Stand 1988 The toxin binding inhibition test as areliable in vitro alternative to the toxin neutralization test in mice for theestimation of tetanus antitoxin in human sera
Similar principle of the in vivo potency test
Decrease of 200 mice per batch of each vaccine and 400 mice per batch
of anti-tetanus serum
Instituto Butantan | 24
dT DT DTP and DTPHB vaccines selectivity
Sample + toxoidSample + both (tetanus and
diphteria) toxoid
DTPHB313 UImL 318 UImL
100 1016
DTP497 UImL 514 UImL
100 1034
Tetanus Toxoid801 UImL 724 UImL
100 904
dT1001 UImL 101 UImL
100 1001
DT1381 UImL 1448 UImL
100 1048
Tetanus antitoxin NIBSC1038 UImL 1058 UImL
100 102
All results between 80-120
Instituto Butantan | 25
dT DT DTP and DTPHB vaccines linearity Diphtheria fraction
Parameter SpecificationExperimental
Results
Correlation
coefficient (r)ge 0950 09979
Y-intercept --------- 00816
slope --------- 09753
Coefficient of
determination (r2)ge 0950 09958
Relative Standard
Deviation (RSD)le 20 1 to 6
Instituto Butantan | 26
dT DT DTP and DTPHB vaccines linearity Tetanus fraction
Parameter SpecificationExperimental
Results
Correlation
coefficient (r)ge 0950 09996
Y-intercept --------- - 03059
slope --------- 1059
Coefficient of
determination (r2)ge 0950 09992
Relative Standard
Deviation (RSD)le 20 2 to 8
Instituto Butantan | 27
dT DT DTP and DTPHB vaccines repeatability Diphtheria fraction
dT(n=7)
DT(n=7)
DTPHB(n=9)
Diphtheria Toxoid(n=8)
DTP(n=7)
Mean (UImL) 338 467 657 668 1038
Standard Deviation 043 071 062 085 107
Relative Standard Deviation
(le20)13 15 9 13 10
An
aly
st
I
dT(n=3)
DT(n=3)
DTPHB(n=3)
Diphtheria Toxoid(n=3)
DTP(n=3)
Mean (UImL) 276 399 609 582 927
Standard Deviation 021 015 025 036 068
Relative Standard Deviation
(le20)8 4 4 6 7
An
aly
st
II
Instituto Butantan | 28
dT DT DTP and DTPHB vaccines repeatability Tetanus fraction
DTPHB(n=3)
DTP(n=3)
Tetanus Toxoid(n=3)
dT(n=3)
DT(n=3)
Mean (UImL) 313 497 801 1001 1381
Standard Deviation 027 068 064 014 026
Relative Standard Deviation
(le20)9 14 8 1 2
An
aly
st
I
DTPHB(n=3)
DTP(n=3)
Tetanus Toxoid(n=3)
dT(n=3)
DT(n=3)
Mean (UImL) 321 53 874 1031 1391
Standard Deviation 012 031 099 098 023
Relative Standard Deviation
(le20)4 6 11 10 2
An
aly
st
II
Instituto Butantan | 29
dT DT DTP and DTPHB vaccines intermediate precision Diphtheria fraction
SAMPLES
ANALYSTS I + II | X(An II) ndash X(An I) | x 100
X(An I)
(le20)
Mean(UImL)
SDRSD(le20)
dT 319 047 15 18
DT 446 067 15 15
DTPHB 645 058 9 7
Diphtheria Toxoid 645 084 13 13
DTP 1005 107 11 11
RE 8992003 (ANVISA) RSD le 5)
Instituto Butantan | 30
dT DT DTP and DTPHB vaccines intermediate precision Tetanus fraction
SAMPLES
ANALYSTS I + II | X(An II) ndash X(An I) | x 100
X(An I)
(le20)
Mean(UImL)
SDRSD(le20)
DTPHB 317 019 6 3
DTP 513 051 10 7
Tetanus Toxoid 837 085 10 9
dT 1016 065 6 3
DT 1386 023 2 1
RE 8992003 (ANVISA) RSD le 5)
Instituto Butantan | 31
dT DT DTP and DTPHB vaccines accuracy Diphtheria fraction
SAMPLESX (ToBI)(UImL)
n = 7
Official ResultIn vivo
(UImL)
n = 1
X (ToBI) x 100
Official Result(80 to 120)
dT 338 30 113
DT 467 49 95
DTPHB 657 60 110
Diphtheria
Toxoid668 66 101
DTP 1038 114 91
Instituto Butantan | 32
dT DT DTP and DTPHB vaccines accuracy Tetanus fraction
SAMPLESX (ToBI)(UImL)
n = 3
Official ResultIn vivo
(UImL)
n = 1
X (ToBI) x 100
Official Result(80 to 120)
DTPHB 313 28 112
DTP 497 46 108
Tetanus Toxoid 801 89 90
dT 1001 123 81
DT 1381 152 91
Instituto Butantan | 33
in vivo e in vitro correlation
dT DT DTP and DTPHB vaccines Diphtheria fraction potency analysis
Instituto Butantan | 34
in vivo e in vitro correlation
dT DT DTP and DTPHB vaccines Tetanus fraction potency analysis
Instituto Butantan | 35
Internal validated ToBI tests presented suitable to estimate the potency not only to
tetanus fraction but ALSO to diphtheria fraction in combined vaccines
Our data met all acceptance validation criteria as specificityselectivity linearity
precision (repeatability and intermediate precision) accuracy and in vitro and in vivo
concordance showed strong correlation (R=096) for both D and T components
The high relevance of these data for replacement of animal testing strongly impacts
the routine of Quality Control turning the analyses faster accurate and cheaper and
more importantly saving the lives of hundred of animals per year
Diphtheria and Tetanus combined vaccine potency by ToBI
Conclusion after internal validation
Instituto Butantan | 36
Av Vital Brasil 1500 ndash Butantatilde - Satildeo Paulo ndash SP -
Brazil
Zip code - 05503-900
(+ 55 11) 26279453
Thank you
patriciacarneirobutantangovbr
Biotech QC team
Instituto Butantan | 22
Diphtheria and Tetanus combined vaccine potency
by ToBI
Alternative methods recommended by Eur Ph and WHO ndash determination of Ab titration (potency)
- T fraction ELISA andor ToBI test
- D fraction ELISA andor Vero cell tests
Our propose
- Both fractions titration by ToBI test
Instituto Butantan | 23
In vitro potency test of vaccines dT DT DTP and DTPHB
+ diphtheria and tetanus toxoid
bull ToBI test (Toxin Binding Inhibition Test)
Hendriksen et al J Biol Stand 1988 The toxin binding inhibition test as areliable in vitro alternative to the toxin neutralization test in mice for theestimation of tetanus antitoxin in human sera
Similar principle of the in vivo potency test
Decrease of 200 mice per batch of each vaccine and 400 mice per batch
of anti-tetanus serum
Instituto Butantan | 24
dT DT DTP and DTPHB vaccines selectivity
Sample + toxoidSample + both (tetanus and
diphteria) toxoid
DTPHB313 UImL 318 UImL
100 1016
DTP497 UImL 514 UImL
100 1034
Tetanus Toxoid801 UImL 724 UImL
100 904
dT1001 UImL 101 UImL
100 1001
DT1381 UImL 1448 UImL
100 1048
Tetanus antitoxin NIBSC1038 UImL 1058 UImL
100 102
All results between 80-120
Instituto Butantan | 25
dT DT DTP and DTPHB vaccines linearity Diphtheria fraction
Parameter SpecificationExperimental
Results
Correlation
coefficient (r)ge 0950 09979
Y-intercept --------- 00816
slope --------- 09753
Coefficient of
determination (r2)ge 0950 09958
Relative Standard
Deviation (RSD)le 20 1 to 6
Instituto Butantan | 26
dT DT DTP and DTPHB vaccines linearity Tetanus fraction
Parameter SpecificationExperimental
Results
Correlation
coefficient (r)ge 0950 09996
Y-intercept --------- - 03059
slope --------- 1059
Coefficient of
determination (r2)ge 0950 09992
Relative Standard
Deviation (RSD)le 20 2 to 8
Instituto Butantan | 27
dT DT DTP and DTPHB vaccines repeatability Diphtheria fraction
dT(n=7)
DT(n=7)
DTPHB(n=9)
Diphtheria Toxoid(n=8)
DTP(n=7)
Mean (UImL) 338 467 657 668 1038
Standard Deviation 043 071 062 085 107
Relative Standard Deviation
(le20)13 15 9 13 10
An
aly
st
I
dT(n=3)
DT(n=3)
DTPHB(n=3)
Diphtheria Toxoid(n=3)
DTP(n=3)
Mean (UImL) 276 399 609 582 927
Standard Deviation 021 015 025 036 068
Relative Standard Deviation
(le20)8 4 4 6 7
An
aly
st
II
Instituto Butantan | 28
dT DT DTP and DTPHB vaccines repeatability Tetanus fraction
DTPHB(n=3)
DTP(n=3)
Tetanus Toxoid(n=3)
dT(n=3)
DT(n=3)
Mean (UImL) 313 497 801 1001 1381
Standard Deviation 027 068 064 014 026
Relative Standard Deviation
(le20)9 14 8 1 2
An
aly
st
I
DTPHB(n=3)
DTP(n=3)
Tetanus Toxoid(n=3)
dT(n=3)
DT(n=3)
Mean (UImL) 321 53 874 1031 1391
Standard Deviation 012 031 099 098 023
Relative Standard Deviation
(le20)4 6 11 10 2
An
aly
st
II
Instituto Butantan | 29
dT DT DTP and DTPHB vaccines intermediate precision Diphtheria fraction
SAMPLES
ANALYSTS I + II | X(An II) ndash X(An I) | x 100
X(An I)
(le20)
Mean(UImL)
SDRSD(le20)
dT 319 047 15 18
DT 446 067 15 15
DTPHB 645 058 9 7
Diphtheria Toxoid 645 084 13 13
DTP 1005 107 11 11
RE 8992003 (ANVISA) RSD le 5)
Instituto Butantan | 30
dT DT DTP and DTPHB vaccines intermediate precision Tetanus fraction
SAMPLES
ANALYSTS I + II | X(An II) ndash X(An I) | x 100
X(An I)
(le20)
Mean(UImL)
SDRSD(le20)
DTPHB 317 019 6 3
DTP 513 051 10 7
Tetanus Toxoid 837 085 10 9
dT 1016 065 6 3
DT 1386 023 2 1
RE 8992003 (ANVISA) RSD le 5)
Instituto Butantan | 31
dT DT DTP and DTPHB vaccines accuracy Diphtheria fraction
SAMPLESX (ToBI)(UImL)
n = 7
Official ResultIn vivo
(UImL)
n = 1
X (ToBI) x 100
Official Result(80 to 120)
dT 338 30 113
DT 467 49 95
DTPHB 657 60 110
Diphtheria
Toxoid668 66 101
DTP 1038 114 91
Instituto Butantan | 32
dT DT DTP and DTPHB vaccines accuracy Tetanus fraction
SAMPLESX (ToBI)(UImL)
n = 3
Official ResultIn vivo
(UImL)
n = 1
X (ToBI) x 100
Official Result(80 to 120)
DTPHB 313 28 112
DTP 497 46 108
Tetanus Toxoid 801 89 90
dT 1001 123 81
DT 1381 152 91
Instituto Butantan | 33
in vivo e in vitro correlation
dT DT DTP and DTPHB vaccines Diphtheria fraction potency analysis
Instituto Butantan | 34
in vivo e in vitro correlation
dT DT DTP and DTPHB vaccines Tetanus fraction potency analysis
Instituto Butantan | 35
Internal validated ToBI tests presented suitable to estimate the potency not only to
tetanus fraction but ALSO to diphtheria fraction in combined vaccines
Our data met all acceptance validation criteria as specificityselectivity linearity
precision (repeatability and intermediate precision) accuracy and in vitro and in vivo
concordance showed strong correlation (R=096) for both D and T components
The high relevance of these data for replacement of animal testing strongly impacts
the routine of Quality Control turning the analyses faster accurate and cheaper and
more importantly saving the lives of hundred of animals per year
Diphtheria and Tetanus combined vaccine potency by ToBI
Conclusion after internal validation
Instituto Butantan | 36
Av Vital Brasil 1500 ndash Butantatilde - Satildeo Paulo ndash SP -
Brazil
Zip code - 05503-900
(+ 55 11) 26279453
Thank you
patriciacarneirobutantangovbr
Biotech QC team
Instituto Butantan | 23
In vitro potency test of vaccines dT DT DTP and DTPHB
+ diphtheria and tetanus toxoid
bull ToBI test (Toxin Binding Inhibition Test)
Hendriksen et al J Biol Stand 1988 The toxin binding inhibition test as areliable in vitro alternative to the toxin neutralization test in mice for theestimation of tetanus antitoxin in human sera
Similar principle of the in vivo potency test
Decrease of 200 mice per batch of each vaccine and 400 mice per batch
of anti-tetanus serum
Instituto Butantan | 24
dT DT DTP and DTPHB vaccines selectivity
Sample + toxoidSample + both (tetanus and
diphteria) toxoid
DTPHB313 UImL 318 UImL
100 1016
DTP497 UImL 514 UImL
100 1034
Tetanus Toxoid801 UImL 724 UImL
100 904
dT1001 UImL 101 UImL
100 1001
DT1381 UImL 1448 UImL
100 1048
Tetanus antitoxin NIBSC1038 UImL 1058 UImL
100 102
All results between 80-120
Instituto Butantan | 25
dT DT DTP and DTPHB vaccines linearity Diphtheria fraction
Parameter SpecificationExperimental
Results
Correlation
coefficient (r)ge 0950 09979
Y-intercept --------- 00816
slope --------- 09753
Coefficient of
determination (r2)ge 0950 09958
Relative Standard
Deviation (RSD)le 20 1 to 6
Instituto Butantan | 26
dT DT DTP and DTPHB vaccines linearity Tetanus fraction
Parameter SpecificationExperimental
Results
Correlation
coefficient (r)ge 0950 09996
Y-intercept --------- - 03059
slope --------- 1059
Coefficient of
determination (r2)ge 0950 09992
Relative Standard
Deviation (RSD)le 20 2 to 8
Instituto Butantan | 27
dT DT DTP and DTPHB vaccines repeatability Diphtheria fraction
dT(n=7)
DT(n=7)
DTPHB(n=9)
Diphtheria Toxoid(n=8)
DTP(n=7)
Mean (UImL) 338 467 657 668 1038
Standard Deviation 043 071 062 085 107
Relative Standard Deviation
(le20)13 15 9 13 10
An
aly
st
I
dT(n=3)
DT(n=3)
DTPHB(n=3)
Diphtheria Toxoid(n=3)
DTP(n=3)
Mean (UImL) 276 399 609 582 927
Standard Deviation 021 015 025 036 068
Relative Standard Deviation
(le20)8 4 4 6 7
An
aly
st
II
Instituto Butantan | 28
dT DT DTP and DTPHB vaccines repeatability Tetanus fraction
DTPHB(n=3)
DTP(n=3)
Tetanus Toxoid(n=3)
dT(n=3)
DT(n=3)
Mean (UImL) 313 497 801 1001 1381
Standard Deviation 027 068 064 014 026
Relative Standard Deviation
(le20)9 14 8 1 2
An
aly
st
I
DTPHB(n=3)
DTP(n=3)
Tetanus Toxoid(n=3)
dT(n=3)
DT(n=3)
Mean (UImL) 321 53 874 1031 1391
Standard Deviation 012 031 099 098 023
Relative Standard Deviation
(le20)4 6 11 10 2
An
aly
st
II
Instituto Butantan | 29
dT DT DTP and DTPHB vaccines intermediate precision Diphtheria fraction
SAMPLES
ANALYSTS I + II | X(An II) ndash X(An I) | x 100
X(An I)
(le20)
Mean(UImL)
SDRSD(le20)
dT 319 047 15 18
DT 446 067 15 15
DTPHB 645 058 9 7
Diphtheria Toxoid 645 084 13 13
DTP 1005 107 11 11
RE 8992003 (ANVISA) RSD le 5)
Instituto Butantan | 30
dT DT DTP and DTPHB vaccines intermediate precision Tetanus fraction
SAMPLES
ANALYSTS I + II | X(An II) ndash X(An I) | x 100
X(An I)
(le20)
Mean(UImL)
SDRSD(le20)
DTPHB 317 019 6 3
DTP 513 051 10 7
Tetanus Toxoid 837 085 10 9
dT 1016 065 6 3
DT 1386 023 2 1
RE 8992003 (ANVISA) RSD le 5)
Instituto Butantan | 31
dT DT DTP and DTPHB vaccines accuracy Diphtheria fraction
SAMPLESX (ToBI)(UImL)
n = 7
Official ResultIn vivo
(UImL)
n = 1
X (ToBI) x 100
Official Result(80 to 120)
dT 338 30 113
DT 467 49 95
DTPHB 657 60 110
Diphtheria
Toxoid668 66 101
DTP 1038 114 91
Instituto Butantan | 32
dT DT DTP and DTPHB vaccines accuracy Tetanus fraction
SAMPLESX (ToBI)(UImL)
n = 3
Official ResultIn vivo
(UImL)
n = 1
X (ToBI) x 100
Official Result(80 to 120)
DTPHB 313 28 112
DTP 497 46 108
Tetanus Toxoid 801 89 90
dT 1001 123 81
DT 1381 152 91
Instituto Butantan | 33
in vivo e in vitro correlation
dT DT DTP and DTPHB vaccines Diphtheria fraction potency analysis
Instituto Butantan | 34
in vivo e in vitro correlation
dT DT DTP and DTPHB vaccines Tetanus fraction potency analysis
Instituto Butantan | 35
Internal validated ToBI tests presented suitable to estimate the potency not only to
tetanus fraction but ALSO to diphtheria fraction in combined vaccines
Our data met all acceptance validation criteria as specificityselectivity linearity
precision (repeatability and intermediate precision) accuracy and in vitro and in vivo
concordance showed strong correlation (R=096) for both D and T components
The high relevance of these data for replacement of animal testing strongly impacts
the routine of Quality Control turning the analyses faster accurate and cheaper and
more importantly saving the lives of hundred of animals per year
Diphtheria and Tetanus combined vaccine potency by ToBI
Conclusion after internal validation
Instituto Butantan | 36
Av Vital Brasil 1500 ndash Butantatilde - Satildeo Paulo ndash SP -
Brazil
Zip code - 05503-900
(+ 55 11) 26279453
Thank you
patriciacarneirobutantangovbr
Biotech QC team
Instituto Butantan | 24
dT DT DTP and DTPHB vaccines selectivity
Sample + toxoidSample + both (tetanus and
diphteria) toxoid
DTPHB313 UImL 318 UImL
100 1016
DTP497 UImL 514 UImL
100 1034
Tetanus Toxoid801 UImL 724 UImL
100 904
dT1001 UImL 101 UImL
100 1001
DT1381 UImL 1448 UImL
100 1048
Tetanus antitoxin NIBSC1038 UImL 1058 UImL
100 102
All results between 80-120
Instituto Butantan | 25
dT DT DTP and DTPHB vaccines linearity Diphtheria fraction
Parameter SpecificationExperimental
Results
Correlation
coefficient (r)ge 0950 09979
Y-intercept --------- 00816
slope --------- 09753
Coefficient of
determination (r2)ge 0950 09958
Relative Standard
Deviation (RSD)le 20 1 to 6
Instituto Butantan | 26
dT DT DTP and DTPHB vaccines linearity Tetanus fraction
Parameter SpecificationExperimental
Results
Correlation
coefficient (r)ge 0950 09996
Y-intercept --------- - 03059
slope --------- 1059
Coefficient of
determination (r2)ge 0950 09992
Relative Standard
Deviation (RSD)le 20 2 to 8
Instituto Butantan | 27
dT DT DTP and DTPHB vaccines repeatability Diphtheria fraction
dT(n=7)
DT(n=7)
DTPHB(n=9)
Diphtheria Toxoid(n=8)
DTP(n=7)
Mean (UImL) 338 467 657 668 1038
Standard Deviation 043 071 062 085 107
Relative Standard Deviation
(le20)13 15 9 13 10
An
aly
st
I
dT(n=3)
DT(n=3)
DTPHB(n=3)
Diphtheria Toxoid(n=3)
DTP(n=3)
Mean (UImL) 276 399 609 582 927
Standard Deviation 021 015 025 036 068
Relative Standard Deviation
(le20)8 4 4 6 7
An
aly
st
II
Instituto Butantan | 28
dT DT DTP and DTPHB vaccines repeatability Tetanus fraction
DTPHB(n=3)
DTP(n=3)
Tetanus Toxoid(n=3)
dT(n=3)
DT(n=3)
Mean (UImL) 313 497 801 1001 1381
Standard Deviation 027 068 064 014 026
Relative Standard Deviation
(le20)9 14 8 1 2
An
aly
st
I
DTPHB(n=3)
DTP(n=3)
Tetanus Toxoid(n=3)
dT(n=3)
DT(n=3)
Mean (UImL) 321 53 874 1031 1391
Standard Deviation 012 031 099 098 023
Relative Standard Deviation
(le20)4 6 11 10 2
An
aly
st
II
Instituto Butantan | 29
dT DT DTP and DTPHB vaccines intermediate precision Diphtheria fraction
SAMPLES
ANALYSTS I + II | X(An II) ndash X(An I) | x 100
X(An I)
(le20)
Mean(UImL)
SDRSD(le20)
dT 319 047 15 18
DT 446 067 15 15
DTPHB 645 058 9 7
Diphtheria Toxoid 645 084 13 13
DTP 1005 107 11 11
RE 8992003 (ANVISA) RSD le 5)
Instituto Butantan | 30
dT DT DTP and DTPHB vaccines intermediate precision Tetanus fraction
SAMPLES
ANALYSTS I + II | X(An II) ndash X(An I) | x 100
X(An I)
(le20)
Mean(UImL)
SDRSD(le20)
DTPHB 317 019 6 3
DTP 513 051 10 7
Tetanus Toxoid 837 085 10 9
dT 1016 065 6 3
DT 1386 023 2 1
RE 8992003 (ANVISA) RSD le 5)
Instituto Butantan | 31
dT DT DTP and DTPHB vaccines accuracy Diphtheria fraction
SAMPLESX (ToBI)(UImL)
n = 7
Official ResultIn vivo
(UImL)
n = 1
X (ToBI) x 100
Official Result(80 to 120)
dT 338 30 113
DT 467 49 95
DTPHB 657 60 110
Diphtheria
Toxoid668 66 101
DTP 1038 114 91
Instituto Butantan | 32
dT DT DTP and DTPHB vaccines accuracy Tetanus fraction
SAMPLESX (ToBI)(UImL)
n = 3
Official ResultIn vivo
(UImL)
n = 1
X (ToBI) x 100
Official Result(80 to 120)
DTPHB 313 28 112
DTP 497 46 108
Tetanus Toxoid 801 89 90
dT 1001 123 81
DT 1381 152 91
Instituto Butantan | 33
in vivo e in vitro correlation
dT DT DTP and DTPHB vaccines Diphtheria fraction potency analysis
Instituto Butantan | 34
in vivo e in vitro correlation
dT DT DTP and DTPHB vaccines Tetanus fraction potency analysis
Instituto Butantan | 35
Internal validated ToBI tests presented suitable to estimate the potency not only to
tetanus fraction but ALSO to diphtheria fraction in combined vaccines
Our data met all acceptance validation criteria as specificityselectivity linearity
precision (repeatability and intermediate precision) accuracy and in vitro and in vivo
concordance showed strong correlation (R=096) for both D and T components
The high relevance of these data for replacement of animal testing strongly impacts
the routine of Quality Control turning the analyses faster accurate and cheaper and
more importantly saving the lives of hundred of animals per year
Diphtheria and Tetanus combined vaccine potency by ToBI
Conclusion after internal validation
Instituto Butantan | 36
Av Vital Brasil 1500 ndash Butantatilde - Satildeo Paulo ndash SP -
Brazil
Zip code - 05503-900
(+ 55 11) 26279453
Thank you
patriciacarneirobutantangovbr
Biotech QC team
Instituto Butantan | 25
dT DT DTP and DTPHB vaccines linearity Diphtheria fraction
Parameter SpecificationExperimental
Results
Correlation
coefficient (r)ge 0950 09979
Y-intercept --------- 00816
slope --------- 09753
Coefficient of
determination (r2)ge 0950 09958
Relative Standard
Deviation (RSD)le 20 1 to 6
Instituto Butantan | 26
dT DT DTP and DTPHB vaccines linearity Tetanus fraction
Parameter SpecificationExperimental
Results
Correlation
coefficient (r)ge 0950 09996
Y-intercept --------- - 03059
slope --------- 1059
Coefficient of
determination (r2)ge 0950 09992
Relative Standard
Deviation (RSD)le 20 2 to 8
Instituto Butantan | 27
dT DT DTP and DTPHB vaccines repeatability Diphtheria fraction
dT(n=7)
DT(n=7)
DTPHB(n=9)
Diphtheria Toxoid(n=8)
DTP(n=7)
Mean (UImL) 338 467 657 668 1038
Standard Deviation 043 071 062 085 107
Relative Standard Deviation
(le20)13 15 9 13 10
An
aly
st
I
dT(n=3)
DT(n=3)
DTPHB(n=3)
Diphtheria Toxoid(n=3)
DTP(n=3)
Mean (UImL) 276 399 609 582 927
Standard Deviation 021 015 025 036 068
Relative Standard Deviation
(le20)8 4 4 6 7
An
aly
st
II
Instituto Butantan | 28
dT DT DTP and DTPHB vaccines repeatability Tetanus fraction
DTPHB(n=3)
DTP(n=3)
Tetanus Toxoid(n=3)
dT(n=3)
DT(n=3)
Mean (UImL) 313 497 801 1001 1381
Standard Deviation 027 068 064 014 026
Relative Standard Deviation
(le20)9 14 8 1 2
An
aly
st
I
DTPHB(n=3)
DTP(n=3)
Tetanus Toxoid(n=3)
dT(n=3)
DT(n=3)
Mean (UImL) 321 53 874 1031 1391
Standard Deviation 012 031 099 098 023
Relative Standard Deviation
(le20)4 6 11 10 2
An
aly
st
II
Instituto Butantan | 29
dT DT DTP and DTPHB vaccines intermediate precision Diphtheria fraction
SAMPLES
ANALYSTS I + II | X(An II) ndash X(An I) | x 100
X(An I)
(le20)
Mean(UImL)
SDRSD(le20)
dT 319 047 15 18
DT 446 067 15 15
DTPHB 645 058 9 7
Diphtheria Toxoid 645 084 13 13
DTP 1005 107 11 11
RE 8992003 (ANVISA) RSD le 5)
Instituto Butantan | 30
dT DT DTP and DTPHB vaccines intermediate precision Tetanus fraction
SAMPLES
ANALYSTS I + II | X(An II) ndash X(An I) | x 100
X(An I)
(le20)
Mean(UImL)
SDRSD(le20)
DTPHB 317 019 6 3
DTP 513 051 10 7
Tetanus Toxoid 837 085 10 9
dT 1016 065 6 3
DT 1386 023 2 1
RE 8992003 (ANVISA) RSD le 5)
Instituto Butantan | 31
dT DT DTP and DTPHB vaccines accuracy Diphtheria fraction
SAMPLESX (ToBI)(UImL)
n = 7
Official ResultIn vivo
(UImL)
n = 1
X (ToBI) x 100
Official Result(80 to 120)
dT 338 30 113
DT 467 49 95
DTPHB 657 60 110
Diphtheria
Toxoid668 66 101
DTP 1038 114 91
Instituto Butantan | 32
dT DT DTP and DTPHB vaccines accuracy Tetanus fraction
SAMPLESX (ToBI)(UImL)
n = 3
Official ResultIn vivo
(UImL)
n = 1
X (ToBI) x 100
Official Result(80 to 120)
DTPHB 313 28 112
DTP 497 46 108
Tetanus Toxoid 801 89 90
dT 1001 123 81
DT 1381 152 91
Instituto Butantan | 33
in vivo e in vitro correlation
dT DT DTP and DTPHB vaccines Diphtheria fraction potency analysis
Instituto Butantan | 34
in vivo e in vitro correlation
dT DT DTP and DTPHB vaccines Tetanus fraction potency analysis
Instituto Butantan | 35
Internal validated ToBI tests presented suitable to estimate the potency not only to
tetanus fraction but ALSO to diphtheria fraction in combined vaccines
Our data met all acceptance validation criteria as specificityselectivity linearity
precision (repeatability and intermediate precision) accuracy and in vitro and in vivo
concordance showed strong correlation (R=096) for both D and T components
The high relevance of these data for replacement of animal testing strongly impacts
the routine of Quality Control turning the analyses faster accurate and cheaper and
more importantly saving the lives of hundred of animals per year
Diphtheria and Tetanus combined vaccine potency by ToBI
Conclusion after internal validation
Instituto Butantan | 36
Av Vital Brasil 1500 ndash Butantatilde - Satildeo Paulo ndash SP -
Brazil
Zip code - 05503-900
(+ 55 11) 26279453
Thank you
patriciacarneirobutantangovbr
Biotech QC team
Instituto Butantan | 26
dT DT DTP and DTPHB vaccines linearity Tetanus fraction
Parameter SpecificationExperimental
Results
Correlation
coefficient (r)ge 0950 09996
Y-intercept --------- - 03059
slope --------- 1059
Coefficient of
determination (r2)ge 0950 09992
Relative Standard
Deviation (RSD)le 20 2 to 8
Instituto Butantan | 27
dT DT DTP and DTPHB vaccines repeatability Diphtheria fraction
dT(n=7)
DT(n=7)
DTPHB(n=9)
Diphtheria Toxoid(n=8)
DTP(n=7)
Mean (UImL) 338 467 657 668 1038
Standard Deviation 043 071 062 085 107
Relative Standard Deviation
(le20)13 15 9 13 10
An
aly
st
I
dT(n=3)
DT(n=3)
DTPHB(n=3)
Diphtheria Toxoid(n=3)
DTP(n=3)
Mean (UImL) 276 399 609 582 927
Standard Deviation 021 015 025 036 068
Relative Standard Deviation
(le20)8 4 4 6 7
An
aly
st
II
Instituto Butantan | 28
dT DT DTP and DTPHB vaccines repeatability Tetanus fraction
DTPHB(n=3)
DTP(n=3)
Tetanus Toxoid(n=3)
dT(n=3)
DT(n=3)
Mean (UImL) 313 497 801 1001 1381
Standard Deviation 027 068 064 014 026
Relative Standard Deviation
(le20)9 14 8 1 2
An
aly
st
I
DTPHB(n=3)
DTP(n=3)
Tetanus Toxoid(n=3)
dT(n=3)
DT(n=3)
Mean (UImL) 321 53 874 1031 1391
Standard Deviation 012 031 099 098 023
Relative Standard Deviation
(le20)4 6 11 10 2
An
aly
st
II
Instituto Butantan | 29
dT DT DTP and DTPHB vaccines intermediate precision Diphtheria fraction
SAMPLES
ANALYSTS I + II | X(An II) ndash X(An I) | x 100
X(An I)
(le20)
Mean(UImL)
SDRSD(le20)
dT 319 047 15 18
DT 446 067 15 15
DTPHB 645 058 9 7
Diphtheria Toxoid 645 084 13 13
DTP 1005 107 11 11
RE 8992003 (ANVISA) RSD le 5)
Instituto Butantan | 30
dT DT DTP and DTPHB vaccines intermediate precision Tetanus fraction
SAMPLES
ANALYSTS I + II | X(An II) ndash X(An I) | x 100
X(An I)
(le20)
Mean(UImL)
SDRSD(le20)
DTPHB 317 019 6 3
DTP 513 051 10 7
Tetanus Toxoid 837 085 10 9
dT 1016 065 6 3
DT 1386 023 2 1
RE 8992003 (ANVISA) RSD le 5)
Instituto Butantan | 31
dT DT DTP and DTPHB vaccines accuracy Diphtheria fraction
SAMPLESX (ToBI)(UImL)
n = 7
Official ResultIn vivo
(UImL)
n = 1
X (ToBI) x 100
Official Result(80 to 120)
dT 338 30 113
DT 467 49 95
DTPHB 657 60 110
Diphtheria
Toxoid668 66 101
DTP 1038 114 91
Instituto Butantan | 32
dT DT DTP and DTPHB vaccines accuracy Tetanus fraction
SAMPLESX (ToBI)(UImL)
n = 3
Official ResultIn vivo
(UImL)
n = 1
X (ToBI) x 100
Official Result(80 to 120)
DTPHB 313 28 112
DTP 497 46 108
Tetanus Toxoid 801 89 90
dT 1001 123 81
DT 1381 152 91
Instituto Butantan | 33
in vivo e in vitro correlation
dT DT DTP and DTPHB vaccines Diphtheria fraction potency analysis
Instituto Butantan | 34
in vivo e in vitro correlation
dT DT DTP and DTPHB vaccines Tetanus fraction potency analysis
Instituto Butantan | 35
Internal validated ToBI tests presented suitable to estimate the potency not only to
tetanus fraction but ALSO to diphtheria fraction in combined vaccines
Our data met all acceptance validation criteria as specificityselectivity linearity
precision (repeatability and intermediate precision) accuracy and in vitro and in vivo
concordance showed strong correlation (R=096) for both D and T components
The high relevance of these data for replacement of animal testing strongly impacts
the routine of Quality Control turning the analyses faster accurate and cheaper and
more importantly saving the lives of hundred of animals per year
Diphtheria and Tetanus combined vaccine potency by ToBI
Conclusion after internal validation
Instituto Butantan | 36
Av Vital Brasil 1500 ndash Butantatilde - Satildeo Paulo ndash SP -
Brazil
Zip code - 05503-900
(+ 55 11) 26279453
Thank you
patriciacarneirobutantangovbr
Biotech QC team
Instituto Butantan | 27
dT DT DTP and DTPHB vaccines repeatability Diphtheria fraction
dT(n=7)
DT(n=7)
DTPHB(n=9)
Diphtheria Toxoid(n=8)
DTP(n=7)
Mean (UImL) 338 467 657 668 1038
Standard Deviation 043 071 062 085 107
Relative Standard Deviation
(le20)13 15 9 13 10
An
aly
st
I
dT(n=3)
DT(n=3)
DTPHB(n=3)
Diphtheria Toxoid(n=3)
DTP(n=3)
Mean (UImL) 276 399 609 582 927
Standard Deviation 021 015 025 036 068
Relative Standard Deviation
(le20)8 4 4 6 7
An
aly
st
II
Instituto Butantan | 28
dT DT DTP and DTPHB vaccines repeatability Tetanus fraction
DTPHB(n=3)
DTP(n=3)
Tetanus Toxoid(n=3)
dT(n=3)
DT(n=3)
Mean (UImL) 313 497 801 1001 1381
Standard Deviation 027 068 064 014 026
Relative Standard Deviation
(le20)9 14 8 1 2
An
aly
st
I
DTPHB(n=3)
DTP(n=3)
Tetanus Toxoid(n=3)
dT(n=3)
DT(n=3)
Mean (UImL) 321 53 874 1031 1391
Standard Deviation 012 031 099 098 023
Relative Standard Deviation
(le20)4 6 11 10 2
An
aly
st
II
Instituto Butantan | 29
dT DT DTP and DTPHB vaccines intermediate precision Diphtheria fraction
SAMPLES
ANALYSTS I + II | X(An II) ndash X(An I) | x 100
X(An I)
(le20)
Mean(UImL)
SDRSD(le20)
dT 319 047 15 18
DT 446 067 15 15
DTPHB 645 058 9 7
Diphtheria Toxoid 645 084 13 13
DTP 1005 107 11 11
RE 8992003 (ANVISA) RSD le 5)
Instituto Butantan | 30
dT DT DTP and DTPHB vaccines intermediate precision Tetanus fraction
SAMPLES
ANALYSTS I + II | X(An II) ndash X(An I) | x 100
X(An I)
(le20)
Mean(UImL)
SDRSD(le20)
DTPHB 317 019 6 3
DTP 513 051 10 7
Tetanus Toxoid 837 085 10 9
dT 1016 065 6 3
DT 1386 023 2 1
RE 8992003 (ANVISA) RSD le 5)
Instituto Butantan | 31
dT DT DTP and DTPHB vaccines accuracy Diphtheria fraction
SAMPLESX (ToBI)(UImL)
n = 7
Official ResultIn vivo
(UImL)
n = 1
X (ToBI) x 100
Official Result(80 to 120)
dT 338 30 113
DT 467 49 95
DTPHB 657 60 110
Diphtheria
Toxoid668 66 101
DTP 1038 114 91
Instituto Butantan | 32
dT DT DTP and DTPHB vaccines accuracy Tetanus fraction
SAMPLESX (ToBI)(UImL)
n = 3
Official ResultIn vivo
(UImL)
n = 1
X (ToBI) x 100
Official Result(80 to 120)
DTPHB 313 28 112
DTP 497 46 108
Tetanus Toxoid 801 89 90
dT 1001 123 81
DT 1381 152 91
Instituto Butantan | 33
in vivo e in vitro correlation
dT DT DTP and DTPHB vaccines Diphtheria fraction potency analysis
Instituto Butantan | 34
in vivo e in vitro correlation
dT DT DTP and DTPHB vaccines Tetanus fraction potency analysis
Instituto Butantan | 35
Internal validated ToBI tests presented suitable to estimate the potency not only to
tetanus fraction but ALSO to diphtheria fraction in combined vaccines
Our data met all acceptance validation criteria as specificityselectivity linearity
precision (repeatability and intermediate precision) accuracy and in vitro and in vivo
concordance showed strong correlation (R=096) for both D and T components
The high relevance of these data for replacement of animal testing strongly impacts
the routine of Quality Control turning the analyses faster accurate and cheaper and
more importantly saving the lives of hundred of animals per year
Diphtheria and Tetanus combined vaccine potency by ToBI
Conclusion after internal validation
Instituto Butantan | 36
Av Vital Brasil 1500 ndash Butantatilde - Satildeo Paulo ndash SP -
Brazil
Zip code - 05503-900
(+ 55 11) 26279453
Thank you
patriciacarneirobutantangovbr
Biotech QC team
Instituto Butantan | 28
dT DT DTP and DTPHB vaccines repeatability Tetanus fraction
DTPHB(n=3)
DTP(n=3)
Tetanus Toxoid(n=3)
dT(n=3)
DT(n=3)
Mean (UImL) 313 497 801 1001 1381
Standard Deviation 027 068 064 014 026
Relative Standard Deviation
(le20)9 14 8 1 2
An
aly
st
I
DTPHB(n=3)
DTP(n=3)
Tetanus Toxoid(n=3)
dT(n=3)
DT(n=3)
Mean (UImL) 321 53 874 1031 1391
Standard Deviation 012 031 099 098 023
Relative Standard Deviation
(le20)4 6 11 10 2
An
aly
st
II
Instituto Butantan | 29
dT DT DTP and DTPHB vaccines intermediate precision Diphtheria fraction
SAMPLES
ANALYSTS I + II | X(An II) ndash X(An I) | x 100
X(An I)
(le20)
Mean(UImL)
SDRSD(le20)
dT 319 047 15 18
DT 446 067 15 15
DTPHB 645 058 9 7
Diphtheria Toxoid 645 084 13 13
DTP 1005 107 11 11
RE 8992003 (ANVISA) RSD le 5)
Instituto Butantan | 30
dT DT DTP and DTPHB vaccines intermediate precision Tetanus fraction
SAMPLES
ANALYSTS I + II | X(An II) ndash X(An I) | x 100
X(An I)
(le20)
Mean(UImL)
SDRSD(le20)
DTPHB 317 019 6 3
DTP 513 051 10 7
Tetanus Toxoid 837 085 10 9
dT 1016 065 6 3
DT 1386 023 2 1
RE 8992003 (ANVISA) RSD le 5)
Instituto Butantan | 31
dT DT DTP and DTPHB vaccines accuracy Diphtheria fraction
SAMPLESX (ToBI)(UImL)
n = 7
Official ResultIn vivo
(UImL)
n = 1
X (ToBI) x 100
Official Result(80 to 120)
dT 338 30 113
DT 467 49 95
DTPHB 657 60 110
Diphtheria
Toxoid668 66 101
DTP 1038 114 91
Instituto Butantan | 32
dT DT DTP and DTPHB vaccines accuracy Tetanus fraction
SAMPLESX (ToBI)(UImL)
n = 3
Official ResultIn vivo
(UImL)
n = 1
X (ToBI) x 100
Official Result(80 to 120)
DTPHB 313 28 112
DTP 497 46 108
Tetanus Toxoid 801 89 90
dT 1001 123 81
DT 1381 152 91
Instituto Butantan | 33
in vivo e in vitro correlation
dT DT DTP and DTPHB vaccines Diphtheria fraction potency analysis
Instituto Butantan | 34
in vivo e in vitro correlation
dT DT DTP and DTPHB vaccines Tetanus fraction potency analysis
Instituto Butantan | 35
Internal validated ToBI tests presented suitable to estimate the potency not only to
tetanus fraction but ALSO to diphtheria fraction in combined vaccines
Our data met all acceptance validation criteria as specificityselectivity linearity
precision (repeatability and intermediate precision) accuracy and in vitro and in vivo
concordance showed strong correlation (R=096) for both D and T components
The high relevance of these data for replacement of animal testing strongly impacts
the routine of Quality Control turning the analyses faster accurate and cheaper and
more importantly saving the lives of hundred of animals per year
Diphtheria and Tetanus combined vaccine potency by ToBI
Conclusion after internal validation
Instituto Butantan | 36
Av Vital Brasil 1500 ndash Butantatilde - Satildeo Paulo ndash SP -
Brazil
Zip code - 05503-900
(+ 55 11) 26279453
Thank you
patriciacarneirobutantangovbr
Biotech QC team
Instituto Butantan | 29
dT DT DTP and DTPHB vaccines intermediate precision Diphtheria fraction
SAMPLES
ANALYSTS I + II | X(An II) ndash X(An I) | x 100
X(An I)
(le20)
Mean(UImL)
SDRSD(le20)
dT 319 047 15 18
DT 446 067 15 15
DTPHB 645 058 9 7
Diphtheria Toxoid 645 084 13 13
DTP 1005 107 11 11
RE 8992003 (ANVISA) RSD le 5)
Instituto Butantan | 30
dT DT DTP and DTPHB vaccines intermediate precision Tetanus fraction
SAMPLES
ANALYSTS I + II | X(An II) ndash X(An I) | x 100
X(An I)
(le20)
Mean(UImL)
SDRSD(le20)
DTPHB 317 019 6 3
DTP 513 051 10 7
Tetanus Toxoid 837 085 10 9
dT 1016 065 6 3
DT 1386 023 2 1
RE 8992003 (ANVISA) RSD le 5)
Instituto Butantan | 31
dT DT DTP and DTPHB vaccines accuracy Diphtheria fraction
SAMPLESX (ToBI)(UImL)
n = 7
Official ResultIn vivo
(UImL)
n = 1
X (ToBI) x 100
Official Result(80 to 120)
dT 338 30 113
DT 467 49 95
DTPHB 657 60 110
Diphtheria
Toxoid668 66 101
DTP 1038 114 91
Instituto Butantan | 32
dT DT DTP and DTPHB vaccines accuracy Tetanus fraction
SAMPLESX (ToBI)(UImL)
n = 3
Official ResultIn vivo
(UImL)
n = 1
X (ToBI) x 100
Official Result(80 to 120)
DTPHB 313 28 112
DTP 497 46 108
Tetanus Toxoid 801 89 90
dT 1001 123 81
DT 1381 152 91
Instituto Butantan | 33
in vivo e in vitro correlation
dT DT DTP and DTPHB vaccines Diphtheria fraction potency analysis
Instituto Butantan | 34
in vivo e in vitro correlation
dT DT DTP and DTPHB vaccines Tetanus fraction potency analysis
Instituto Butantan | 35
Internal validated ToBI tests presented suitable to estimate the potency not only to
tetanus fraction but ALSO to diphtheria fraction in combined vaccines
Our data met all acceptance validation criteria as specificityselectivity linearity
precision (repeatability and intermediate precision) accuracy and in vitro and in vivo
concordance showed strong correlation (R=096) for both D and T components
The high relevance of these data for replacement of animal testing strongly impacts
the routine of Quality Control turning the analyses faster accurate and cheaper and
more importantly saving the lives of hundred of animals per year
Diphtheria and Tetanus combined vaccine potency by ToBI
Conclusion after internal validation
Instituto Butantan | 36
Av Vital Brasil 1500 ndash Butantatilde - Satildeo Paulo ndash SP -
Brazil
Zip code - 05503-900
(+ 55 11) 26279453
Thank you
patriciacarneirobutantangovbr
Biotech QC team
Instituto Butantan | 30
dT DT DTP and DTPHB vaccines intermediate precision Tetanus fraction
SAMPLES
ANALYSTS I + II | X(An II) ndash X(An I) | x 100
X(An I)
(le20)
Mean(UImL)
SDRSD(le20)
DTPHB 317 019 6 3
DTP 513 051 10 7
Tetanus Toxoid 837 085 10 9
dT 1016 065 6 3
DT 1386 023 2 1
RE 8992003 (ANVISA) RSD le 5)
Instituto Butantan | 31
dT DT DTP and DTPHB vaccines accuracy Diphtheria fraction
SAMPLESX (ToBI)(UImL)
n = 7
Official ResultIn vivo
(UImL)
n = 1
X (ToBI) x 100
Official Result(80 to 120)
dT 338 30 113
DT 467 49 95
DTPHB 657 60 110
Diphtheria
Toxoid668 66 101
DTP 1038 114 91
Instituto Butantan | 32
dT DT DTP and DTPHB vaccines accuracy Tetanus fraction
SAMPLESX (ToBI)(UImL)
n = 3
Official ResultIn vivo
(UImL)
n = 1
X (ToBI) x 100
Official Result(80 to 120)
DTPHB 313 28 112
DTP 497 46 108
Tetanus Toxoid 801 89 90
dT 1001 123 81
DT 1381 152 91
Instituto Butantan | 33
in vivo e in vitro correlation
dT DT DTP and DTPHB vaccines Diphtheria fraction potency analysis
Instituto Butantan | 34
in vivo e in vitro correlation
dT DT DTP and DTPHB vaccines Tetanus fraction potency analysis
Instituto Butantan | 35
Internal validated ToBI tests presented suitable to estimate the potency not only to
tetanus fraction but ALSO to diphtheria fraction in combined vaccines
Our data met all acceptance validation criteria as specificityselectivity linearity
precision (repeatability and intermediate precision) accuracy and in vitro and in vivo
concordance showed strong correlation (R=096) for both D and T components
The high relevance of these data for replacement of animal testing strongly impacts
the routine of Quality Control turning the analyses faster accurate and cheaper and
more importantly saving the lives of hundred of animals per year
Diphtheria and Tetanus combined vaccine potency by ToBI
Conclusion after internal validation
Instituto Butantan | 36
Av Vital Brasil 1500 ndash Butantatilde - Satildeo Paulo ndash SP -
Brazil
Zip code - 05503-900
(+ 55 11) 26279453
Thank you
patriciacarneirobutantangovbr
Biotech QC team
Instituto Butantan | 31
dT DT DTP and DTPHB vaccines accuracy Diphtheria fraction
SAMPLESX (ToBI)(UImL)
n = 7
Official ResultIn vivo
(UImL)
n = 1
X (ToBI) x 100
Official Result(80 to 120)
dT 338 30 113
DT 467 49 95
DTPHB 657 60 110
Diphtheria
Toxoid668 66 101
DTP 1038 114 91
Instituto Butantan | 32
dT DT DTP and DTPHB vaccines accuracy Tetanus fraction
SAMPLESX (ToBI)(UImL)
n = 3
Official ResultIn vivo
(UImL)
n = 1
X (ToBI) x 100
Official Result(80 to 120)
DTPHB 313 28 112
DTP 497 46 108
Tetanus Toxoid 801 89 90
dT 1001 123 81
DT 1381 152 91
Instituto Butantan | 33
in vivo e in vitro correlation
dT DT DTP and DTPHB vaccines Diphtheria fraction potency analysis
Instituto Butantan | 34
in vivo e in vitro correlation
dT DT DTP and DTPHB vaccines Tetanus fraction potency analysis
Instituto Butantan | 35
Internal validated ToBI tests presented suitable to estimate the potency not only to
tetanus fraction but ALSO to diphtheria fraction in combined vaccines
Our data met all acceptance validation criteria as specificityselectivity linearity
precision (repeatability and intermediate precision) accuracy and in vitro and in vivo
concordance showed strong correlation (R=096) for both D and T components
The high relevance of these data for replacement of animal testing strongly impacts
the routine of Quality Control turning the analyses faster accurate and cheaper and
more importantly saving the lives of hundred of animals per year
Diphtheria and Tetanus combined vaccine potency by ToBI
Conclusion after internal validation
Instituto Butantan | 36
Av Vital Brasil 1500 ndash Butantatilde - Satildeo Paulo ndash SP -
Brazil
Zip code - 05503-900
(+ 55 11) 26279453
Thank you
patriciacarneirobutantangovbr
Biotech QC team
Instituto Butantan | 32
dT DT DTP and DTPHB vaccines accuracy Tetanus fraction
SAMPLESX (ToBI)(UImL)
n = 3
Official ResultIn vivo
(UImL)
n = 1
X (ToBI) x 100
Official Result(80 to 120)
DTPHB 313 28 112
DTP 497 46 108
Tetanus Toxoid 801 89 90
dT 1001 123 81
DT 1381 152 91
Instituto Butantan | 33
in vivo e in vitro correlation
dT DT DTP and DTPHB vaccines Diphtheria fraction potency analysis
Instituto Butantan | 34
in vivo e in vitro correlation
dT DT DTP and DTPHB vaccines Tetanus fraction potency analysis
Instituto Butantan | 35
Internal validated ToBI tests presented suitable to estimate the potency not only to
tetanus fraction but ALSO to diphtheria fraction in combined vaccines
Our data met all acceptance validation criteria as specificityselectivity linearity
precision (repeatability and intermediate precision) accuracy and in vitro and in vivo
concordance showed strong correlation (R=096) for both D and T components
The high relevance of these data for replacement of animal testing strongly impacts
the routine of Quality Control turning the analyses faster accurate and cheaper and
more importantly saving the lives of hundred of animals per year
Diphtheria and Tetanus combined vaccine potency by ToBI
Conclusion after internal validation
Instituto Butantan | 36
Av Vital Brasil 1500 ndash Butantatilde - Satildeo Paulo ndash SP -
Brazil
Zip code - 05503-900
(+ 55 11) 26279453
Thank you
patriciacarneirobutantangovbr
Biotech QC team
Instituto Butantan | 33
in vivo e in vitro correlation
dT DT DTP and DTPHB vaccines Diphtheria fraction potency analysis
Instituto Butantan | 34
in vivo e in vitro correlation
dT DT DTP and DTPHB vaccines Tetanus fraction potency analysis
Instituto Butantan | 35
Internal validated ToBI tests presented suitable to estimate the potency not only to
tetanus fraction but ALSO to diphtheria fraction in combined vaccines
Our data met all acceptance validation criteria as specificityselectivity linearity
precision (repeatability and intermediate precision) accuracy and in vitro and in vivo
concordance showed strong correlation (R=096) for both D and T components
The high relevance of these data for replacement of animal testing strongly impacts
the routine of Quality Control turning the analyses faster accurate and cheaper and
more importantly saving the lives of hundred of animals per year
Diphtheria and Tetanus combined vaccine potency by ToBI
Conclusion after internal validation
Instituto Butantan | 36
Av Vital Brasil 1500 ndash Butantatilde - Satildeo Paulo ndash SP -
Brazil
Zip code - 05503-900
(+ 55 11) 26279453
Thank you
patriciacarneirobutantangovbr
Biotech QC team
Instituto Butantan | 34
in vivo e in vitro correlation
dT DT DTP and DTPHB vaccines Tetanus fraction potency analysis
Instituto Butantan | 35
Internal validated ToBI tests presented suitable to estimate the potency not only to
tetanus fraction but ALSO to diphtheria fraction in combined vaccines
Our data met all acceptance validation criteria as specificityselectivity linearity
precision (repeatability and intermediate precision) accuracy and in vitro and in vivo
concordance showed strong correlation (R=096) for both D and T components
The high relevance of these data for replacement of animal testing strongly impacts
the routine of Quality Control turning the analyses faster accurate and cheaper and
more importantly saving the lives of hundred of animals per year
Diphtheria and Tetanus combined vaccine potency by ToBI
Conclusion after internal validation
Instituto Butantan | 36
Av Vital Brasil 1500 ndash Butantatilde - Satildeo Paulo ndash SP -
Brazil
Zip code - 05503-900
(+ 55 11) 26279453
Thank you
patriciacarneirobutantangovbr
Biotech QC team
Instituto Butantan | 35
Internal validated ToBI tests presented suitable to estimate the potency not only to
tetanus fraction but ALSO to diphtheria fraction in combined vaccines
Our data met all acceptance validation criteria as specificityselectivity linearity
precision (repeatability and intermediate precision) accuracy and in vitro and in vivo
concordance showed strong correlation (R=096) for both D and T components
The high relevance of these data for replacement of animal testing strongly impacts
the routine of Quality Control turning the analyses faster accurate and cheaper and
more importantly saving the lives of hundred of animals per year
Diphtheria and Tetanus combined vaccine potency by ToBI
Conclusion after internal validation
Instituto Butantan | 36
Av Vital Brasil 1500 ndash Butantatilde - Satildeo Paulo ndash SP -
Brazil
Zip code - 05503-900
(+ 55 11) 26279453
Thank you
patriciacarneirobutantangovbr
Biotech QC team
Instituto Butantan | 36
Av Vital Brasil 1500 ndash Butantatilde - Satildeo Paulo ndash SP -
Brazil
Zip code - 05503-900
(+ 55 11) 26279453
Thank you
patriciacarneirobutantangovbr
Biotech QC team